Clinical Development
FGF401
Protocol CFGF401X2101 / [STUDY_ID_REMOVED]
A phase I/II, multicenter, open -label study of oral FGF401 in 
adult patients w ith hepatocellular carcinoma or solid 
malignancies characterized by positiv e FGFR4 and KLB 
expression
Document type Amended Protocol Version
EUDRACT number 2014-002929-35
Version number 05 (Clean )
Development phase I
Document status Final
Release date 27-Sep-2018
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis

Novartis Confidential Page 2
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Table of contents
Table of contents ................................................................................................................. 2
List of figures
...................................................................................................................... 8
List of tables ........................................................................................................................ 8
List of abbreviations .......................................................................................................... 11
Glossary  of terms ............................................................................................................... 14
Protocol summary :
............................................................................................................. 15
Amendment 5 (27 -
Sep-2018) ............................................................................................ 18
Amendment 4 (06 -Dec-2016) ............................................................................................ 21
Amendment 03 .................................................................................................................. 24
Amendment 02 .................................................................................................................. 24
Amendment 01 .................................................................................................................. 25
1Background ........................................................................................................................ 26
1.1 Overview of disease pathogenesis, epidemiology
 and current treatment .............. 26
1.2 Introduct ion to investigational treatments ............................................................. 26
1.2.1 Overview of FGF401 ............................................................................ 26
1.2.2
Overview of PDR001............................................................................ 30
1.2.3
Overview of FGF401 and PDR001....................................................... 31
2
Rationale ............................................................................................................................ 32
2.1 Study  rationale and purpose ................................................................................... 32
2.2 Rationale for the s tudy design ............................................................................... 33
2.2.1 FGF401 single agent ............................................................................. 33
2.2.2 FGF401 in combination with PDR001 ................................................. 35
2.3 Rationale for dose and regimen selection .............................................................. 35
3Objectives and endpoints ................................ ................................ ................................ ...36
4Study  design ...................................................................................................................... 39
4.1 Description of stud y design ................................................................................... 39
4.1.1 FGF401 single agent ............................................................................. 40
4.1.2 FGF401 in combination with PDR001 ................................................. 41
4.2 Timing of interim anal yses and design adaptations ............................................... 42
4.3 Definition of end of the study ................................................................................ 43
4.4 Early study termination .......................................................................................... 43
5Population ................................ ................................ ................................ .......................... 44
5.1 Patient population .................................................................................................. 44
5.2 Inclusion criteria .................................................................................................... 44
5.3 Exclusion criteria ................................................................................................... 46

Novartis Confidential Page 3
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
6Treatment ................................ ................................ ................................ ........................... 50
6.1 Study  treatment ...................................................................................................... 50
6.1.1 Dosing regimen ..................................................................................... 50
6.1.2 Ancillary  treatments .............................................................................. 51
6.1.3 Treatment duration ................................................................................ 52
6.2 Dose escalation guidelines ..................................................................................... 52
6.2.1 Starting dose rationale ........................................................................... 52
6.2.2 Provisional dose levels .......................................................................... 53
6.2.3
Guidelines for dose escalation and determination of MTD .................. 54
6.2.4 Definitions of dose limiting toxicities (DL Ts)...................................... 57
6.3 Dose modifications
................................................................................................ 58
6.3.1 Dose modification and dose delay ........................................................ 58
6.3.2 Follow-up for toxicities ......................................................................... 64
6.3.3 Anticipated risks and safety  concerns of the study drug ....................... 65
6.4
Concomitant medications ...................................................................................... 65
6.4.1 Permitted concomitant therap y
............................................................. 65
6.4.2 Permitted concomitant therap y requiring caution and/or action ........... 66
6.4.3 Prohibited concomitant therap y
............................................................ 66
6.5 Patient numbering, treatment assignment or randomization ................................. 67
6.5.1
Patient numbering ................................................................................. 67
6.5.2 Treatment assignment ........................................................................... 67
6.6 Study  drug preparation and dispensation ............................................................... 67
6.6.1 Study  drug packaging and labeling ....................................................... 67
6.6.2 Drug supply  and storage ........................................................................ 68
6.6.3 Study  drug compliance and accountabilit y
........................................... 68
6.6.4 Disposal and destruction ....................................................................... 68
7
Visit schedule and assessments ......................................................................................... 69
7.1 Study  flow and visit schedule ................................................................................ 69
7.1.1 Molecular pre -screening ........................................................................ 77
7.1.2 Screening ............................................................................................... 77
7.1.3 Treatment period ................................................................................... 78
7.1.4 Discontinuation of Study Treatment ..................................................... 79
7.1.5 Withdrawal of consent .......................................................................... 80
7.1.6 Follow up period ................................................................................... 81
7.1.7 Lost to follow -
up................................................................................... 81
7.2 Assessment ty pes................................................................................................... 82

Novartis Confidential Page 4
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
7.2.1 Efficacy  assessments ............................................................................. 82
7.2.2 Safety  and tolerability  assessments ....................................................... 83
7.2.3 Pharmacokinetics and immunogenicit y assessments ............................ 89
94
8Safety  monitoring and reporting ........................................................................................ 98
8.1 Adverse events ....................................................................................................... 98
8.1.1
Definitions and reporting ...................................................................... 98
8.1.2 Laboratory  test abnormalities .............................................................. 100
8.2 Serious adverse events ......................................................................................... 100
8.2.1
Definitions........................................................................................... 100
8.2.2
Reporting............................................................................................. 101
8.3 Pregnancies .......................................................................................................... 102
8.4 Warnings and precautions .................................................................................... 102
8.5 Data Monitoring Committee ................................................................................ 102
8.6 Steering Committee ............................................................................................. 103
9Data collection and management ..................................................................................... 104
9.1 Data confidentiality ............................................................................................. 104
9.2 Site monitoring .................................................................................................... 104
9.3
Data collection..................................................................................................... 105
9.4 Database management and quality  control ................................ .......................... 105
10Statistical methods and data anal ysis.............................................................................. 106
10.1 Analy sis sets ........................................................................................................ 106
10.1.1 Full Anal ysis Set ................................................................................. 106
10.1.2 Safety  Set
............................................................................................ 107
10.1.3
Per-Protocol Set .................................................................................. 107
10.1.4 Dose -
determining anal ysis set............................................................. 107
10.1.5 Pharmacokinetic anal ysis set
............................................................... 107
10.2 Patient demographics/other baseline characteristics ........................................... 108
10.3 Treatments (stud y treatment, 
concomitant therapies, compliance) ..................... 108
10.3.1 Study  treatment ................................ ................................ ................... 108
10.3.2 Concomitant therapies ......................................................................... 108
10.3.3 Compliance ......................................................................................... 108
10.4 Primary  obje ctive ................................................................................................. 108
10.4.1 Variable ............................................................................................... 109
10.4.2 Statistical hy pothesis, model, and method of analysis ........................ 109
10.4.3 Handling of missing values/censoring/discontinuations ..................... 113

Novartis Confidential Page 5
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
10.4.4 Supportive analy ses............................................................................. 113
10.5 Secondary  objectives ........................................................................................... 114
10.5.1 Efficacy  objectives .............................................................................. 114
10.5.2 Safety  objectives ................................................................................. 114
10.5.3 Pharmacokinetics ................................................................................ 116
118
118
10.7 Interim anal ysis................................ ................................ ................................ ....118
10.7.1 FGF401 single agent ........................................................................... 118
10.7.2 FGF401 in combination with PDR001 ............................................... 119
10.8
Sample size calculation........................................................................................ 119
10.8.1 FGF401 single agent ........................................................................... 119
10.8.2 FGF401 in combination with PDR001 ............................................... 121
10.9 Power for anal ysis of key secondary  variables
.................................................... 125
11
Ethical considerations and adminis trative procedures .................................................... 125
11.1 Regulatory
 and ethical compliance ...................................................................... 125
11.2 Responsibilities of the investigator and IRB/ IEC/REB ....................................... 125
11.3 Informed consent procedures
............................................................................... 125
11.4 Discontinuation of the study ................................................................................ 126
11.5 Publication of study  protocol and results ............................................................. 126
11.6 Study  documentation, record keeping and retention of documents
..................... 126
11.7 Confidentiality  of study  documents a nd patient records ..................................... 127
11.8
Audits and inspections......................................................................................... 127
11.9 Financial disclosures ............................................................................................ 127
12Protocol adherence .......................................................................................................... 128
12.1 Amendments to the protocol ................................................................................ 128
13References (available upon request) ................................................................................ 129
14Appendices ...................................................................................................................... 132
14.1 Appendix 1 
–Guidelines for response, duration of overall response, TTF, 
TTP, progression- free survival and overall survival (based on RECIST 1.1) .....132
14.1.1 Introduction ......................................................................................... 134
14.1.2 Efficacy  assessments ........................................................................... 134
14.1.3
Definitions........................................................................................... 134
14.1.4 Disease measurability .......................................................................... 134
14.1.5 Eligibility  based on measurable disease .............................................. 135
14.1.6 Methods of tumor measurement -general guidelines ......................... 135

Novartis Confidential Page 6
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
14.1.7 Baseline documentation of target and non -target lesions ................... 137
14.1.8 Follow -up evaluation of target and non -target lesions ........................ 137
14.1.9 Follow -up and recording of lesions ..................................................... 138
14.1.10 Non-
nodal lesions................................................................................ 138
14.1.11 Nodal lesions ....................................................................................... 138
14.1.12 Determination of target lesion response .............................................. 139
14.1.13 Determination of non -target lesion response ...................................... 140
14.1.14 New lesions ......................................................................................... 141
14.1.15 Evaluation of overall lesion response ................................................. 142
14.1.16 Efficacy  definitions ............................................................................. 142
14.1.17 Best overall response ........................................................................... 142
14.1.18 Time to event variables ....................................................................... 145
14.1.19 Progression
-free survival .................................................................... 145
14.1.20 Overall survival ................................................................................... 145
14.1.21 Time to progression ............................................................................. 145
14.1.22 Time to treatment failure ..................................................................... 145
14.1.23 Duration of response ........................................................................... 146
14.1.24 Time to response ................................................................................. 147
14.1.25 Definition of start and end dates for time to event variables .............. 147
14.1.26 Handling of pat ients with non -measurable disease only  at baseline ...148
14.1.27 Sensitivity  analy ses............................................................................. 149
14.1.28 Data handling and programming rules ................................................ 151
14.1.29 Study /project specific decisions .......................................................... 151
14.1.30 End of treatment phase completion ..................................................... 151
14.1.31 End of post -treatment follow -up (study  phase completion) ................ 152
14.1.32 Medical validation of programmed overall lesion response ............... 152
14.1.33 Programming rules .............................................................................. 153
14.1.34
Calculation of ‘time to event’ variables.............................................. 153
14.1.35 Incomplete assessment dates ............................................................... 153
14.1.36 Incomplete dates for last known date patient alive or death ............... 153
14.1.37 Non-target lesion response .................................................................. 153
14.1.38 Study /project specific programming ................................................... 153
14.1.39 Censoring reason ................................................................................. 154
14.1.40 References (available upon request) ................................................... 155
14.2 Appendix 2 
–Child -Pugh classification of severity of liver disease ................... 156
14.3 Appendix 3 – Hepatocellular carcinoma staging sy stems ................................... 157

Novartis Confidential Page 7
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
14.4 Appendix 4 – Prohibited concomitant medications and permitted concomitant 
medications requiring caution.............................................................................. 158
14.5 Appendix 5 – Guidelines for management of diarrhea........................................ 158
14.6 Appendix 6 - Guidelines for management of h yperphosphatemia ...................... 160
162
14.8 Appendix 8 – Test meal guidelines ..................................................................... 163
14.9 Appendix 9 -Guidelines for immune -related Response Criteria (irRC) using 
one
-dimensional measurements (simulating RECIST 1.1) ................................. 164
14.9.1 Introduction ......................................................................................... 164
14.9.2 New lesions and non -target lesions ..................................................... 164
14.9.3 Follow -
upevaluation of target and non -target lesions ........................ 165
14.9.4 Definitions of respons e categories and evaluation of overall lesion 
response ............................................................................................... 165
14.9.5 References (available upon request) ................................................... 166
 
166
166
166
176
181
14.11 Appendix 11
-Recommended management algorithms for suspected toxicities. 182
14.11.1 GI adverse event management algorithm ............................................ 183
14.11.2 Renal adverse event management algorithm ....................................... 184
14.11.3 Pulmonary  adverse event management algorithm
.............................. 185
14.11.4 Endocrinopath y management algorithm ............................................. 186
14.11.5
Skin adverse event management algorithm......................................... 187
14.11.6
Hepatic adverse event management algorithm ................................... 188
14.11.7 References (available upon request) ................................................... 189

Novartis Confidential Page 8
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
List of figures
Figure 4 -1 Study  design .......................................................................................... 39
Figure 4 -
2 Study  design -FGF401 in combination with PDR001 .......................... 41
Figure 4 -3 Study  Flow ............................................................................................ 42
162
List of tables
Table 3
-1 Objectives and related endpoints ................................ .......................... 37
Table 6-1 Dose and treatment schedule................................................................. 50
Table 6
-2 FGF401 Provisional dose levels ............................................................ 53
Table 6
-3 Criteria for defining dose- limiting toxicities......................................... 57
Table 6-4 Criteria for interruption and re-initiation of FGF401  as single 
agent and in combination with PDR001 ............................................... 60
Table 6
-5 Criteria for interruption and re- initiation of PDR001 treatment ........... 64
Table 7-1 Visit evaluation schedule (applicable for protocol amendment 04 -
following approval of protocol amendment 05 refer to Table 7 -1b 
below) .................................................................................................... 70
Table 7
-1b Visit evaluation schedule – applicable upon approval of protocl 
amendment 05 ....................................................................................... 76
Table 7
-2 Imaging collection plan ......................................................................... 82
Table 7
-3 ECOG performance status ..................................................................... 84
Table 7
-4 Local clinical laboratory  parameters collection plan (applicable for 
protocol amendment 04 -following approval of protocol 
amendment 05 refer to Table 7 -4b below) ................................ ............ 85
Table 7-4b Local clinical laboratory  parameters collection plan -applicable 
upon approval of protocol amendment 05 ............................................ 85
Table 7
-5 Central clinical laboratory  parameters collec tion plan** ...................... 86
Table 7-6 Central ECG collection plan ................................................................. 89
Table 7
-7 Phase I parts: Pharmacokinetic blood collection log for QD 
FGF401 administration ......................................................................... 90
Table 7
-8 Phase II parts: Pharmacokinetic blood collection log for QD 
FGF401 admi nistration ................................ ................................ ......... 91
Table 7-9 Phase I parts: Pharmacokinetic blood collection log for BID 
FGF401 administration (if BID dosing is implemented) ...................... 91
Table 7-10 Phase II parts: Pharmacokinetic blood collection log for BID 
FGF401 administration (if BID dosing is implemented) ...................... 92
Table 7-11 Schedule of blood (serum) collection for PDR001 PK and IG for 
patients participating in phase I of FGF401 and PDR001 
combination ........................................................................................... 93

Novartis Confidential Page 9
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Table 7-12 Schedule of blood (serum) collection for PDR001 PK and IG for 
patients participating in Phase II of FGF401 and PDR001 
combination ........................................................................................... 93
94
96
Table 10
-1 Noncompartmental pharmacokinetic parameters ................................ 117
Table 10-2 Probability  of Success under different number of sample size in 
Group 1 (drop rate = 15%) .................................................................. 120
Table 10
-3 Probability  of Success under different number of sample size in 
Group 2 (drop rate = 15%) .................................................................. 121
Table 10
-4 Cumulative probability  (upper tail) of r esponses observed or more 
given true ORR and 20 patients .......................................................... 121
Table 10
-5 Operating Characteristics (scenario 1: the percentages of FGF 19
positive and FGF19 negativ e patients enrolled in the Stage 1 are 
20% and 80%) ..................................................................................... 123
Table 10
-6 Operating Characteristics (scenario 2: the percentages of FGF 19
positive and FGF19 negative patients enrolled in the Stage 1 are 
40% and 60%) ..................................................................................... 124
Table 14
-1 Response criteria for target lesions ..................................................... 139
Table 14
-2 Response criteria for non -target lesions .............................................. 140
Table 14
-3 Overall lesion response at each assessment ........................................ 142
Table 14
-4 Overall lesion response at each assessment: patients with non -
target disease onl y............................................................................... 149
Table 14
-5 Options for event dates used in PFS, TTP, duration of response ........ 150
Table 14-6 Child -Pugh score calculation .............................................................. 156
Table 14
-7 Child -Pugh score interpretation .......................................................... 156
Table 14
-8 Barcelona -Clinic L iver Cancer s ystem............................................... 157
Table 14
-9 Prohibited c oncomitant medications ................................................... 158
Table 14
-10 Permitted concomitant medications requiring caution........................ 158
Table 14-11 Criteria for interruption and re-initiation of FGF401 treatment for 
diarrhea management .......................................................................... 159
Table 14
-12 Criteria for for interruption and re -initiation of FGF401 treatment 
for h yperphosphatemia management .................................................. 160
163
Table 14
-14 Test me al examples ............................................................................. 164
Table 14
-15 Overall response at each assessment ................................................... 166
169
169

Novartis Confidential Page 10
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
 
170
170
171
174
176
 
178
179
179
 
179
.180
180
 
181

Novartis Confidential Page 11
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
List of abbreviations
AASLD American Association for the Study of Liver Diseases
AE Adverse Event
AFP Alpha -fetoprotein
ALT Alanine aminotransferase/glutamic pyruvic transaminase/GPT
ANC Absolute neutrophil count
AST Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT
ATC Anatomic -Therapeutic -Chemical classification
ATP Adenosine triphosphate
AUC Area under the concentration -time curve
b.i.d. bis in diem /twice a day
BAS Bile acid sequestrant
BCLC Barcelona Clinic Liver Cancer
BCRP Breast Cancer Resistance Protein
BCS Biopharmaceutics classification system
BHLRM Bayesian hierarchical logistic regression model
BLRM Bayesian logistic regression model
BOR Best overall response
BSA Body surface area
BSEP Bile Salt Export Pump
BUN Blood urea nitrogen
cfDNA Cellfree DNA
CL Clearance
Cmax Maximum observed concentration
Cmin Minimum observed concentration
CMO&PS Chief Medical Office and Patient Safety
CNS Central nervous system
COPD Chronic obstructive pulmonary disease
CR Complete response
CRO Contract Research Organization
CSR Clinical study report
CRS Cytokine Release Syndrome
CTCAE Common terminology criteria for adverse events
Ctrough The concentration that is just prior to the beginning of, or at the end, of a dosing interval
CYP Cytochrome P450
DCR Disease control rate
DDI Drug -Drug interaction
DDS Dose -determining analysis set
DLT Dose Limiting Toxicity
EC Ethics Committee
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF electronic case report form
EOT End of Treatment
EWOC Escalation with overdose control
FAS full analysis set
FGF Fibroblast growth factor

Novartis Confidential Page 12
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
FGFR Fibroblast growth factor receptor
FU follow -up
G-CSF Granulocyte colony stimulating factor
GI Gastro -Intestinal
GLP Good laboratory practice
GM-CSF Granulocyte macrophage colony stimulating factor
HBV Hepatitis B virus
HCC Hepatocellular carcinoma
hCG Human Chorionic Gonadotropin
HCV Hepatitis C virus
HDL High-density lipoprotein
HIV Human immunodeficiency v irus
HLM Human liver microsomes
i.v. intravenous
IC50 Inhibitory concentration (at half -maximum inhibition)
ICF Informed consent form
ICH International Conference on Harmonization
IEC Independent Ethics Committee
IFN-γ Interferon -gamma
IG Immunogenicity
IL Interleukin
INR International normalized ratio
irAE Immune -related adverse event
IRB Institutional Review Board
irRC Immune -related response criteria
IUD intrauterine device
IUS intrauterine system
KD constant of dissociation
KLB β-Klotho
LC-MS/MS Liquid chromatography -tandem mass spectrometry 
LDL Low-density lipoprotein
LLOQ Lower limit of quantification
M-CSF Macrophage colony stimulating factor
MRP Multidrug resistance -associated protein
MTD Maximum Tolerated Dose
NADPH Nicotinamide adenine dinucleotide phosphate
NTCP Na+-taurocholate cotransporting polypeptide
OATP Organic anion -transporting polypeptide
ORR Overall response rate
OS Overall survival
p.o. per os /by mouth/orally
P-gp P-glycoprotein
p/t Phosphorylated over total
PAS Pharmacokinetic analysis set
PBMCs Peripheral blood mononuclear cells
PBPK Physiologically -based pharmacokinetics
PD Pharmacodynamics

Novartis Confidential Page 13
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
PD-1 Programmed Death -1
PD-L Programmed Death -Ligand
PFS Progression -free survival
PK Pharmacokinetics
PR Partial response
PPI Proton pump inhibitors
PPS Per-Protocol Set
PT Prothrombin time
Q3W Every three weeks
Raf Rapidly accelerated fibrosarcoma
RAP The Report and Analysis Plan (RAP) is a regulatory document which provides evidence of 
preplanned analyses
REB Research Ethics Board
RECIST Response Evaluation Criteria in Solid Tumors
RP2D Recommended phase two dose
SAE Serious Adverse Event
SD Stable Disease
SEB Staphylococcal Enterotoxin B
SI unit International System of Units
SJS Stevens Johnson Syndrome
SOP Standard Operating Procedure
T1/2 Terminal half -life
TACE Transarterial chemoembolization
TEN Lyell syndrome/toxic epidermal necrolysis
Tmax Time to reach observed maximum concentration
TNFα Tumor necrosis factor -α
TSH Thyroid -stimulating hormone
TTP Time to progression
UGT Uridine diphosphate glucuronyltransferase
ULN Upper limit of normal
Vss Volume of distribution (at steady state)

Novartis Confidential Page 14
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Glossary  of terms
Assessment A procedure used to generate data required by the stu dy
Biologic Sa mples A biological speci men including, for ex ample, blood (plas ma, serum), saliva, 
tissue, urine, stool, etc. t aken fr om a study subject or study patient
Cohort A group of newly enrolled patients treated at a specific dose and regimen (i.e.
treatment group) at the same time
Cycles Number and timing or recommended repetitions of therapy are usually expressed 
as number of days (e.g.: q21 days)
Dose level The dose of drug given to the patient (total daily or weekly etc.) 
Enrollment Point/ti me of patient entry into the study; the point at which informed consent must 
be obtained (i.e. prior to starting any of the procedures described in the protocol)
Investigational drug The study treatment whose properties are being tested in the study; this definition 
is consistent with US CFR 21 Section 312.3 and is synonymous with 
“investigational new drug.”
Investigational treatment Drug whose properties are being tested in the study as well as their associated 
placebo and active treatment controls (when applicable). This also includes 
approved drugs used outside of their indication/approved dosage, or that are 
tested in a fixed combination. Investigational treatment generally does not include 
other study treatments administered as concomitant background therapy required 
or allowed by the protocol when used in within approved indication/dosage
Medication number A unique identifier on the label of each study treatment package which is linked to 
one of the treatment groups of a study
Personal Data Subject information collected by the Investigator that is transferred to Novartis for 
the purpose of the clinical trial. This data includes subject identifier information, 
study information and biological samples .
Stratum A group of patients enrolled and treated in same specific condition (e.g. food 
intake condition)
Subject Number (Subject 
No.)A unique identifying number assigned to each patient/subject who enrolls in the 
study
Study treatment Includes any drug or combination of drugs in any study arm administered to the 
patient (subject) as part of the required study procedures, including placebo and 
active drug run -ins.
In specific examples, it is important to judge investigational treatment component 
relationship relative to a study treatment combination; study treatment in this case 
refers to the investigational and non -investigational treatments in combination.
Study treatment 
discontinuationPoint/time when patient permanently stops taking study treatment for any reason; 
may or may not also be the point/time of premature patient withdrawal
Variable Identifier used in the data analysis; derived directly or indirectly from data 
collected using specified assessments at specified timepoints
Withdrawal of consent Withdrawal of consent from the study occurs only when a subject does not want 
to participate in the study any longer, and does not allow any further collection of 
personal data .

Novartis Confidential Page 15
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Protocol summary : 
Protocol number CFGF401X2101
Title A phase I/II, multicenter, open -label study of oral FGF401 in adult patients with 
hepatocellular carcinoma or other solid tumors characterized by positive FGFR4 
and KLB expression
Brief title FGF401 in HCC and solid tumors characterized by positive FGFR4 and KLB 
expression
Sponsor and Clinical 
PhaseNovartis
Phase I/II
Investigation ty pe Drug
Study  type Interventional
Purpose and rationale The purpose of this study is to determine the maximum tolerated dose (MTD) or 
recommended phase II dose (RP2D) of FGF401 as single agent and in 
combination with PDR001 in patients with hepatocellular carcinoma and as 
single agent in other solid tumors characterized by positive FGFR4 and KLB 
expression; and to estimate the preliminary anti -tumor activity of FGF401 single 
agent and in combination with PDR001 in these popul ations.
Based on preclinical studies, FGF401 is a highly potent, selective FGFR4 
inhibitor, thereby making it a good candidate for use in the clinic. Positive 
prediction for sensitivity to FGF401 was identified to be associated with positive 
expression of FGFR4, KLB and FGF19. Based on the emerging clinical efficacy
results, the combination of FGF401 with PDR001 will be evaluated in parallel to
the FGF401 single agent , in unselected HCC population for both parts of the 
study .
Primary  Objective(s) and 
Key Secondary  ObjectivePhase I: To estimate the MTD or RP2D of FGF401 single agent and in 
combination with PDR001
Phase II: To investigate the anti-tumor activity of FGF401 single agent and in 
combination with PDR001
Secondary  Objectives ● To characterize the safety and tolerability of FGF401 single agent and in 
combination with PDR001
● To further investigate the anti-tumor activity of FGF401 single agent and in 
combination with PDR001
● To characterize the PK properties of FGF401 single agent and in combinat ion 
with PDR001
● To evaluate food effect on FGF401 exposure and safety profile
Study  design This study has been designed as a phase I/II, multi-center, open -label study 
starting with a phase I dose escalation part followed by a phase II dose 
expansion p art. Oral FGF401 and intravenous PDR001 (for the FGF401 and 
PDR001 combination part) will be administered as per protocol until patient 
experiences unacceptable toxicity, progressive disease and/or treatment is 
discontinued at the discretion of the investigator or withdrawal of consent. A 
cycle is defined as 21 days.
The phase II part of the FGF401 and PDR001 combination has a 2-stage study 
design with an interim efficacy analysis in unselected HCC patients and a sub -
group futility analysis, based onFGF19 pathway activation if the efficacy criteria 
are not satisfied . Enrollment with a molecularly selected population will continue 
at Stage 2 if the futility criteria are not satisfied .
Population Phase I -FGF401 single agent : adult patients with hepato cellular carcinoma or 
other solid malignancies characterized by positive FGFR4 and KLB expression.
Phase II -FGF401 single agent : 
Group 1: adult HCC patients from Asian countries
Group 2: adult HCC patients from non -Asian regions
Group 3: adult other solid tumor patients, characterized by positive FGFR4 and 
KLB expression regardless of geography
FGF401 and PDR001 combination: adult patients with advanced HCC

Novartis Confidential Page 16
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Key Inclusion criteria 1. Patients (male or female) ≥ 18 years of age
2. ECOG Performance Status ≤ 1
3. Presence of at least one measurable lesion according to RECIST v1.1. 
4. FGF401 single agent -Phase I and Phase II -Group 3: Patients with confirmed 
positive expression of FGFR4 and KLB at pre -screening.
5. For HCC patients: the diagnosis must be made b ased on AASLD Guidelines 
with confirmed stage C advanced HCC (BCLC staging classification). Current 
cirrhotic status of Child -Pugh class A (5 -6 points), with no encephalopathy and/or 
ascites.
6. FGF401 single agent -Phase I and Phase II, Group 3: Patients with HCC or 
advanced solid tumors, who have progressed despite standard therapy or are 
intolerant of standard therapy, or for whom no standard therapy exists.
7. FGF401 single agent -Phase II, Groups 1 and 2: HCC patients previously 
treated with sorafenib f or advanced HCC with documented disease progression 
during or after discontinuation of sorafenib treatment, or intolerance to sorafenib 
treatment.
8. FGF401 in combination with PDR001 -Phase I and Phase II : Advanced HCC 
patients who have received up to 2 pr evious lines of systemic treatment and one 
treatment must have included sorafenib with documented disease progression 
during or after discontinuation of sorafenib treatment, or intolerance to sorafenib 
treatment
9. FGF401 in combination with PDR001-Phase I I-Stage 2: Documented FGF19 
expression level and/or FGF19 pathway activation
Key Exclusion criteria 1. Previous treatment with a selective FGF19 -FGFR4 targeted therapy and/or 
pan-FGFR inhibitor.
2. For HCC patients in FGF401 single agent -Phase II part: an y previous systemic 
anti-cancer therapies other than sorafenib or any anti-cancer therapy (including 
locoregional therapy) after disease progression during or after sorafenib 
treatment.
3. Ongoing active diarrhea requiring medications (e.g. BAS, loperamide )
4. Irritable bowel syndrome with signs/symptoms and requires medications
5. Symptomatic CNS metastases which are neurologically unstable or requiring 
increasing doses of steroids to control their CNS disease.
6. Patient having out of range laboratory val ues defined as:
● Hematology
Hemoglobin ≤ 9 g/dL (SI Units: 90 g/L)
Platelet count < 75000/mm3
Absolute neutrophil count (ANC) < 1500/mm3
● Chemistry
Total bilirubin > 1.5 x ULN
AST and/or ALT > 3 x ULN
Serum creatinine > 1.5 x ULN and/or cre atinine clearance < 40mL/min
● Coagulation: PT > 4 seconds more than the ULN or INR >1.7
7. Unable to stop any prohibited medications, including CYP1A2, CYP2C9 and 
CYP3A4/5 substrates with a narrow therapeutic index and known BSEP efflux 
transporter inhibitors.
Additional exclusion criteria for FGF401 and PDR001 combination:
8. Impaired cardiac function
9. History of liver or other organ transplantation
10. Patients who discontinued prior anti -PD-1/PD -L1 therapy due to an anti PD-
1/PD -L1-related toxicity
Investigational and 
reference therapyThe investigational therapy is FGF401 single agent and FGF401 in combination 
with PDR001 . There is no reference therapy.
Efficacy  assessments Tumor assessment per RECIST v1.1 for FGF401 s ingle agent; RECIST v1.1 and 
irRC forFGF401+PDR001 combination
Safety  assessments Incidence and severity of AEs and SAEs, including changes in laboratory values, 
vital signs and ECGs

Novartis Confidential Page 17
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Other assessments PK parameters
Immunogenicity analysis for PDR001
 
 
Data analy sis Phase I: in order to estimate the MTD and/or RP2D of the FGF401 single agent
and in combination with PDR001 , the corresponding primary ana lysis method s
are based on Bayesian  adaptive model sforthe dose escalation with overdose 
control (E WOC) principle.
Phase II: For the FGF401 single agent, a nti-tumor activity will be primarily 
assessed in terms of overall response rate (ORR) for solid tu mor patients and 
time to progression ( TTP) for HCC patients .For FGF401 in combination with 
PDR001, anti -tumor activity will be primarily assessed in terms of ORR for HCC 
patients.
The study data will be analyzed and reported based on all patients’ data of the 
Phase I and Phase II parts up to the time when all patients have potentially 
completed at least six cycles of treatment or discontinued the study.
Key words Phase I/II, FGF401, PDR001, PD -1, FGFR4 selective inhibitor, positive 
expression of FGFR4, KL B, FGF19 pathway

Novartis Confidential Page 18
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Amendment 5 (27 -Sep -2018 ) 
Amendment rationale 
The main purposes of this amendment are: 
To incorporate health authority -requested language requiring study  treatment 
discontinuation in the event of Stevens -Johnson sy ndrome (SJS)/ toxic epidermal 
necrol ysis (TEN) (already  implemented as part of an urgent safet y measure released on 15 
June 2018) and,
To reduce study  visits and assessments to ease the burden on patients who have been on 
study  for more than 7 cycles, while maintaining access to study  treatment and monitoring 
safet y. 
After the occurrence of a case of Stevens -Johnson syndrome in a study  with PDR001 in 
combination with another investigational agent, the dose modification guidelines for protocols 
using PDR001 were updated to mandate permanent discontinuation of study  treatment for 
patients who experience SJS or Lyell syndrome/toxic epidermal necrolysis (TEN). This change 
has alread y been implemented as part of an urgent safet y measure released on 15 June 2018. 
This protocol amend ment is now finalizing these changes in the dose modification section and 
corresponding tables describing the criteria for interruption and re -initiation of study  treatment.
The primary  objective sin the Phase I parts (FGF401 single agent and in combinatio n with 
PDR001) of the stud y have been reached. Enrol lment in the Phase II part of the FGF401 single 
agent has been completed . As of 03 July 2018, patient enrollment in this study  has been halted 
and the phase II part of the FGF401 in combination with PDR00
1 will not be initiated. This 
enrollment halt was due to business reason and was not a consequence of any  safet y concerns.
As of 01 September 2018, 9 patients r emain on treatment, 6 patients o n the FGF4 01 single agent 
and 3 patients o n FGF401 in combinatio n with PDR001 .This amendment will reduce the stud y 
assessments in order to ease the visit and sampling burden for these patients.
All of these patients have been on study  for more than 7 cycles and are tolerating study  treatment 
well. Their safety  profiles are consistent with the overall cumulative safety  data for FGF401 
and PDR001. The most commonly  reported AEs suspected to be related to study  treatment 
include diarrhea, AST and AL T elevations which are thought to be on target effects of FGFR4 
inhibition (refer to the current version of FGF401 IB) and will continue to be monitored for 
these patients. 
The required study  visits for patients who receive FGF401 as single agent arereduced from 
every  3 to every  6 weeks and the efficacy  assessments are reduced from every  6 to every  12 
weeks. The study  visits for p atients who receive FGF401 in combination with PDR001 remain 
the same in alignment with the PDR001 regimen of every  3
 weeks and the efficacy  assessments 
are reduced from every  6 to every  12 weeks. For all patients the basic panel of clinical laborator y 
parameters wi ll be performed at each study  visit . Other assessments and visits willcontinue to 
be performed at the investigator’s discretion following standard of care at the site. 
The central review of ECGs is no longer required and cardiac assessments may be performed 
at the investigator’s discretion following local standard of care, since the available data and 
analysis of centrall y reviewed ECGs collected during the study, do not ind icate cardiac risk. In 

Novartis Confidential Page 19
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
addition, the pharmacokinetic, immunogenicit y collections will be stopped since 
sufficient samples have been collected for anal ysis to support the study  objectives. 
Additional changes introduced with this amendment are described below:
The blood sample collection for the assessment of cy tokines in the event of a cy tokine 
release sy ndrome (CRS) was removed.  In this protocol, the assessment of cy tokines in the 
event of CRS is retrospective and is not utilized to support clinical treatment decision by  
study  investigators. In addition, clinically  assessed events of cytokine release sy ndrome 
were not reported in this study . 
To align with the EMA standard term list, the PDR001 pharmaceutical form has been 
updated to “Powder for solution for infusion”.
The withdrawal of consent language was revised to differentiate sample use after a patient 
withdraws consent based on different regulations/laws around the world.
Other minor corrections were made for consistency and/or clarifications.
Study status
A total of 160 patients have been treated with FGF401 as single agent, 74 in the dose escalation 
and 86 in the Phase II part. A total of 12 patients have been treated with FGF401 in combination 
with PDR001; all patients were en rolled in the dose escalation part. Due to the enrollment halt, 
the Phase II part of the combination did not start.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike thr ough red font for deletions and red underline for insertions.
Glossary  of terms has been updated to add the “Personal data” term and revise the 
“Withdrawal of consent” term. 
Tables 6- 4 and 6 -5 are modified to mandate permanent discontinuation of study  treatment 
for patients who experience SJS or Ly ell sy ndrome/toxic epidermal necrol ysis (TEN) –as 
per the USM letter dated 15 June 2018.
Section 6.3.2 and Table 6 -5 are updated to remove the collection of blood samples for 
cytokines measurement.
Section 6.6 a nd 6.6.6: The pharmaceutical form for PDR001 was changed to “powder for 
solution for infusion”.
Section 7 has been updated in all relevant sub -sections as follows: 
New tables for reduced assessments (Table 7 -1b) and for the local clinical laboratory  
parameters collection plan (Table 7 -4b) are added.
Sections 7.1.4, 7.1.6 and 7.2.1 have been updated to include reduced frequency of 
efficacy  assessments and clarify  that the central collection of imaging data is not 
required.
Section 7.2.2 has been update d to remove the following assessments: height, weight, 
performance status, coagulation, urinaly sis, , thyroid functions, 
cytokines and cardiac evaluations. I n addition, vital signs will be performed only  for 
patients treated with FGF401 in combination with PDR001. 

Novartis Confidential Page 20
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Sections 7.2.3 and 7.2.4 have been updated to remove further sample collections for 
pharmacokinetic  assessments.
Section 7.1.5 Withdrawal of consent language was updated.
Section 8.2.2 and Section 8.3: The name of the Novartis Drug Safet y and Epidemiology  
department was updated to Chief Medical Office and Patient Safety . In addition, 
clarification was added in the pregnancy  section to specify  that the follow -up of the newborn 
will be for 12 months.
Section 14- 4: Appen dix 4 was updated to remove from Table 14-10 (Permitted concomitant 
medications requiring caution) duplicate records of drugs which were also listed in Table 
14-9 (Prohibited concomitant medications).
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review 
Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes in this amendment identified above as being related to the USM have alread y been 
implemented by a USM letter issued on 15 June 2018. These chan ges are required for patient 
safet y (i.e. necessary  to eliminate immediate hazards to the trial subjects ICH GCP 3.3.8). 
Therefore they were required to have been implemented prior to IRB/IEC approval of this 
amendment. 
All other changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

Novartis Confidential Page 21
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Amendment 4 (06-Dec -2016)
Amendment rationale 
As of 15 November 2016, the Phase I part of the study  has been completed with a total of 67
patients enrolled and received different dose levels (ranging from 50mg QD to 150mg QD) of 
FGF401 as asingle agent administered under fasted or fed conditions. The RP2D for FGF401 
single agent was declared in 29 July  2016 as 120mg QD administered under fasted conditions. 
This decision was based on the analysis of available patients' safet y, pharmacokineti c, 
pharmacod ynamic and efficacy  data. In parallel, cohorts of FGF401 administered under fed 
conditions are being explored at the dose level of 80mg QD and 120mg QD with no dose 
limiting toxicities (DLTs)observed so far. The Phase II part of the study  is ongoing with 17 
patients enrolled in all 3 Group sand treated with FGF401 single agent at the RP2D dose level . 
The primary  purpose of this amendment is to add a combination treatment of FGF401 and 
PDR001 , a humanized anti-programmed death -1 (PD-1) IgG4 antibody , in patients with 
advanced hepatocellular carcinoma. 
This amendment is introducing a dose escalation part, in order to identify a MTD/RP2D for the 
FGF401 and PDR001 combination and will be followe d by a two stage Phase II part in order to 
further characterize the safet y and evaluate the clinical activity  of the combination in parallel to 
the FGF401 single agent. The introduction of the FGF401 and PDR001 combination treatment 
is based on the rationa le that both FGFR4 and PD-1 inhibition have demonstrated promising 
anti-tumor activity  in patients with HCC and that the combination will provide additional 
clinical benefit to patients. Emerging results from biomarker associative studies from the Phase 
I -FGF401 single agent available data support the removal of the FGFR4/KLB/FGF19 
molecular screening selection requirement for HCC patients in the Phase II part of the FGF401 
single agent. Molecular screening for these biomarkers will not be performed either for the dose 
escalation or the first stage of the Phase II in the FGF401 and PDR001 combination; however, 
based on the planned interim analy sis results it may  be introduced in the Stage 2 -Phase II part 
of the combination treatment.
This amendment also introduces the collection of tumor tissue upon the development of 
acquired resistance to treatment. The emergence of acquired resistance to therap y is a major 
problem for patients with cancer. The purpose of collecting this tumor sample along with a
sample of normal tissue to aid in the identification of somatic variants in the tumor is to identify 
genetic changes in the tumor that may underlie treatment resistance.
Furthermore, additional updates in patients’ eligibility  criteria and other operational aspe cts of 
the protocol are being implemented in this amendment as described below:
The laboratory  values in the exclusion criteria section and other eligibility  criteria for 
enrollment in the FGF401 single agent part have been amended to align with the eligibility  
requirements for the FGF401 and PDR001 combination. In addition, the laboratory  values for 
bilirubin have been amended in order to be consistent with CTCAE versio n 4.03 grading and 
clarification was added for the coagulation parameters.
Language has been updated in the protocol to differentiate among the discontinuation of study 
treatment or stud y visits, the withdrawal of consent and the lost to follow -up patients.

Novartis Confidential Page 22
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
The methods of highl y effective contraception, SAE reporting and publication language of 
study  protocol and results have been updated to reflect the most recent Novartis definitions, 
procedures and policies.
The list of concomitant medications that are prohibited and to be used with caution has been 
updated based on the latest internal drug-drug interaction guideline. The restrictions of 
concomitant use of acid-reducing agents, including the prohibition of proton pump inhibitors 
(PPI), are also removed, considering the accompanying gastric s ymptoms which are often seen 
in HCC patients. T his removal is supported by the preliminary  GastroPlus PBPK modeling 
results using the available human PK data from the FGF401 single agent -Phase I part of the 
study . These results suggest minimally  negative impact on FGF401 exposures with PPI co-
administr ation.
Other minor changes and corrections were made throughout the protocol for consistency and/or 
clarifications
.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike thr ough red font for deletions and red underline for insertions.
All relevant Sections, Tables and Figures throughout the protocol were updated to include 
the addition of FGF401 in combination with PDR001 and to distinguish between FGF401 
administered as single agent or in combination with PDR001. 
The following new sections, tables and appendices have been added for PDR001: Section 
1.2.2 and Section 1.2.3 -Overview of PDR001 and of the FGF401 and PDR001 
combination; Section 6.1.2- Ancillary  treatments; Table 6-5- criteria for interruption and 
re-initiation of PDR001; Section 14.9 -Guidelines for immune -related Response Criteria 
(irRC); Section 14.11 -Recommended management algorithms for PDR001 -suspected 
toxicities. 
Section 1.2.1.2 has been updated with FGF401 clinical experience.
Section 2- Rationale, Section 4 -Study  design, Section 5 -Population, Section 7.1.1-
Molecular pre -screening, , Section 10- Statistical Methods and 
data anal ysisand Tables 7 -1 and 7- 14 , have been updated to remove molecular pre -
screening requirements from HCC patients (Group 1 and Group 2) in FGF401 single agent 
Part II.
Specific requirements for Japan have been added in Section 5.2- Inclusion criteria and 
Section 7.1- Study  Flow and visit schedule
Clarification for the possibility  to introduce a BID dosing regimen for FGF401 has been 
added in Section 4.1 -Study  design and Section 6.1.1 -Dosing regimen. 
Section 4.1 -Description of study , Tables 7-1, 7- 3 and 7 -4 and Section 9.3- Data collection: 
references to the optional companion protocol have been removed since the requirements 
to study  the mechanisms of resistance to study  treatment are now included in this 
amendment.
Section 5.3- Exclusion criteria: The methods of highl y effective contraception have been 
updated and clarification of the post -menopausal clinical profile was added. I n addition, 
the prohibition of treatment with proton pump inhibitors (PPI) has been deleted.

Novartis Confidential Page 23
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Section 6.4.2 and Section 6.4.3: The restri ctions of concomitant use of acid -reducing 
agents, including the prohibition of PPI , have been removed. 
Section 7.1.4 has been updated to clarify  patient’s discontinuation from study  treatment; 
new sections (Section 7.1.5 and Section 7.1.7) have been adde d to describe the withdrawal 
of consent and lost to follow -up.
Section 8.2.2 has been updated to include clarifications on SAE reporting.
Section 8.6- Steering Committee, has been updated to include the planned interim anal ysis 
for the Phase II part of the FGF401 and PDR001 combination. 
Section 11.5 has been updated to reflect latest procedures on the publication of study  
protocol and results.
Section 14.4- list of concomitant medications that are prohibited and to be used with 
caution has been updated based on the latest internal 
DDI guideline .
Section 14.10 has been added to include the Bay esian model used for the combination 
treatment.
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Comm ittee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

Novartis Confidential Page 24
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Amendment 03
Amendment rationale
The purpose of this amendment is to add the amylase and lipase measurements to the local 
chemistry  laboratory  parameters collection plan in order to align with the criteria for dose-
limiting toxicities specified in the protocol.
Changes to the protocol
Table 7-4, Local clinical laboratory  parameters collection plan , has been updated to addamylase 
and lipase under Chemistry  test category .
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
IRB/IEC/REB A pproval
A copy of this amended protocol will be sent to the Institut ional Review Board 
(IRBs)/Independent Ethics Committee ( IECs) and Health Authorities.
The changes described in this amended protocol require I RB/IEC approval.
The changes herein affect the Informed Consent. Sites are required to update andsubmit for 
appro val a revised Informed Consent that takes into account the changes described in this 
protocol amendment.
Amendment 02
Amendment rationale
The rationale for the amendment is to compl y with the health authority  suggestion to include 
the following:
clarifica tion of the starting dose planned for exploratory food effect cohort
clarification of the prophy lactic treatment with anti -emetics in cy cle 1
[For Japan only]
specification of the informed consent procedure when patient is under the age of 20 years
specifi cation of the additional ECG collection on Cy cle 1 Day  1 for Japanese patients only
Changes to the protocol
Section 4.1, Description of study  design, specifically  for exploratory  food effect cohort has been 
updated to indicate the starting dose of the fed cohort under different circumstance.
Section 6.3.3, Anticipated risks and safety  concerns of the study  drug, has been updated to 
specify  the proph ylactic treatment with anti -emetics is prohibited in cy cle 1.
Table 7-6, Central ECG collection plan, has been updated to add additional triplicate 12-lead 
ECG collection at 2 hour post -dose on Cy cle 1 Day  1.

Novartis Confidential Page 25
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Section 11.3, Informed consent procedures, has been updated to indicate the Japan specific 
requirement of legal representative when patient is under the age of 20 years.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
IRB/IEC/REB A pproval
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee ( IECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
Amendment 01
Amendment rationale
The rationale for the amendment is tocomply with health authorit y request toupdate the 
definition of Grade 3 diarrhea and Grade 3 h ypercalcemia based on the NCI CTCAE.
Additionally , typo corrections have been made.
Changes to the protocol
Table 6-2, Criteria for defining dose-limiting toxicities have been modified based on the 
CTCAE and therefore footnotes b and c have been deleted.
Table 7-9 and Table 7-10, Pharmacokinetic blood collection log for BID administration, have 
been updated to correct ty pos of dose ref erence ID.
Table 18-1, Criteria for interruption and re-initiation of FGF401 treatment for diarrhea 
management has been modified based on the CTCAE and therefore footnote b has been deleted.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using 
strike through red font for deletions and red underlined for insertions.
IRB/IEC/REB A pproval
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee ( IECs)and Health Authorities .
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informe d Consent that takes into account 
the changes described in this protocol amendment.

Novartis Confidential Page 26
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
1 Background
1.1 Overview of disease pathogenesis, epidemiology  and current 
treatment
Hepatocellular carcinoma (HCC) is the fifth most common form of cancer worldwide and the 
third most common cause of cancer -related deaths. HCC often occurs in the background of a 
cirrhotic liver. Most cases of HCC (approximately 80%) are associated with chronic hepatitis 
B virus (HBV) or hepatitis C virus (HCV) infections ( Raza A et al 2014 , El-Serag HB 2012 ). 
Potentially  curative therapies, such as surgical resection, liver transplant or other local 
treatments, result in survival rates of between 50-70% at 5 years for patients with early stage 
HCC (Llovet and Bruix 2008). However, despite advances in diagnostic techniques and 
increased surveillance, the majority  of HCC cases present with advanced, inoperable tumors.
Untreated patients with intermediate stage HCC (multinodular asymptomatic tumors without 
an invasive pattern) have a median survival of 16 months. Treatment with transarterial 
chemoembolization (TACE), where the chemotherap y agent is directly  introduced into the 
vessels feeding the tumor, followed by embolization, extends the median survival of this group 
of patients to approximately  19-20 months ( Llovet and Bruix 2008).
HCC is considered to be a chemo -resistant tumor. Despite reports of partial responses to 
doxorubicin in a small number of patients, 
no clear survival advantage has been shown with 
this agent, and its use is limited due to its toxicity in patients with liver function impairment 
(Lopez et al 2006). TACE was the only treatment that had been associated with prolonged 
survival in intermediate HCC until the approval of the multikinase inhibitor sorafenib, which 
targets intracellular Raf serine/threonine kinase isoforms including Raf -1 (or C-Raf), wild-type 
B-Raf and mutant B -Raf and other cell surface kinases.
Two phase III studies have been published that compare sorafenib to placebo in advanced HCC 
patients in the first-line setting (i.e. patients with no prior systemic therapy ): The “SHARP” 
study  was conducted primarily  in non- Asian countries and reported a median time to tumor 
progression (TTP) and overall survival (OS) of 5.5 months and 10.7 months, respective ly, in 
the group of patients treated with sorafenib (Llovet et al 2008). The second study  was conducted 
in Asia-Pacific region, reported median TTP and OS of 2.8 and 6.2 months, respectivel y (Cheng 
et al 2009 ).
The patterns of treatment for HCC are different in various parts of the world and may have 
accounted for the difference in OS and TTP results observed in the SHARP study  and the Asia -
Pacific sorafenib study . 
1.2 Introduction to investigational treatment s
1.2.1 Overview  of FGF401
FGF401 is a Biopharmaceutics classification system (BCS )class II compound with low 
solubility  at pH 6.8, high permeability  and 
low to moderate food effect risk.  FGF401 is a highly  
selective and potent FGFR4 inhibitor through binding the ATP site of FGFR4. FGF401 inhibits 
HCC and gastric cancer cell lines expressing FGFR4, KLB and FGF19 (triple positive) with 

Novartis Confidential Page 27
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
excellent selectivity  over non-sensitive cell lines. In xenograft models, FGF401 induces 
regression/stasis in triple positive HCC tumors. In addition to expression by triple positive 
tumors, FGF19 is also induced in the ileum in response to bile acids
, circulates in the human 
body  and might stimulate the growth of the tumors expressing FGFR4 and KLB (double 
positive ).Considering thesupportive preclinical data, FGF401 provides a unique opportunit y 
to target solid tumors and specificall y HCC characterized by double or triple biomarkers 
positiv ity.

Novartis Confidential Page 28
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 29
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
1.2.1.2 FGF401 clinical experience
This first in human study started enrollment on 29-Dec-2014. A s of 30-May- 2016, a total of 
42patients have been treated with FGF401 as single agent at different dose levels from 50 mg
to150mgQD under fasted or fed (light meal) conditions .
Four DLTs were observed in three out of 33patients that were included in the dose determining 
analysis set. The DLTs were :ALT increase in one patient at 50 mg QDfasted ;AST increase in 
one patient at 150mg QD fasted ; AST and AL T elevation, which was considered two -DLTs in 
one patient at 150mg QD fasted . The maximum tolerated dose (MTD) for FGF401 as single 
agent was not reached. The recommended phase II dose (RP2D) for FGF401 as single agent 
wasdetermined to be 120 mg QD under fasted condition .
Overall, the most common AEs (
≥ 15%) considered possibly  related to FGF401 were diarrhea 
(66.7%), AST increase (40.5%) and ALT increase (38.1%) including Grade 3 or Grade 4 events 
experienced b y one (2.4%) , seven (16.7%) and six (14.3%) patients respectively .
Preliminary  results from the dose escalation part of the stud y demonstrated objective responses 
in 3 out of 39 patients (7.69%) with HCC (2 confirmed and 1 
non-confirmed partial response 
[PR]). None of the patients with objective responses had detectable FGF19 expressi on by  RT-
PCR. In addition, exploratory  studies performed to date have not identified an association 
between tumor metrics and either FGF19, FGFR 4, or KLB expression. These observations 
suggest that HCC patients have the potential to benefit from the FGF401 treatment irrespect ive 
of their FGF19, FGFR 4 orKLB expr ession level, as measured b y RT -PCR
.
1.2.1.3 Clinical pharmaco kinetics and metabolism
As of the PK cut -off date 04-Feb- 2016, a total of 31 patients were administered FGF401 orall y 
as a capsule atdoses ranging from 50 to 150 mg QD either fed (light meal) or fasted. FGF401 
was well absorbed, with Tmax ranging from 1.0 to 2.9 hours. Absorption was independent of 
dose and unchanged after multiple oral doses . FGF401 has a short to moderate T1/2, which 
ranged from 3.9 to 7.5 hours, a
nd also appeared to be independent of dose and time. Plasma 
drug expos ure of FGF401 increased with increasing doses with a trend toward under 
proportional ity. Drug accumulation of FGF401 following multiple dosing was minimal. No 
substantial exposure difference was observed in clinic between fed (light meal) and fasted 
cohorts at 80 mg. 
The plasma concentrations of FGF401 within a stead y-state dosing interval almost all exceeded 
the preclinical in vivo pFGFR4 I C90 value, as well as the in vitro cellul ar pFGFR4 IC90 at the 
starting dose of 50 mg. 

Novartis Confidential Page 30
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Human metabolism, excretion and clinical drug-drug interaction studies have not yet been
performed .  
 
 
 
1.2.2 Overview  of PDR001
PDR001 is a high-affinity , ligand -
blocking, humanized anti-PD-1 IgG4 antibody  that blocks 
the binding of Programmed Death -Ligand 1 (PD-L1)and Programmed Death Ligand -2 (PD-
L2)to Programmed Death -1 (PD-1). PDR001 recognizes PD-1 in cynomolgus monkey s and 
shows functional activity in vitro/ex vivo . 
1.2.2.2 PDR001 Cli nical experience
The first in human phase I/II 
study  [CPDR001X2101] started enrollment on 27 April 2015 and 
is ongoing in patients with advanced malignancies. The dose escalation part of the study  was 
completed with a total of 58 patients treated at the do selevels of 1, 3 and 10 mg/kg every  two 
weeks and 3 and 5 mg/kg ever y four weeks . No patient experienced a D LT. The PK anal ysis of 
the dose escalation data using a population approach and the expected wide therapeutic index  
of PD-1 inhibitors support the use of flat dosing for PDR001 of 400 mg every  four weeks or 
300 mg every  three weeks ( Q3W ). The expected PDR001 Ctrough concentrations using either 
dosing regimen exceed the EC50 for PD-1 blockade by approximately  75-fold in an ex vivo 
assay  in peripheral blood mononuclear cells (PBMCs ). Based on the available PK and safet y 
data, the RP2D of PDR001 has been declared as 400 mg i.v. every  four weeks or 300 mg i.v. 
Q3W for combination treatment regimens for which this may be more convenient. 

Novartis Confidential Page 31
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
PDR001 is current ly being studied alone or in combination with other agents in ongoing p hase 
I/Ib/II clinical trials. The preliminary  toxicity  profile appears to be similar to that of marketed 
inhibitors of PD-1 including the type, severity and frequency  of occurrence of immune -
mediated adverse events. As observed with other PD -1 inhibitors, immune -mediated toxicities 
observed with PDR001 are reversible in many cas es. In some cases, they may require treatment 
with corticosteroids. Certain toxicities are expected to be lifel ong and may  require replacement 
therap y with hormones, for example in the case of hypothy roidism. The most frequent suspected 
AEs (data cut-off: 17-Dec- 2015 ) included diarrhea (8 patients, 13.8%), fatigue (8 patients, 
13.8%), nausea (6 patients, 10.3%), hypothy roidism (5 patients, 8.6%), pruritus (5 patients, 
8.6%), vomiting (4 patients, 6.9%), anemia (3 patients, 5.2%), constipation (3 patients, 5.2%), 
decreased appetite (3 patients, 5.2%), dry  mouth (3 patients, 5.2%) and maculopapular rash (3 
patients, 5 .2%).
Based on the preliminar y data, PDR001 was well tolerated with a safet y pro file similar to those 
of other marketed anti- PD-1 antibodies. 
1.2.3 Overview  of FGF401 and PDR001
1.2.3.1 Non clinical and clinical experience with the FGF401 and PDR001 
combination
There is no experience with this combination in the non- clinical and clinical setting.
1.2.3.2 Potential of drug interactions
Specifi c studies to investigate DDI have not been conducted with FGF401 and PDR001. As an 
antibody , PDR001 is eliminated through protein catabolism and target -mediated disposition.
Cytokines produced by activated ly mphocy tes may  impact the levels of Pgp and the activity  of 
P450 enzymes. The clinical relevance of cytokines impacting levels of Pgp and P450 with 
administration of PDR001 is unknown but considered unlikely. FGF401 is a small molecule 
eliminated mainly  by hepatic metabolism with both phase I and II enzy mes involved.
Pharmacokineti c DDI between FGF401 and PDR001 is therefore not expected .
1.2.3.3 Potential overlapping toxicities
From the preclinical safety  profile of FGF401 and PDR001 no overlapping target organ toxicit y 
is expected. However, preliminary clinical data from the ongoing single agent CFGF401 X2101
study suggests that FGF401 associated toxicities may overlap with those of PD-1 inhibitors 
including PDR001 observed in the clinic. 
Potential overlapping toxicit ies include diarrhea and increased AST/ALT, which have been 
reported forPD-1 inhibitors including PDR001. Lipase increase is another potential 
overlapping toxicity , which although not reported for PDR001 ,hasbeen reported for other PD-
1 inhibitors.

Novartis Confidential Page 32
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
2 Rationale
2.1 Stud y rationale and purpose
FGF19 has unique specificity  for FGFR4 . In addition, cellular co-expression of KLB is required 
for FGF19 binding to FGFR4 and for the subsequent intracellular signaling . Therefore, the 
distribution and the relative levels of FGFR4 and KLB dictate the organ/tumor of FGF19 action
(Lin et al 2007 , Lin et al 2012 ).
FGF19 -FGFR4 pathway  play s an important homeostatic physiological role in the regulation of 
bile acid homeostasis
. The expression of FGF19 is induced in the ileum in response to bile acids 
that are released into the intestinal lumen after feeding. FGF19 then circulates to the 
liver where 
FGFR4 and KLB are highly  co-expressed to suppress CYP7A1, the rate-limiting enzy me for 
bile acid synthesis. FGF19 also limits bile acid release into the intestine by triggerin g 
gallbladder filling. In this manner, FGF19 serves as a key regulator in thepostprandial negative 
feedback loop modulating bile acid sy nthesis and release ( Lin et al 2012, Mellor 2014).
Recent data suggests that the FGF19 -FGFR4 signaling network may be a key driver in certain 
forms of HCC, making the pathway  an interesting, emerging molecular target for potential 
therapeutic intervention (Ho et al 2009 , Miura et al 2012 , Poh et al 2012). 
In vivo, the ectopic expression of FGF19 in the skeletal muscle in mice promotes hepatocy te 
proliferation and induces HCC formation in a paracrine fashion (Nicholes et al 2002) a nd an 
anti-FGF19 monoclonal antibody  prevents tumor formation (Desnoy ers et al 2008). Further, 
when FGF19 transgenic mice were bred with FGFR4 knockout mice, they failed to develop 
liver tumors highligh ting the relevance of FGFR4 in FGF19 -
driven HCC ( French et al 2012 ).
Several publications  that FGF19 aberrant expression, occurring as a 
consequence of focal gene amplificatio n (11q13) or by some other yet unknown mechanism, 
occurs in subsets of HCCs, where FGFR4 and KLB are also co-expressed. In this setting, FGF19 
leads to constitutive FGFR4 activation by acting in an autocrine fashion (Sawey  at el 2011;
Guagnano et al 2012 ).
Other publications indicated that a subset of HCC patients characterized by elevated FGFR4 
and/or FGF19 expres sion in the tumors have a poorer prognosis and might be amenable to anti -
FGFR4 therap y (Ho et al 2009
, Miura et al 2012 , Poh et al 2012).
FGF401 is a highly  selective and potent FGFR4 inhibitor ,which will be developed in patients 
with HCC or other solid malignancies characterized by positive expression of FGFR4 and KLB. 
The initial clinical strate gy for the FGF401 development was driven by the following 
assumptions:
1.Clinical activity  of FGF401 will be restricted to patients with double (FGFR4+andKLB+) 
or triple (FGFR4+andKLB+andFGF19+) positive solid tumors, and it is assumed that 
HCC will ac count for >9 5% of the patients enrolled in the phase I . The incidence of 
double positiv ityin other solid tumors is very  low (1 -2%).Within the HCC patient 
population however , approximate ly30-40% of tumors are double positive and around 10-
15% are triple p ositive. 
2.FGF19 secreted from non
-tumor cells, e.g. ileum, stromal cell, might stimulate the growth 
of the double positive tumors and it might act as agrowth factor in triple positive tumors.

Novartis Confidential Page 33
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Preliminary  results from the dose escalation part of thisstudy  demonstrated objective responses 
in 3 out of 39 patients (7.69%) with HCC (2 conf irmed and 1 non -confirmed PR).  
 
 
hese observations suggest that HCC 
patients have the potential to benefit from the FGF401 treatment irrespective of their FGF19, 
FGFR4 or KLB expr ession level, as measured b y RT-PCR . 
Additionally , preliminary  results showing objective clinical activity in 2 out of 8 patients (1 
unconfirmed PR and 1 stable disease [SD])were recently  reported in a clinical study  with 
anothe r FGFR4 inhibitor in advanced HCC patients. These patients were FGF19 positive by 
IHC (Kim ENA 2016). Collectively  these data further implicate the FGFR4 pathway  as a driver 
in HCC and suggest that the FGFR4 inhibition may have a role in the treatment of HCC.
Recent clinical studies have h ighlighted the potential of targeting the PD-L1/PD -1 pathway  in 
HCC. A phase I /II stud y of Nivolumab, a monoclonal antibody  that results in PD -1 checkpoint 
inhibition, showed durable responses in advan ced HCC; the objective response rate was 16% 
and the 9 -month overall survival rate was 71% ( Bruno ASCO 2016 ). This study also suggested 
that Nivolumab has a manageable safet y profile in HCC, including i n those patients with HBV 
and HCV infections. 
Together , these clinical results suggest that the combined inhibition of the FGFR4 signal with 
FGF401 and the inhibition of PD-1with the checkpoint inhibitor PDR001 may lead to 
additional clinical benefit for patients with advanced HCC.
In this study  the safet y and clinical activity  of the FGF401 and PDR001 combination will be 
evaluated in parallel to FGF401 single agent, in an unselected HCC population . Associative 
studies of immunomodul atory  and FGF pathway  expression changes in tumor and blood 
samples with clinical outcome will be retrospectively  explored.
2.2 Rationale for the study  design
2.2.1 FGF401 single agent
Phase I part
The design of the phase I, open label, dose finding part was chosen in order to establish the 
MTD and/or RP2D of FGF401 in patients with HCC or solid tumors characterized by  positive 
expression of FGFR4 and KLB. The dose escalation will be guided by  a Bay esian hierarchical 
logistic regression model (BHLRM). This model estimates the relationship between dose and 
the probability  of a patient experiencing a DLT in fasted condition (stratum 1) and in fed 
condition (stratum 2). The BHLRM will allow for both full exchangeability  between the strata 
parameters and non-exchangeabili ty between strata parameters. In this way the model has the 
flexibility  to allow for both the case in which the dose-toxicity  relationship is similar for the 
two strata, and the case in which the relationship is different for each. In the event that the 
relationship is similar, then the model structure will allow borrowing of information between 
the two strata, which will in turn lead to improved estimation of the dose -toxicity  relationship.

Novartis Confidential Page 34
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
This model is a hierarchical adaptation of the Bayesian logistic regression model (BLRM), a 
well-established method to estimate the MTD and/or RP2D in cancer patients. The BHLRM 
will be guided by  the escalation with overdose control (EWOC) principle to control the risk of 
DLT in future patients on study . The use of Bayesian response adaptive models for small 
datasets has been accepted by EMEA (“Guideline on clinical trials in small populations”, 
February  1, 2007) and endorsed by  numerous publications ( Babb et al 1998 ,Neuenschwander 
et al 2008, Bailey  et al 2009), and its development and appropriate use is one aspect of the 
FDA’s Critical Path Initiative.
The decisions on new dose levels are made by the Investigators and Novartis study  personnel 
and will be based upon the recommendations made by the BHLRM, patient tolerability  and 
safet y, PK,  and efficacy information available at the time of the decision ( Section 6.2.3).
Phase II part
Once the MTD and/or RP2D has been defined, a phase II part will open at the MTD or RP2D 
to further characterize safety , anti-tumor activity  and PK profile of FGF401 at this dose. The 
phase II part will include 3 
Groups as summarized in Figure 4-1, each having specific 
enrollment criteria.
Group 1 will enroll HCC patients from Asian countries
Group 2 will enroll HCC patients from non -Asianregions
Group 3 will enroll patients with other solid malignancies regardless of the ge ography
Epidemiology  and preclinical data supports the feasibility  and activity  of FGF401 in HCC 
patients
,respectively . Considering that the treatment guidance for HCC (specifically  the 
locoregional treatments such as percutaneous hepatic arterial emboliz ation, radiofrequency 
ablation, and percutaneous interventional therap y) are different in various parts of the world 
reflect edin the difference in OS and TTP results observed in the SHARP study  and the Asia-
Pacific sorafenib studies, subgrouping based on the geograph y and corresponding patterns of 
treatment will be implemented in this study . The HCC patients recruited in Asian countries will 
be enrolled in Group 1 and the HCC patients from non -Asianregions will be enrolled in Group 
2.
For Japan, the epide miology  pattern of hepatitis viral infection (HCV infections) is more similar 
to the non -Asianregions instead of other Asian countries (HBV infections) ( Bosch et al 2004 ). 
However, the patterns of treatment for locall yor advanced HCC may account for the difference 
in efficacy  results. I
n some clinical studies, Japan has been stratified into the Asian group due 
to the similarity  in term oflocoregional treatment (number of TACE ) (Lencioni et al 2012, 
Johnson et al 2013 ). In this study , considering the relevance of the locoregional treatment , Japan 
will be sub grouped into Group 1 (Asian patient s).
Group 1 and Group 2 will focus on characterizing the activit y and tolerability  of FGF401 in 
HCC patients irrespective of their FGFR4, KLB and FGF19 expression
. 
Group 3 will focus on characterizing the activity  and tolerability  of FGF401 in any  other s olid 
tumor patients with double positive expression. Preclinical data supports the activity  of FGF401 
in one of the gastric cancer cell lines and may  potentially  work on other tumor ty pes based on 
the mechanism described in Section 2.1.

Novartis Confidential Page 35
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Exploratory  food effect cohort
. Within the p hase I part, the
exploratory  food effect cohort (s)will be included to assess the effect of food uptake on FGF401 
PK properties and safet y profiles in the patients.
According to the human physiology, w hen a meal is ingested, gallbladder empty ing occurs and 
delivers bile acids to the small intestinal lumen. This physiological release of bile acids might 
be increased byFGF401 administered under fed condition. Therefore, the food effect 
exploration coupled with laboratory analysis described in Table 7-1will also help to understand 
the food effect on  AEs under different feeding 
conditions. 
2.2.2 FGF401 in combination w ith PDR001
Phase I part
Thedesign of the phase I, open label, dose finding part was chosen in order to characterize the 
safet y and tolerabilit y of FGF401 in combin ation with PDR001 in patients with advanced HCC 
and determine a RP2D or MTD. The dose escalation will be 
guided by a Bayesian Logistic 
Regression Model (BLRM) . The use of Bayesian response adaptive models is a well-established 
method to estimate the MTD an d/or RP2D in cancer patients as described above and in Section 
6.2.3. 
Phase II PartThe Phase II part of the FGF401 in combination with PDR001 will start once a 
MTD and/or RP2D is identified. This part has a staged study  design. Initially  the study  will 
enroll HCC patients without molecular selection. If the clinical activity in this unselected 
population is below the pre-defined target range ,the clinical activity  will befurther evaluated 
in sub
-groups of patients, based upon FGF19 expression and/or FGF19 pathway activation to 
inform next decisions for clinical development (see Section 4.2). This design provides the 
opportunity  to evaluate the combinat ion in a molecular pre- selected HCC population, should 
the combination have limited activity  in an unselected population. Considering the difference 
in OS and TTP results observed in the SHARP study  and the Asia-Pacific sorafenib studies, 
sensitivity  anal yses b y geographic region will be explored.
2.3 Rationale for dose and regimen selection
The starting dose and regimen of FGF401 single agent is 50 mg once daily  based on the 
preclinical safet y and tolerability  data.  
 
 
  
 
 
 
 

Novartis Confidential Page 36
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
For the dose escalation part of the FGF401 and PDR001 combination ,the starting dose is 80mg 
QD for FGF401 and 300mg Q3W for PDR001.
The RP2D for single agent FGF401 is 120mg QD admi nistered under fasted condition. The 
dose of 80mg QD for FGF401 was selected for the combination as itis one dose level below 
the RP2D.
The dose of 300mg Q3W for PDR001, as a flatfixed dose, was selected as this is the RP2D for 
single agent PRD001 declared in the [CPDR001X2101 ]study .
The selected 
starting dose of FGF401 on a continuous daily  schedule in combination with the 
fixed dose of PDR001 administered every  3 weeks is supported by the risk assessment .This 
includes that the starting dose meets the EWOC with the new combination BLRM that leverages 
single agent FGF40 1 and PDR001 dose-DLT data. Although pharmacokinetic DDI between 
FGF401 and PDR001 is not expected (Section 1.2.3.2 ), the exposure of FGF401 and PDR001 
will be monitored in the study to assess an y potenti al DDI . 
3 Objectives and endpoints
Objectives and related endpoints are described in Table 3
-1below.

Novartis Confidential Page 37
Amended Protocol Version 0 5 (Clean) Protocol No. CFGF401X2101
Table 3-1 Objectives and related endpoints
Objective Endpoint Anal ysis
Primary Refer to Section 10.4
Phase I part
To estimate the MTD and/or RP2D of FGF401
single agent and in combination with PDR001Incidence rate and characteristics of DLT during the first cycle of dosing for FGF401 
single agent and during the first two cycles of dosing for FGF401 in combination with 
PDR001
Phase II part
To investigate the anti-tumor activity of FGF401
single agent and in combination with PDR001FGF401 single agent: Group 1 and Group 2: Time to progression (TTP); Group 3:
Overall response rate (ORR), bas ed on local assessment per RECIST v1.1
FGF401 in combination with PDR001: ORR based on local assessment per RECIST 
v1.1. 
Secondary  (Phase I and II part) Refer to Section 10.5
To characterize the safety and tolerability of 
FGF401 single agent and in combination with 
PDR001Safety: Incidence and severity of AEs and SAEs, including changes in laboratory 
values, vital signs andECG s
Tolerability: Dose interruptions andreductionsRefer to Section 10.5.2
To further investigate the anti -tumor activity of 
FGF401 single agent and in combination with 
PDR001Phase I part
BOR, ORR, DCR, TTP and OS, based on local assessment per RECIST v1.1 for 
FGF401 sing le agent or RECISTv1.1. and irRC for the FGF401 and PDR001 
combination
Phase II part- FGF401single agent
Group 1 and Group 2: BOR, ORR, OS and DCR, based on local assessment per 
RECIST v1.1
Group 3: BOR, DCR, OS and PFS, based on local assessment per RECIST v1.1
Phase II part- FGF401 and PDR001 combination
TTP, PFS, OS, BOR, DOR and DCR, based on local assessment per RECIST v1.1. 
and irRCRefer to Section 10.5.1
To characterize the PK properties of:
-FGF401 single agent and in combination with 
PDR001 
-PDR001 in combination with FGF401 Plasma concentration of FGF401 , PDR001 and PK parameters including but not 
limited to C max, Cmin, AUC inf, AUC last, AUC tauand T 1/2Refer to Section 10.5.3
To assess immunogenicity of PDR001 Presence and/or concentration of anti -PDR001 antibodies Refer to Section 10.5.3

Novartis Confidential Page 38
Amended Protocol Version 0 5 (Clean) Protocol No. CFGF401X2101
Objective Endpoint Anal ysis
Phase I part -FGF401 single agent
To evaluate food effect on FGF401 exposure 
and safety profile● Plasma concentration of FGF401 and PK parameters when dosing under fed 
condition
● Safety: Incidence and severity of AEs and SAEs, including changes in laboratory 
values, vital signs andECG swhen dosing under fed conditionRefer to Section 10.5.3.2.3

Novartis Confidential Page 39
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
4 Study  design
4.1 Description of study  design
This study  has been designed as a phase I/II, multi- center, open -label study  starting with a phase 
I dose escalation part followed by a phase II dose expansion part. The study treatment will be 
taken until patient experiences unacceptable toxicity , progressive disease and/or treatment is 
discontinued at the discretion of the investigator or patient’s withdrawal of consent. Figure 4-1
summarizes the study  design overall while Figure 4 -2provides additional details for the study 
design for 
the FGF401 and PDR001 combination .
FGF401 will be administered on a continuous once daily (QD) dosing regimen for both FGF401 
single agent and in combination with PDR001 parts . However, based upon emerging FGF401 
clinical safet y, efficacy and related exposure -response anal ysis data, theFGF401 dose regimen 
may change from QD to BID at an y time during the study for all newl y enrolled patients.
Figure 4-1 Study  design
*refer to Figure 4 -2for additional detailsMolecular pre-screen/FGF 
single agent ( newly
obtained tumor samples ) 
Phase I & Phase II-Group3 
onlyPhase I Phase II
FGF401 single agent
HCC/Solid tumor
FGFR4++ KLB+
Dosing in fasted stage
FGF401 single agent
HCC/Solid tumor
FGFR4++ KLB+
Dosing in fedstageFGF401 
single agent
MTD/RP2DFGF401 single agent -Group 2:
HCC, non -Asian regions (N~40)
withretrospective analysis for
FGFR4/KLB/FGF19FGF401 single agent -Group 1:
HCC, A sian countries (N~40)
withretrospective analysis for
FGFR4/KLB/FGF19
FGF401 single agent -Group 3:
Solid malignancies , regardless ofthe
geography (N~20)
FGFR4++ KLB+
FGF401+ PDR001 combination*
HCC  ( N ~35 to 55)
Stage 1 unselected HCC → Stage 2 molecularly 
selected HCC (based on analyses results after 
Stage 1)combination
MTD/RP2DFGF401 in combination
with PDR001
unselected HCC patients

Novartis Confidential Page 40
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
4.1.1 FGF401 single agent
Phase I part
In the phase I  part, patients with HCC or other advanced solid tumors characterized by positive 
FGFR4 and KLB expression will be enrolled. Patients will be tested for the expression of 
FGFR4 and KLB in the molecular pre -screening of this study  to confirm the eligibility, refer to 
Section 
7.1.1 for details. A BHLRM with EWOC will guide the dose escalation to determine 
the MTD and/or RP2D. At least 21evaluable patients should be treated in the phase Ipart, for 
the model to have reasonable operating characteristics relating to its MTD and/or RP2D 
recommendation. If significant activity  is seen early  in the phase I dose escalation, then a 
recommended dose may be identified and the phase II Groups may be initiated without 
determination of the MTD; therefore fewer than 21 patients may  be required.
Phase II part
Once the MTD and/or RP2D is declared, additional patients with advanced HCC or other solid 
tumors bearing positive FGFR4 and KLB expression will be enrolled into 3 
Groups to assess 
the preliminary  anti-tumor activit y of FGF401 in Phase II dose expansion part. HCC patients 
will be enrolled irrespective of the FGFR 4 and KLB expression which will be analyzed 
retrospectivel y. For patients with other solid tumors ,positive FGFR4 and KLB expression is 
required for enrollment. HCC patients recruited in Asian countries will be enrolled in Group 1 ;
HCC patients from non-Asianregions will be enrolled in Group 2; patients with other solid 
malignancies regardless of the geograph y will be enrolled in Group 3. 
Each group within the phase II dose expansion part will target a different number of patients. 
Details of the sample size calculations leading to the patient numbers are provided in Section 
10.8. Group 1 and Group 2 will enroll around 40 patients each and Group 3 will enroll 
approximate ly20 patients.
Exploratory  food effect cohort
Within the p hase I part, the exploratory  food effect cohort (s)will be included to assess FGF401 
PK properties, safet y and tolerability  in patients under fed conditions. This food effect cohort 
will start when  clinical activity  is 
observed and will be conducted in parallel with the phase I fasted dose escalation. If at this time, 
the MTD under the fasted condition hasnot been declared yet,the starting dose of the fed cohort 
will be equal or lower than the highest dose shown to be tolerated during the first cycle in the 
cohort of fasted patients. I
fat this time, the MTD under fasted conditions has been declared, the 
starting dose of the fed cohort will be lower than the MTD under the fasted condition. For both 
scenarios, the starting dose of the fed cohort will satisfy  the escalation with overdose control 
(EWOC) criterion. The fed dose escalation will be guided by a BHLRM . The decision to 
continue wi th fed and/or fasted condition in t he phase I and phase II part(s) will be made by the 
Investigators and Novar tis study  personnel based on the tolerability, safety profile , PK, PD and 
efficacy  information available at the time of the decision. The dosing regimen and 
administration requireme nts are outlined in Section 6.1.1.
PK samples will be collected following the same PK collection schedule selected for the phase 
I part of the stud y (refer to 
Table 7-7 and Table 7 -9).

Novartis Confidential Page 41
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
4.1.2 FGF401 in combination w ith PDR001
Figure 4 -2summarizes the study  design for FGF401 in combination with PDR001.
Figure 4-2 Study  design -FGF401 in combination with PDR001
Phase I part
In the Phase I part cohorts of patients will be treated with FGF401 incombination with a fixed 
dose of PDR001 until the MTD is reached or a recommended Phase II dose is established. The
FGF401 dose will be increased and the PDR001 dose will remain constant. For each untested 
dose level the administration of the first dose of the study  treatment will bestaggered by 24 
hours for the first three patients. The dose escalation will be guided by  a BLRM following the 
EWOC principle. A minimum of 12 patients are required in the phase I part for the model to 
have reasonable operating characteristics to determine the MTD of FGF401 in combination 
with PDR001 . Ifsignificant activity  is seen early  in the phase I dose escalation, then a 
recommended dose may be identified and the phase II part may be initiated without 
determination of the MTD; therefore fewer than 12 patients may  be required .
Phase II part
The Phase II part of this study  has a 2-stage design.In Stage 1, approximately 35 HCC patients 
will be enrolled without molecular selection (e.g. irrespective of their FG FR4, KLB or FGF19 
expression). Upon completion of the Stage 
1enrollment, an interim analy sis will be performed 
to assess the clinical activity  in this population. The phase II part will be stop ped at Stage 1, if 
the criteria for substantial efficacy  as described in Section 4.2 and Section 10.7.2 are met.Additional HCC patients
enrolled based on 
positive/negative
FGF19 expression and/or 
FGF19 pathway  activation FGF19 positive
N ~25
If FGF19 positive 
patients from 
Stage 1 < 25FGF19 negative
N ~25
If FGF19 negative 
patients from Stage 
1 < 25unselected HCC 
FGF401 + 
PDR001Unselected HCC 
withretrospective analysis forFGF19 pathway activation
N~35MTD/
RP2DPhase II Phase I
Stage 2Stage 1
Interim analysis in unselected 
HCC population
Efficacy evaluation 
criteria NOT satisfied 
FGF19 pathway activation
sub-group analysis
and/orFutility criteria NOT satisfied Efficacy 
evaluation 
criteria 
satisfied 
Futility criteria 
satisfied Enrollment 
completed
Enrollment 
completed

Novartis Confidential Page 42
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Should these criteria not be met, sub-group analy sis, based upon FGF19 expression and/or 
FGF19 pathway  activation will be performed .
Based on the futility  criterion specified in Section 4.2 and Section 10.7.2, if the efficacy  in a
sub-groupis insufficient, no further patients will be enrolled to that subgroup . Otherwise, 
enrollment will continue until a total of approximately  25 patients are identi fied for the specific 
sub
-group (s) in order to further assess the efficacy . At this time, molecular pre-screening will 
be employ ed in order to identify  the appropriate molecular sub- group (s).
The sub- group anal ysis will be based upon FGF19 pathway expression and/ or activation.  T he 
molecular sub-group will be defined based upon emerging molecular data and associative 
analyses 
of the FGF401 single agent parts of the study and the definition for each sub-group 
will be available at the time of the interim analysis. If based on these associative studies, a 
molecular sub-group is not identified, patient enrollment will not continue beyond Stage 1.
Study visit flow
Thestudy  includes different periods starting by Molecular pre-screening (applicable only for 
Phase I and Group 3 in Phase II of FGF401 single agent and at Stage 2 of FGF401 and PDR001 
combination should it proceed ), Screening, Treatment, End of Treatment, Disease progression 
follow -up (if applicable), Safety  follow -
up (refer to Section 7.1.6 )and then ended by Survival 
follow -up period (Figure 4-3).
Figure 4-3 Study  Flow
*Refer to Section 7.1.6 for additional details .
4.2 Timing of interim analy ses and design adaptations
Noformal interim anal ysis will take place in theFGF401 single agent part. 
In the phase I partsof this study for both FGF401 single agent and FGR401 in combination 
with PDR001 , the MTD and/or RP2D will be determin edbased on available safet y, tolerability , 
PK,  and efficacy  data, guided by the recommendations from the Bayesian model using 
EWOC criterion and pa
rticipating investigators. The phase II part will then begin as specified 
in Section 
4.1. Details about the timing of data monitoring can be found in Section 8.5and 
Section 10.7.
In the Phase II part of the FGF401 in combination with PDR001
, a 2-stage design with interim 
efficacy  evaluation of this combination treatment in HCC patients will be used. Stage 1will 
initially  enroll approximately  35 HCC patients irrespective of their FGFR4, KLB or FGF19 
expression status. An interim analysis of efficacy will be performed after the first 35 patients 
have 
been enrolled and have had at least one-post treatment tumor evaluation or discontinued 
earlier (Stage 1).Interim decision making will be primarily  based on the estimation of ORR Molecular pre -
screening 
as applicableScreening TreatmentEnd of treatment 
due to disease 
progression
End of treatment 
for reason other 
than disease 
progression i.e. A ESafety FU* 
and disease 
progression FUSurvival FUSafety FU* 

Novartis Confidential Page 43
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
based on local assessment per RECI ST v1.1. Based on the interim efficacy  evaluation, the phase 
II part will not be continued after Stage 1 if the posterior probabilit y of ORR in the unselected 
population included in the no/limited 
anti-tumor activity  interval [0, 0.15) is less than 0.10 and 
the posterior median ORR is 0.30 or more. Considering the exploratory  nature of the study, 
when the aforementioned criteria are not met but the evaluation of overall efficacy  and safety 
suggests that the treatment is promising for further development, decision to stop at Stage 1 for 
success can als o be made by  Novartis . 
Should the efficacy  criteria not be met, go/no go decision to S tage 2 will be made byevaluating 
theanti-tumor activity  in subg roups defined bythe FGF19 expression and/or FGF19 pathwa y 
activation based on the predictive probability  of ORR. If a subgroup(s) satisfies the criterion 
that the predictive probability  to not meet the efficacy criteria (i.e. posterior probability  of ORR 
included in the no/limited anti -tumor activity  interval is less than 0.10 and the posterior median 
ORR is 0.30 or more) at the final analysis is not greater than 0.90, and the number of patients 
in that subgroup is less than 25, the study  will move to Stage 2 and further enrollment to that 
subgroup will be permitted until a total number of approximately  25 patients is reached to 
further characterize efficacy  within that subgroup. I f 25 or more patients are alread y enrolled to 
the subgroup, interim analy sis will be performed but no further enrollment will be allowed in 
that subgroup.
4.3 Definition of end of the study
The study  will end when the treatment period, safety  follow -up, disease progression follow -up 
and survival follow -up have been completed for all patients as described inSection 7.1.6, or 
when the stud y is terminated early.
Completion of the survival follow -up period will occur once a minimum of 80% of patients in 
the phase II part of both FGF401 s ingle agent and FGF401 in combination with PDR001 have 
died, have 
been lost to follow -up, or have been followed for survival forminimum 18months 
after receiving thefirst 
dose of study  treatment, whichever is sooner seeSection 7.1.6 .
See Section 10 Statistical Methods and Data Analy sis for details of timing of the primary 
analysis and final reporting of data.
The disease and survival follow -
up evalu ations might not be completed in case Novartis decides 
to stop enrollment prematurely. In such cases, end of study  will be when the treatment period 
and the safety  follow -up have been completed for all patients .
4.4 Early study  termination
The study  can be terminated at any  time for any  reason by  Novartis. Should this be necessary, 
the patient should be seen as soon as possible for an End of Treatment (EOT) visit, and the 
assessments for EOT as described in Section 7.1.4 should be performed for a prematurel y 
withdrawn patient. The investigator may be informed of additional procedures to be followed 
in order to ensure that adequate consideration is given to the protection of the patient’s interests. 
The investigator will be responsible for informing IRBs and/or ECs of the early  termination of 
the trial.

Novartis Confidential Page 44
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
5 Population
5.1 Patient population
The phase I part of this trial with oral FGF401 as single agent will be conducted in adult patients 
with hepat ocellular carcinoma or other solid malignancies characterized by positive FGFR4 and 
KLB expression. The phase II part will include 3 Groups as summarized in Figure 4 -1.
FGF401 in combination with PDR001 will be administered in adult patients with advanced 
HCC.
Theexpression of FGFR4, KLB and FGF19 will be tested by aNovartis designated laboratory , 
see Section 7.1.1 andSection 7.2.4 .
The investigator or designee must ensure that only patients who meet all the following inclusion 
and none of the exclusion criteria are offered treatment in the study .
5.2 Inclusion criteria
Patients eligi ble for inclusion in this study  have to meet all of the following criteria:
1.Written informed consent must be obtained prior to any   procedures that are not 
considered standard of care. [ For Japan only: written consent is necessary  both from the 
patient and his/her legal representative if he/she is under the age of 20 years.]
2.
Patients (male or female) ≥ 18 y ears of age
3.ECOG Performance Status ≤ 1
4.Presence of at least one measurable lesion according to RECIST v1.1 (see Section 14.1). 
For HCC patients, lesions previously  treated with loco -regional therap y, such as radiation 
therap y, hepatic arterial embolization, radiofrequency ablation, and percutaneous 
interventional therap y should not be considered measur able unless progression is noted at 
baseline.
5.Patients must 
have a site of disease amenable to biopsy  and be suitable and willing to 
undergo the stud y’s required biopsies according to treating institution’s guidelines and 
requirements for such procedure s.
6.Inclusion criteria specific for FGF401 single agent Patients with confirmed positive 
expression of FGFR4 and KLB at molecular pre-screening for Phase I and Phase II -
Group 3 . The biomarker positivity will be defined by  a Novartis designated laboratory . 
Patients with FGFR4 mutations can be enrolled in the study  following discussion and 
agreement with Novartis.
7.Phase I part:
a.Patients with HCC or advanced solid tumors, who have progressed despite standard 
therapies ,areintolerant of standard therap y, or for whom no standard therapy  exists.
b.For HCC patients:
a.Diagnosis of advanced HCC according to the AASL D Guidelines
b.HCC stage C according to the BCL C staging classification

Novartis Confidential Page 45
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
c.Current cirrhotic status of Child- Pugh class A (5 -6 points), with no 
encephalopath y and /or ascites. Child -Pugh status must be calculated based on 
clinical findings and laboratory  results during the Screening period.
8.Phase II part :
a.Group 1: HCC patients from Asian countries
b.Group 2: HCC patients from non -Asianregions
For Group 1 and 2:
a)Diagnosis of advanced HCC according to the AASL D Guidelines
b)HCC stage C according to the BCL C staging classification
c)Prior sy stemic treatment with sorafenib for advanced HCC with documented 
disease progression during or after discontinuation of sorafenib t reatment, or 
intolerance to sorafenib treatment. Specifically , this can be defined as:
Documented radiological confirmation (radiology  scans or report) of disease 
progression during or after sorafenib treatment. [For France onl y: patients must 
have receive d at least 8 weeks of prior sorafenib treatment.]
Intolerance to sorafenib (at an y dose and/or duration) is defined as documented 
sorafenib -related Grade 3 or 4 adverse events that led to sorafenib 
discontinuation.
d)Current cirrhotic status of Child- Pugh cl ass A (5 -6 points), with no 
encephalopath y and/or ascites. Child -Pugh status must be calculated based on 
clinical findings and laboratory  results during the Screening period.
c.Group 3: Patients with other advanced solid tumor
a)Patients have progressed despit e standard therapies, areintolerant of standard 
therap y, or for whom no standard therap y exists.
Inclusion criteria specific for FGF401 in combination with PDR001
9.Patients with HCC as defined below:
a.Diagnosis of advanced HCC according to the AASL D Guidelines
b.HCC stage C according to the BCL C staging classification
c.Current cirrhotic status of Child- Pugh class A (5 -6 points), with no encephalopathy  
and/or ascites. Child -Pugh status must be calculated based on clinical findings and 
laboratory  results during the Screening period
10.Patients who have received up to 2 previous lines of systemic treatment for advanced 
HCC and one treatment must have included sorafenib with documented disease 
progression during or after d iscontinuation of sorafenib treatment, or intolerance to 
sorafenib treatment. Specifically , this can be defined as
:
Documented radiological confirmation (radiology  scans or report) of disease 
progression during or after sorafenib treatment. [For France onl y: patients must have 
received at least 8 weeks of prior sorafenib treatment.]
Intolerance to sorafenib (at any  dose and/or duration) is defined as documented 
sorafenib -related Grade 3 or 4 adverse events that led to sorafenib discontinuation.
11.For Phase II-Stage 2: Documented FGF19 expression level and/or FGF19 pathway  
activation by a Novartis designated laboratory .

Novartis Confidential Page 46
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
5.3 Exclusion criteria
Patients eligible for this study  must not meet anyof the following criteria:
1.Previous treatment with a selective FGF19 -FGFR4 target edtherapy and/or pan- FGFR 
inhibitor .
2.Impairment of gastrointestinal (GI) function or GI disease that may  significantly  alter the
absorption of oral FGF401 (e.g., ulcerative diseases, uncontrolled nausea, vomiting ,small 
bowel resection).
3.Patient have received prior therapies within the following time frames prior to the first 
dose of study  treatment:
a.For HCC patients in Phase II (FGF401 singl e agent) : 
previous sy stemic anti -cancer therap y other than s orafenib
last dose of sorafenib therapy  ≤2 weeks from study  treatment start
any other anti -cancer therap y (including locoregional therap ye.g.hepatic arterial 
embolization, radio
-frequency  ablation, radiation therap y) after disease 
progression during or after sorafenib treatment with the exception of palliative 
radiotherap y to a limited field, such as for the treatment of bone pain.
b.For HCC patients in FGF401 combination with PDR001:
last dose of systemic anti -cancer therap y with sorafenib: ≤2 weeks or
unconjugated monoclonal antibody  therapies ≤ 6 weeks or 5 half-lives, 
whichever is shorter
last dose of conven tional cy totoxic chemotherapy : ≤2 weeks ( ≤6 weeks for 
nitrosoureas and mitomycin -C)
any other anti -cancer therap y (including locoregional the rapy e.g. hepatic arterial 
embolization, radio- frequency  ablation, radiation therap y) after disease 
progr ession during or after last sy stemic treatment with the exception of 
palliative radiotherap y to a limited field, such as for the treatment of bone pain .
c.For other solid tumor patients: 
The last dose of conventional cy totoxic chemotherapy : ≤2weeks ( ≤6 weeks for 
nitrosoureas and mitomycin -C)
Biologic altherapy  (e.g., antibodies): ≤6weeks
Non-cytotoxic small molecule therapeutics (e.g., s orafenib): ≤5 half-lives or ≤2 
weeks (whichever is longer)
Previous wide field radiotherap y (including therapeutic radio isotopes such as 
strontium 89) ≤ 4 weeks and limited field radiation for palliation ≤ 2 weeks
Participation in a prior investigational stud y within 7 days or within 5 half -lives 
of the investigational product, whichever is longer
Note: exceptions to the above prior therap y timeframes are possible, on a case by case basis, 
following discussion and mutual agreement between I nvestigator and Novartis.
4.Malig nant disease, other than that being treated in this study . Exceptions to this exclusion 
include the following: malignancies that were treated curativel y and have not recurred 

Novartis Confidential Page 47
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
within 3 y ears prior to study  entry ; completel y resected basal cell and squamous cell skin 
cancers and completel y resected carcinoma in situ of an y type.
5.Symptomatic CNS metastases which are neurologically  unstable , or CNS metastases 
requiring local CNS directed therap y (such as radiotherap y or surgery), or  increasing 
doses of corticosteroid s within 2 weeks of first dose of study treatment .
Note: Patients with controlled CNS metastases may participate in this trial. Patients must 
be neurologicall y stable, having no new neurologic deficits on clinical examination, and 
no new findings on CNS imaging for 4 weeks and before receiving the first dose of study  
treatment and not requiring steroid therap yfor at least two weeks before receiving the 
first dose of study  treatment. 
6.Any medical condition that would, in the investigator’s judgment, prevent the patient’s 
participation in the clinical study  due to safet y concerns or compliance with clinical study 
procedures. An y severe, acute, or chronic medical or psychiatric condition or laboratory 
abnormality  that may  increase the risk associated wi th study  participation or study  
treatment administration or that may  interfere with the interpretation of study  results and, 
in the judgment of the investigator, would make the patient inappropriate for the study .
7.Ongoing active diarrhea requiring medicati ons (e.g. bile acid sequestrant (BAS ), 
loperamide)
8.Irritable bowel sy ndrome with sign s/symptom s orrequires medications
9.Current evidence of calcium- phosphate homeostasis impairment , defined as:
a.Inorganic phosphorus > 5.5 mg/dL
b.Total calcium > 11.5 mg/dL
c.Ionized serum calcium > 1.5 mmol/L
d. Patients with current evidence of endocrine alteration of calcium/phosphate 
homeostasis, e.g. parath yroid disorders, tumor lysis, tumoral calcinosis etc.
10.Patient having out of range laboratory  values defined as:
Hematolog y
a)Hemoglobin < 9 g/dL (SI Units: 90 g/L)
b) Platelet count < 75000/mm3
c)Absolute neutrophil count (ANC) < 1500/mm3
Chemistry
a)Total bilirubin > 1.5 x ULN, except for patients with Gilbert’s sy ndrome who are 
excluded if total bilirubin > 3.0 x UL N or direct bili rubin > 1.5 x ULN
b)AST or ALT > 3 x ULN
c)Serum creatinine > 1.5 x ULN or creatinine clearance (calculated using the 
Cockcroft -Gault formula or measured) < 40 mL/min
Coagulation: PT >4 seconds more than the ULN or INR > 1.7
11.Patients receiving treatment with CYP1A2, CYP2C9 and CYP3A4/5 substrates with a 
narrow therapeutic index (NTI) that cannot be discontinued for the duration of the study  
(refer to Appendix 4).
12.

Novartis Confidential Page 48
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
13.Patients receiving known BSEP efflux transporter inhibitors that cannot be discontinued 3 
days prior to the start of study  treatment and during the course of the study  (refer to 
Appendix 4 ).
14.Pregnant or nursing (lactating) wom en, where pregnancy  is defined as the state of a 
female after conception and until the termination of gestation, confirmed b y a positive 
human chorionic gonadotropin (hCG) laboratory  test.
15.Women of child- bearing potential, defined as all women phy siologica lly capable of 
becoming pregnant, unless they  are using highly  effective methods of contraception 
during dosing with study  treatment and for the following duration after discontinuation of 
study  treatment :
For patients enrolled in FGF401 single agent: 3 days  after the last dose of FGF401
For patients enrolled in FGF401 in combination with PDR001: 150 day
s after the last 
dose of PDR001, and3 day s after the last dose of FGF401 in case s where PDR001 
was discontinued more than 150 day s before the last dose of FGF401
Highl y effective contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
subject. Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y), total hy sterectomy or tubal ligation at least six weeks before taking 
study  treatment. In case of oophorectom y alone, only when the reproductive status of 
the woman has been confirmed by  follow up hormone level assessment
Male sterilization (at least 6 months prior to screening). For female subjects on the 
study  the vasectomized male partner should be the sole partner for tha t subject .
Use of oral, injected or implanted hormonal methods of contraception or placement o f 
an intrauterine device (IUD) or intrauterine s ystem (IUS), or other forms of hormonal 
contraception that have comparable efficacy  (failure rate <1%), for exampl e hormone 
vaginal ring or transdermal hormone contraception . 
In case of use of oral contraception women should have been stable on the same pill 
for a minimum of 3 months before taking stud y treatment.
Women are considered post -menopausal and not of child bearing potential if they  have 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile 
(e.g. age appropriate [generall y age from 40 to 59 years] , history  of vasomotor sy mptoms
[e.g. hot flush] )in the absence of other medical justification, or have had surgical bilateral 
oophorectom y (with or without hy sterectomy ), total hy sterectomy or tubal ligation at least 
six weeks ago. In the case of oophorectomy  alone, only  when the reproductive status of
the woman has been confirmed by follow up hormone level assessment is she considered 
not of child bearing potential.
16.Sexually  active males unless they  use a condom during intercourse while receiving study  
treatment and for the following period after the l ast dose of study  treatment , and should 
not father a child in this period. 
For patients enrolled in FGF401 single agent: 3 days after the last dose of FGF401

Novartis Confidential Page 49
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
For patients enrolled in FGF401 in combination with PDR001: 150 day s after the last 
dose of PDR001 , and 3 day s after the last dose of FGF401 in cases where PDR001 
was discontinued more than 150 day s before the last dose of FGF401
A condom is required to be used also b y vasectomized men in order to prevent delivery of 
the drug via seminal fluid.
17. M ajor surgery  within 2 weeks of receiving the first dose of study  treatment 
(mediastinoscopy , insertion of a central venous access device and insertion of a feeding 
tube are not considered major surgery ).
In addition patients eligible for the FGF401 in comb ination with PDR001 part must not 
meet any of the below criteria:
18.Clinically  significant pleural effusion that either required tapping or is associated with 
shortness of breath.
19.Known human immunodeficiency  virus (HIV) infection or known acquired 
immunodef iciency  syndrome .
20.Active HBV or HCV infection. Patients whose disease is controlled under antiviral 
therap ycan be included.
21.Active known or suspected autoimmune disease. Patients with vitiligo, residual 
hypothy roidism only  requiring hormone replacement, p soriasis not requiring s ystemic 
treatment or conditions not expected to recur in the absence of an externa l trigger can be 
included. Patients previously  exposed to anti -PD-1/PD-L1 treatment who are adequatel y 
treated for skin rash or with replacement thera py for endocrinopathies can be included.
22.History  of severe hy persensitivity  reactions toany ingredient of study  treatment and other 
mAbs and/or their excipients
23. Impaired cardiac function or clinically significant cardiac disease, including any  of the 
following: 
Clinically  significant or uncontrolled heart disease such as congestive heart failure 
requiring treatment ( New York Heart Association Grade ≥ 2), uncontrolled 
hypertension (defined by Systolic Blood Pressure > 160 mmHg/ Diastolic Blood 
Pressure > 100mmHg (average of three consecutive readings) at rest despite medical 
treatment, clinicall y significant arrh ythmia
QTcF > 470 msec on screening ECG (as mean of triplicate ECGs) or congenital long 
QT sy ndrome
Acute myocardial infarction or unstable angina pectoris < 3 months prior to screening
24.Use of s ystemic chronic steroid therapy  (≥ 10mg/day  prednisone or equivalent )or an y 
immunosuppressive therapy
 two weeks prior to start of study  treatment. Topical, inhaled, 
nasal and ophthalmic steroids are allowed .
25.Use of an y live vaccines against infectious diseases within 4 weeks of initiation of study  
treatment (except inactivated seasonal influenza vaccines).
26.Use of hematopoietic colony -stimulating growth factors (e.g. G -CSF, GM -CSF, M -CSF), 
thrombopoietin mimetics or erythroid stimulating agents ≤ 2 weeks prior to start of study  
treatment. If ery throid stimulating agents were initiated more than 2 weeks prior to the 
first dose of study  treatment and the patient is on a sta ble dose, they  can be maintained .
27.History  of liver or other organ transplantation.

Novartis Confidential Page 50
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
28.History  of immunotherapy -induced pneumonitis or current pneumonitis grade > 2.
29.Patients who discontinued prior anti -PD-1/PD -L1 therap y due to an anti PD -1/PD -L1-
related toxi city.
6 Treatment
6.1 Stud y treatment
The study  treatments areFGF401 as single agent or FGF401 in combination with PDR001 .
There is no reference therap y.
6.1.1 Dosing regimen
Table 6-1 Dose and treatment schedule
Study drugs Pharmaceutical form and 
route of administrationDose Frequency and/or 
Regimen
FGF401 capsule for oral use as assigned once daily ( QD) on a 
continuous schedule
PDR001 intravenous infusion 300m g every three weeks 
(3QW )
Patients will be assigned to receive FGF401 on a continuous once daily  dosing regimen or the 
combination of FGF401 on a continuous once daily dosing regimen and PDR001 administered 
every  three weeks.
The FGF401 dose regimen may  change from QD to BID at any  time during the study  (Section 
4.1).
FGF401
FGF401 will be administered orally  on a flat scale of mg/day  and not by  weight or BSA. 
FGF401 should be taken as follows:
Patients should be instruct ed to take their dose at approximately  the same time every  day.
On day s when blood for PK samples need to be collected prior to taking study  drug, 
patients should be instructed to bring their drug supply  to the site, and take the dose in the 
clinic, under supervision of the site personnel.
Each dose should be taken with a glass of water and consumed over as short a time as 
possible unless otherwise instructed.
Patients should be instructed to swallow pill(s) whole and to not chew or open them.
FGF401 should be administered in the fasted state, at least 1 hour before or 2 hours after a 
meal (unless otherwise instructed). Water and other medications are permitted during this 
period.
On day s of PK/
 sampling, every  effort must be made to capture the time of an y 
vomiting within 4 hours of drug administration in both source documents and 
corresponding eCRF. The occurrence and frequency  of any  vomiting and/or diarrhea (or 

Novartis Confidential Page 51
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
increase stool frequency ) during a treatment cy cle must be noted in the Adverse Events 
eCRF.
If vomiting occurs during the course of the treatment, no re- dosing of the patient is 
allowed before the next scheduled dose.
If the patient forgets to take his/her dail y dose, then he/she should take FGF401 within 6 
hours after the missed dose. If more th an 6 hours have passed, then that dose should be 
omitted and the patient should continue treatment with the next scheduled dose.
Patients should inform the investigational site staff of an y missed or delay ed doses.
Exploratory  food effect cohort -FGF401 single agent
Patients will be treated under fed conditions only  when he/she is allocated to the food 
effect cohort in the phase I  part.
Patients enrolled in the food effect cohort s will receive each dose of FGF401 with a light 
meal. FGF401 needs to be administered within 30 minutes following the assigned meal, 
see Appendix 8 for test meal guidance.
On day s of PK profiles collecti on (Section 7.2.3.1), t he light breakfast will be adapted to 
the local preference and prepared b y a registered dietician.
PDR001
PDR001 will be administered via intravenous infusion once every  3 weeks
(Section 6.6). 
Sequence of FGF401 and PDR001 administration
FGF401 will be administered prior to PDR0 01 along with PDR001 pre-medication (if pre-
medication is necessary ). The sequence will allow consiste nt time of daily  dosing for FGF401. 
A minimum of 1 hour must pass from the time ofFGF401 
dose administration to the 
administration of PDR001.
6.1.2 Ancillary  treatments
6.1.2.1 Infusion reactions with PDR001
Patient s should not receive pre-medication to prevent aninfusion reaction before the first 
infusion of study  treatment, in order to determine if pre-medication is necessary . If a patient 
experiences an infusion reaction, he/she may receive pre-medication on subsequent dosing days. 
The pre -medication should be chosen per institutional standard of care, at the discretion of the 
treating ph ysician.
Acute allergic reactions should be treated as needed per institutional standard of care. In the 
event of anaphy lactic/anaphy lactoid reactions, this includes any therapy necessary  to restore 
normal cardiopulmonary  status. If a patient experiences a Grade 3 anaphy lactic/anaph ylactoid 
reaction, the patient will discontinue study  treatment. The patient may  resume study  treatment 
following documented discussion with the Novar tis medical monitor. Guidelines on 
management of infusion reactions are provided in Table 6-5.
The CTCAE category of “Infusion related reaction” should be used to describe study  treatment 
related infusion reactions, unless the investigator considers another category, such as “Allergic 

Novartis Confidential Page 52
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
reaction,” “Anaph ylaxis,” or “Cytokine release syndrome” more appropriate in a specific 
situation .
6.1.3 Treatment duration
Patients may continue study  treatment until they  experience an y of the following:
Disease progression (radiologicall y documented according to RECI ST v1.1) as assessed 
by the Investigator if they  are treated with FGF401 single agent
Disease progression per irRC if they  are treated with FGF401 in combination wit h 
PDR001. These patients should not be withdrawn from study  treatment due solely  to 
progressive disease per RECI ST v1.1. Refer to Section 7.1.3 and Section 7.1.4 for further 
details.
Unacceptable toxicity  
Treatment is discontinued at the discretion of the Investigator or the patient
Patients who permanently discontinue the study  treatment for any reason other than disease 
progression or withdrawal of consen t shall continue efficacy  assessments as scheduled in the 
protocol Section 7.1.5 until the time of disease progression.
6.2 Dose escalation guidelines
6.2.1 Starting dose rationale
The recom mended starting dose of FGF401 single agent for patients enrolled in this trial is 50 
mg p.o. administered continuously  once daily (see Appendix 7). This dose is expected to be 
safe and might be pharmacologically  active based on human efficacious dose prediction . Safet y 
of the starting dose is supported by results of 4-week Good Laboratory  Practice (GLP )
toxicology  studies conducted in mice and dogs  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 

Novartis Confidential Page 53
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
 
The starting dose of FGF401 in combination with PDR001 is 80mg QD (fasted) which is one 
dose level below the declared RP2D for FGF401 as single agent. The RP2D for FGF401 as 
single agent is 120mg QD administered under fasted conditions.
PDR001 will be administered at a fixed dose of 300mg i.v. every  three weeks which is the 
RP2D dec lared for PDR001 as single agent.
The starting dose of the FGF401 in combination with PDR001 selected satisfies the EWOC 
criteria (Section 2.3 ) for the combination BLRM .
6.2.2 Provisional dose levels
Table 6-2 describes the starting dose and the dose levels that may be evaluated during this trial
for FGF401 single agent and in combination with PDR001 . Dose escalation will continue until 
MTD is reached and/or RP2D is determined. At all decision time points, the BLRM permits 
alterations in the dose increments based on the observed DLTs.
If at any time during the phase I of the FGF401 single agent part of the study , the pre-clinical 
and/or clinical data suggest change of dosing schedule, such as BID dosing or intermittent 
dosing, then the starting total daily  dose will be a dose that has previously been confirmed to 
bewell tolerated on a continuous once daily dosing schedule within this study and is suppo rted 
by an adjusted BLRM (see Section 6.2.3.1 and Section 10.4 for details). 
With the exception of starting dose level 1, actual dose levels will be determined following a 
discussion with the participating Investigators during the dose escalation teleconferences.
The dose for PDR001 will be fixed for all dose escalation cohorts in the FGF401 and PDR001 
combination part of the study  (Section 6.2.1 ).
Table 6-2 FGF401 Provisional dose levels
Dose level Proposed total daily  dose* Increment from previous dose
FGF401 as single agent
-2** 20 mg -33.3%
-1** 30 mg -40%
1 50 mg (starting dose)
2 100 mg 100%
3 200 mg 100%
4 250 mg 25%
5 300 mg 20%
6 400 mg 33%
7 500 mg 25%

Novartis Confidential Page 54
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Dose level Proposed total daily  dose* Increment from previous dose
FGF401 in combination with PDR001
-1 50mg -37.5%
1 80 mg starting dose
2 120mg 50%
*It is possible for additional and/or intermediate dose levels to be added during the course of the study. 
Dose levels may also be skipped if the safety data and BLRM analyses support a higher increase limited to 
at most 100% increase in dose level (e.g. a dose increase from 100 mg to 200 mg with the same 
frequency). Cohorts may be added at any dose level below the MTD/RP2D in order to better understand 
safety, PK 
**Dose level -1 and -2 represent treatment doses for patients requiring a dose reduction f rom the starting 
dose level. No dose reduction below dose level -2 is permitted for this study.
6.2.3 Guidelines for dose escalation and determination of MTD
6.2.3.1 MTD definition
The MTD is defined as the highest drug dosage not expected to cause DLT in 33% or more of 
the treated patients in the evaluation period of FGF401 single agent and FGF401 in combination 
with PDR001 during the phase I respective partsof the study .Theevalu ation period of DLTs 
for the dose escalation decisions is defined as 1 cycle (21 days) from treatment start for FGF401 
single agent and as 2 cycles (42 days) starting from the first dose of PDR001 administered in 
combination with FGF401 . Adverse events andlaboratory  abnormalities considered to be DLTs 
are defined in Table 6 -3.
6.2.3.2 Dose cohort modification
For the purposes of dose escalation decisions, each cohort will consist of 1to 6 newly  enrolled 
evaluab
le patients for the FGF401 single agent and, 3 to 6newl y enrolled evaluable patients for 
the FGF401 in combination with PDR001 , who will be treated at the specified dose level. The 
first cohort will be treated with the starting dose as described in Section 6.2.1 .For the FGF401 
and PDR001 combination, for each untested dose level the administration of the first dose of 
the study  treatment will be staggered b y 24 hours for the first three patients .
When two patients
enrolled in an escalation arm(FGF401 single agent or in combination with PDR001; who may 
be in different cohorts) have experienced a toxicity  of CTCAE grade 2 for which relationship 
to study  drug cannot be ruled out; or when any single patient experiences a DLT or AE of 
CTCAE grade 3 or greater during Cycle 1, the cohort size will be changed to between 3 and 6 
evaluable patients for the current and subsequent cohorts.
Patients must complete a minimum of 1 cycleof treatment with FGF401 single agent and a 
minimum of 2 cycles of treatment with FGF401 in combination with PDR001, with the 
minimum safety  evaluation and drug exposure or have had a DLT within the evaluation period 
to be considered evaluable for dose escalation decisions (Section 10.1.4 ). Dose escalation 
decisions will occur when the cohort of patients has met these 
criteria. 
Dose escalation decisions will be made by Investigators and Novartis study  personnel. 
Decisions will be based on a synthesis of all relevant data available from all dose levels 
evaluated in the ongoing study  including safet y information, DLTs, all CTCAE Grade ≥ 2 
toxicity  data during the DLT evaluation period, PK  data from evaluable patients. The 
recommended dose for the next cohort of patients will be guided by  the Bayesian model swith 

Novartis Confidential Page 55
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
EWOC principle ( Section 2.2). The adaptive Ba yesian methodology provides an estimate of all 
dose levels of FGF4 01single agent and FGF401 in combination with PDR001 that do not 
exceed the MTD for each treatment and incorporates all DLT information at all dose levels for 
this estimation. In general, the next dose will have the highest chance that the DLT rate will fall 
in the target interval [16-33%) and will alway s satisfy  the EWOC principle. In all cases, the 
dose for the next cohort will not exceed a 100% increase from the previous dose. Smaller 
increases in dose and/or changes of dosing schedule may be recommende d by the Investigators 
and Sponsor upon consideration of all of the available clinical data. Any dose escalation 
decisions made by Investigators and Novartis personnel will not exceed the dose level 
recommended b y the Bayesian model using the EWOC principle. If needed to better define the 
dose-toxicity  relationship additional patients may be enrolled to the current dose level, to a 
preceding dose level, or to an intermediate dose level before proceeding with further dose 
escalation.
If 2 patients in a previously  untested dose level experience a DLT, enrollment to that cohort 
will stop, the Bayesian model will be updated and the next cohort will be opened at the next 
lower dose level or an intermediate dose level that satisfies the EWO C criteria. However, if 2 
patients in a new cohort at a previously  tested dose level experience a DLT (e.g., a total of 8 
patients are treated on this dose level with 2 DL T observed), further enrollment to that cohort 
will stop, the Bayesian model will be updated with this new information and re-evaluation of 
the available safet y, PK,  data will occur. By incorporating information gained at the 
preceding dose cohorts, additional patients may  be enrolled into the current dose cohort only  if 
the dose still meets the EWOC criteria and as agreed by  Investigators and Novartis personnel. 
Alternativel y, if recruitment to the same cohort may  not resume, a new cohort of patients may 
be recruited to a lower dose as agreed by Investigators and Novartis personnel and if the 
Bayesian model predicts that the risk for this lower dose to exceed the MTD remains below 25% 
(EWOC). Re-escalation may then occur if data in subsequent cohorts supports this (EWOC 
criteria are satisfied) and Investigators and Novartis personnel agree.
Dose escalation will continue until identification of the MTD or a suitable lower dose for 
expansion. This will occur when the following conditions are met:
1.at least 6 patients have been treated at this dose 
2. this dose satisfies one of the followin g conditions:
a.the posterior probabilit y of targeted toxicity  at this dose exceeds 50% and is the 
highest among potential doses, or
b.a minimum of 21 patients for the FGF401 sin gle agent and a minimum of 12 patients 
for the FGF401 in combination with PDR001 have alread y been treated on the trial, or
c.significant activity  is seen earl y in the phase I part, in which case a recommended 
dose for expansion may  be made and the phase II Groups may be initiated without 
determination of the MTD
3.it is the dose recommended for patients, either per the model or by review of all clinical 
data b y Novartis and Investigators in a dose -escalation teleconference.
To better understand the safet y, tolerabilit y and PK of FGF401 as single agent and in 
combination with PDR00 1, additional cohorts of patients may be enrolled at preceding dose 
levels, or to intermediate dose levels before or while proceeding with further dose escalation.

Novartis Confidential Page 56
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
If a decision is made to escalate to a higher dose level but one or more additional patient( s) 
treated at the preceding dose level experiences a DLT during the first cycleof treatment, then 
the Bayesian model will be updated with this new information before any additional patients 
are enrolled at that higher dose level.  Patients ongoing will continue treatment at their assigned 
dose levels.
In the event of a change in dosing schedule for either FGF401 single agent or FGF401 in 
combination with PDR001 , then a new Bayesian model will be set up.  This new Bayesian 
model will have the same functiona l form as that described in Section 10.4.2.1 (for FGF401 
single agent) and in Section 10.4.2.2 (for FGF401 in combination with PDR001) and will
incorp
orate existing dose escalation data in the prior distribution sand a starting dose will be 
identified at that time. Subsequent dosing decisions for the new schedule will follow the same 
rules defined within the above paragraphs of this section.
6.2.3.3 Implementation of dose escalation decisions
To implement dose escalation decisions, the available toxicity  information (including adverse 
events and laboratory  abnormalities that are not DLTs), the recommendations from the
Bayesian model , and the available PK  information will all be evaluated by the 
Investigators and Novartis study  personnel (including the study  physician and statistician) 
during a dose decision meeting by  teleconference. Drug administration at the next higher dose 
level may not proceed until the investigator receives written confirmation from Novartis 
indicating that the results of the previous dose level were evaluated and that it is permissible to 
proceed to a higher dose level.
6.2.3.4 Intra -Patient dose escalation
Intra -patient dose escalation is not permitted at any  time within the first 4cycles of treatment. 
After the fourth cycle is completed, individual patients may be considered for treatment at a 
dose of FGF401 higher than the dose to which they were initially  assigned. In order for a patient 
to be treated at a higher dose of FGF401, he or she must have tolerated the lower dose for at 
least four cycles of therapy  without experiencing any treatment -related toxicity  defined as 
CTCAE grade ≥ 2 or worse than baseline at the lower dose originall y assigned. Moreover, the 
new, higher dose with which the patient is to be treated must be a dose that has completed 
evaluation and has not exceeded the maximum tolerated dose (MTD). 
There is no limit to the number of times a patient may have hisor her dose of FGF401 increased. 
For any further increase after the initial intra-patient dose escalation, the same rules as for the 
initial intra -patient dose escalation will appl y. 
Consultation and agreement with Novartis must occur prior to an y intra- patient dose escalation 
occurring. These changes must be recorded on the Dosage Administration Record eCRF. Data 
from the DLT evaluation period at the new dose level will not be formally  included into the 
statistical model describing the relationship betwe en dose and occurrence of DLT. However, 
this data will be incorporated into the clinical assessment of safet y within a dose escalation 
teleconference.

Novartis Confidential Page 57
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
6.2.4 Definitions of dose limiting toxicities (DLTs)
A dose-limiting toxicity  (DLT) is defined as an adverse event or abnormal laboratory  value 
assessed as unrelated to disease, disease progression, inter-current illness, or concomitant 
medications that occurs within the evaluation period of DLTsand meets any of the criteria 
included inTable 6-3. For the purpose of dose-escalation decisions, DLTs will be considered 
and included in the Bayesian model . However, events occurring after the DLT evaluation period 
may contribute to the determination of the RP2D. DLTs w ill not be collected during the phase 
II dose expansion part sof the study . 
The investigator must notify  the Sponsor immediately  of any unexpected CTCAE grade ≥ 3 
adverse events or laboratory  abnormalities. Prior to enrolling patients into a higher dose l evel, 
CTCAE grade 
≥ 2 adverse events will be reviewed for all patients at the current dose level.
Table 6-3 Criteria for defining dose -limiting toxicities
ToxicityAny of the following criteria occurring in the evaluation period during the phase I 
part of the study for which relationship to study  treatment cannot be ruled out a
Hematology Any Grade 3 hematologic toxicity, lasting for >7 consecutive days
Any ≥Grade 4 hematologic toxicity of any duration
≥Grade 3 Febrile neutropenia 
Renal ≥Grade 3 serum Creatinine increased
Pancreas Grade 3 Lipase or Serum Amylase increased (asymptomatic), which is not resolved to ≤ 
Grade 2 within 7 days
Grade 4 Lipase or Serum Amylase increased (asymptomatic) of any duration
≥Grade 3 Pancreatitis
Cardiac ≥Grade 3 cardiac disorders
≥Grade 3 ECG QTc corrected interval prolonged
Any cardiac event that is symptomatic or requiring medical intervention
General 
disordersGrade 3 Fatigue, lasting for >7 consecutive days
Gastrointestinal 
disordersGrade 2 Diarrhea, which is not resolved to ≤ Grade 1 within 7 days after starting an 
adequate treatment
Grade 3 Diarrhea 
lasting for more than 24 hours after starting an adequate treatment
OR
improved to Grade 2 within 24 hours but not resolved to ≤ Grade 1 within 7 days after 
starting an adequate treatment
≥Grade 4 Diarrhea
Grade 3 Nausea, lasting for >48 hours, despite the use of adequate treatment
≥Grade 3 Vomiting, lasting for >24 hours, despite the use of anti-emetic therapy
Hepatic For patient’s baseline bilirubin within normal range: Blood bilirubin increased to > 2.0 x ULN
For patient’s baseline bilirubin out of normal range: Blood bilirubin increased to > 1.5 times 
above baseline
For patient’s baseline AST orALT within normal range: AST or ALT increased to > 5.0 x 
ULN
For patient’s baseline AST or ALT out of normal range: AST or ALT increased to > 3 times 
above baseline AND > 5.0 x ULN
Metabolic Serum Pi > 7.0 mg/dL which is not resolved to ≤ 7.0 mg/dL within 7 days after the maximum 
dosing of phosphorus lowering therapy

Novartis Confidential Page 58
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Serum Pi > 9.0 mg/dL
≥ Grade 3 hypercalcemia
Other toxicity Any other CTCAE Grade ≥3 toxicity (except those that can be resolved within 7 days and 
are considered by the investigator to be not clinically important)
Other clinically significant toxicities, including  a single event or multiple occurrences of the 
same event that lead to a dosing delay of > 7 days in theevaluation period , may be 
considered to be DLTs by the Investigators and Novartis, even if not CTCAE grade 3 or 
higher.
In addition, the below criteria are considered as DLTs only for the FGF401 and PDR001 combination 
Eye disorders Grade 2 eye pain or changes in vision that does not respond to topical therapy and does 
not improve to Grade 1 within 2 weeks of the initiation of topical therapy or requires 
systemic treatment
Infection Grade 3 infection or fever in the absence of neutropenia lasting for > 5 consecutive days
Grade 4 infection
Pneumonitis Grade 2 pneumonitis not resolving within 7 days after starting treatment with corticosteroids
≥Grade 3 pneumonitis
Immune -
mediated
toxicitiesGrade 3 immune mediated toxicities which are not resolved to ≤ Grade 1 within 7 days 
despite treatment with corticosteroids.
Grade 4 immune media ted toxicities
a CTCAE version 4.03 will be used for all grading.
6.3 Dose modifications
6.3.1 Dose modification and dose delay
For patients who do not tolerate the protocol -specified dosing schedule due to treatment related 
toxicities, dose adjustments are permitted in order to allow the patient to continue the study 
treatment. 
Patients in the FGF401 and PDR001 combination, who discontinue treatment due to PDR001
or FGF401 related toxicities may continue treatment with FGF401 or PDR001 single agent
respectivel y,after documented discussion with the 
Novartis medical monitor.
All changes in the administration of FGF401 or PDR001 must be recorded on the respective 
Dosage Administration Record eCRF page s.
The following guidelines for FGF401 either administered as single agent or in combination with 
PDR001 need to be applied:
For the phase I dose escalation part of the study , dose reductions for FGF401 during the 
evaluation period of DLTs are onl y allowed if a DL T is observed and recorded. 
All dose modifications should be based on the worst preceding toxicity  and guidelines are 
provide d inTable 6
-4.
If a patient requires a dose interruption of >21 days from the intended day of the next 
scheduled dose, then the patient must be discontinued from the study treatment .
In exceptional situ ations, study  treatment may  continue even if the patient experienced one 
of the treatment stopping rules.  The decision to allow for continuation of treatment will be 
made on a case-by-case basis following documented discussion between the Novartis
medical monitor and the Investigator.

Novartis Confidential Page 59
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
If a patient remains on study treatment despite dose interruption of > 21 days, i.e.patient 
with evidence of clinical benefit and in the opinion of the investigator it is in the best interest 
of the patient to remain on study, then the rationale for remaining on the study  and the
decision and documentation of the discussion with the Novartis medical monitor must be 
available in the source documentation and described as an investigator comment in the 
eCRF.
The following guidel ines for PDR001 need to be applied:
Dose reductions are not permitted for PDR001.
PDR001 may  be delay ed due to toxicities . The PDR001 dosing may  resume once the
adverse event has resolved to 
≤Grade 1 or to the patient’s screening value and the start of 
the cycle will be shifted accordingl y. Disease assessments will continue to occur at the 
frequency  that was originally  specified within protocol .
Overall, for adverse events of potential immune -related etiology (irAE) that do not recover 
to ≤ Grade 1 or patient’s screening value at a dose of immunosuppression of ≤ 10 mg/day  
prednisone or equivalen t within 12 weeks after initiation of immunosuppressive therap y, 
PDR001 must be permanently  discontinued.
If a patient experiences an AE meeting the criteria for DLT as outlined in Section 6.2.4
(including events occurring after cy cle 2), treatment with PDR001 should be withheld. 
The same applies for an y Grade 3 irAE that would require the use of s ystemic steroids. A 
decision to resume treatment with PDR001 following the occurrence of a DL T or any  
Grade 3 irAE is at the discretion of the Investigator. 
If the Investigator considers it to be in the patient’s best interest to resume therapy  befor e 
the toxicity  has resolved to G rade 1, or to resume without dose reduction of FGF401 if 
applicable, this may  be permitted on a case by  case basis, following documented 
discussion with the Novartis medical monitor.
If more than 12 consecutive weeks are required b efore recovery  from PDR001- related 
toxicities, then the patient must permanently  discontinue PDR001 treatment .
Table 6-4 and Table 6 -5outline the recommended dose modification s for selected 
toxicities. Additional recommended dose modification s are provided in the Appendix 11, 
which outlines management algorithms for the following groups of AEs: Pulmo nary, 
Gastrointestinal
, Renal, Endocrinopath y, Hepatic and Skin.

Novartis Confidential Page 60
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Table 6-4 Criteria for interruption and re -initiation of FGF401 as single agent and in combination with PDR001
Recommended Dose Modifications for FGF401
For the FGF401 in combination with PDR001 treatment: Dose level maintenance, dose omission and treatment discontinuation refer to both FGF401 and PDR001. 
Reduction of one dose level refers to FGF401 only while PDR001 dose level should be maintained, unless otherwise specified.
Worst toxicity
CTCAE v4.03 GradeRecommended dose modifications any time during a cycle of therapy (including intended day of dosing)
No toxicity Maintain dose level
Investigations (Hematologic)
Neutropenia (Neutrophil count decreased)
Grade 3 (ANC < 1000 -500/mm3) Maintain dose level, if not resolved to ≤ Grade 1 or baseline* within 7 days, then omit dose until resolved to ≤ 
Grade 1 or baseline, and then ↓1 dose level
Grade 4 (ANC < 500/mm3) Omit dose until resolved to ≤ Grade 1 or baseline, then ↓1 dose level
Thrombocytopenia (Platelet count decreased)
Grade 3 (PLT < 50,000 –25,000/mm3) Maintain dose level, if not resolved to ≤ Grade 1 or baseline within 7 days, then omit dose until resolved to ≤ 
Grade 1 or baseline, and then ↓1 dose level
Grade 4 (PLT < 25,000/mm3) Omit dose until resolved to ≤ Grade 1 or baseline, then ↓1 dose level
Grade 3 Febrile neutropenia Omit dose until resolved, then:
If resolved in ≤ 7 days, then maintain dose level
If resolved in >7 days, then ↓1 dose level
Investigations ( Renal)
Serum creatinine increased 
Grade 1 (> 1 -1.5 x baseline; > ULN -1.5 x ULN) Maintain dose level
Grade 2 (> 1.5 –3.0 x baseline; > 1.5 -3.0 x ULN) Maintain dose level
Grade 3 ( > 3.0 x baseline; > 3.0 -6.0 x ULN) Omit dose until resolved to ≤ Grade 1 or baseline, then ↓1 dose level
Grade 4 (> 6.0 x ULN) Omit dose and discontinue patient from study drug treatment
Investigations (Pancreatic)
Asymptomatic Amylase and/or Lipase increased
Grade 3 (> 2.0 -5.0 x ULN) Maintain dose level, if not resolved to ≤ Grade 1 or baseline within 7 days, then omit dose until resolved to ≤ 
Grade 1 or baseline, and then ↓1 dose level
Grade 4 (> 5.0 x ULN) Omit dose and discontinue patient from study drug treatment

Novartis Confidential Page 61
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Recommended Dose Modifications for FGF401
For the FGF401 in combination with PDR001 treatment: Dose level maintenance, dose omission and treatment discontinuation refer to both FGF401 and PDR001. 
Reduction of one dose level refers to FGF401 only while PDR001 dose level should be maintained, unless otherwise specified.
Worst toxicity
CTCAE v4.03 GradeRecommended dose modifications any time during a cycle of therapy (including intended day of dosing)
≥Grade 3 Pancreatitis Omit dose and discontinue patient from study drug treatment
Investigations (Hepatic)
Blood bilirubin increased
For patient’s baseline total bilirubin is ≤ ULN
> ULN –2.0 x ULN Maintain dose level
> 2.0 -3.0 x ULN Omit dose and consider excluding immune mediated etiology **until resolved to ≤ 2.0 x ULN, then:
If resolved in ≤ 7 days, then ↓1 dose level (any subsequent > 2.0 x ULN requiring discussion  with Novartis)
If resolved in > 7 days, then discontinue patient from study drug treatm ent
> 3.0 x ULN Omit dose and discontinue patient from study drug treatment
Blood bilirubin increased
For patient’s baseline total bilirubin is > ULN
> ULN – 1.5 times above baseline Maintain dose level
> 1.5 – 3.0 times above baseline Omit dose and consider excluding immune mediated etiology** until resolved to ≤ 1.5 times above baseline, 
then:
If resolved in ≤ 7 days, then ↓1 dose level (any subsequent > 1.5 times above baseline requiring discussion  
with Novartis)
If resolved in > 7 days, then discontinue patient from study drug treatment
> 3.0 times above baseline Omit dose and discontinue patient from study drug treatment
AST and/or ALT increased
For patient’s baseline AST/ALT are ≤ ULN
Grade 1 (> ULN –3.0 x ULN)Maintain dose level
Grade 2 (> 3.0 -5.0 x ULN)Maintain dose level
Grade 3 (> 5.0 –20.0 x ULN) Omit dose and consider excluding immune mediated etiology** until resolved to ≤ Grade 1, then:
If resolved in ≤ 7 days, then ↓1 dose level (any subsequent > 5.0 x ULN requiring discussion  with Novartis)
If resolved in > 7 days, then discontinue patient from study drug treatment
Grade 4 (> 20.0 x ULN) Omit dose and discontinue patient from study drug treatment
AST and/or ALT increased
For patient’s baseline AST/ALT are > ULN

Novartis Confidential Page 62
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Recommended Dose Modifications for FGF401
For the FGF401 in combination with PDR001 treatment: Dose level maintenance, dose omission and treatment discontinuation refer to both FGF401 and PDR001. 
Reduction of one dose level refers to FGF401 only while PDR001 dose level should be maintained, unless otherwise specified.
Worst toxicity
CTCAE v4.03 GradeRecommended dose modifications any time during a cycle of therapy (including intended day of dosing)
> ULN – 3.0 times above baseline Maintain dose level
> 3.0 –5.0 times above baseline but < 5.0 x ULN Maintain dose level
> 3.0 –5.0 times above baseline AND > 5.0 x ULN Omit dose and consider excluding immune mediated etiology** until resolved to ≤ Grade 1, then:
If resolved in ≤ 7 days, then ↓1 dose level (any subsequent > 5.0 x ULN requiring discussion  with Novartis)
If resolved in > 7 days, then discontinue patient from study drug treatment
> 5.0 times above baseline Omit dose and discontinue p atient from study drug treatment
Metabolic
Hyperphosphatemia Please refer to the guidelines for study drug -induced hyperphosphatemia provided in Appendix 6 .
Hypercalcemia
Grade 1 Maintain dose level
Grade 2 Maintain dose level and start adequate therapy immediately
≥Grade 3 Start adequate therapy immediately and omit dose until resolved to ≤ G1, then:
If resolved in ≤ 7 days, then 1 dose level
If resolved in > 7 days, then discontinue patient from study drug treatment
Gastrointestinal disorders
Diarrhea
Grade 1 -4Please refer to the guidelines for FGF401 -induced diarrhea provided in Appendix 5 .If diarrhea is not improved 
with cholestyramine, consider immune mediated toxicity and refer to guidelines provided in Appendix 11
Grade 3 Nausea Maintain dose level, if not resolved to ≤ Grade 2 within 48 hours despite the use of adequate treatment, then 
omit dose until resolved to ≤ Grade 2, and then ↓1 dose level
≥ Grade 3 Vomiting Maintain dose level, if not resolved to ≤ Grade 2 within 24 hou rs after the optimal anti -emetic therapy start, then 
omit dose until resolved to ≤ Grade 2, and then ↓1 dose level
General disorders
Grade 3 Fatigue Maintain dose level, if not resolved to ≤ Grade 2 within 7 days, then omit dose until resolved to ≤ Grade 2, and 
then ↓1 dose level
Stevens -Johnson sy ndrome (SJS), or Ly ell 
syndrome/toxic epidermal necroly sis (TEN)Permanently  discontinue study  treatment .
Other adverse events

Novartis Confidential Page 63
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Recommended Dose Modifications for FGF401
For the FGF401 in combination with PDR001 treatment: Dose level maintenance, dose omission and treatment discontinuation refer to both FGF401 and PDR001. 
Reduction of one dose level refers to FGF401 only while PDR001 dose level should be maintained, unless otherwise specified.
Worst toxicity
CTCAE v4.03 GradeRecommended dose modifications any time during a cycle of therapy (including intended day of dosing)
Grade 1 or 2 Maintain dose level
Grade 3 Omit dose until resolved to ≤ grade 1, then ↓1 dose level . 
Note: Dose level can be maintained in case they are resolved within 7 days and are considered not clinically 
important.
Grade 4 Omit dose and discontinue patient from study
All dose modifications should be based on the worst preceding toxicity.
CTCAE version 4.03 will be used for all grading.
*baseline refers to respective laboratory values before start of the study treatment
**in case immune mediated etiology cannot be excluded; consider following the guidelines in Appendix 11

Novartis Confidential Page 64
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Table 6-5 Criteria for interruption and re -initiation of PDR001 treatment
Recommended dose modifications for PDR001
Worst toxicity CTCAE v4.03 grade Anytime during a cycle of therapy and after the DLT evaluation period *
Infusion Reaction
Grade 1 Infusion interruption not indicated; decrease infusion rate until recovery of 
symptoms
Grade 2 Stop infusion of PDR001. 
Before resuming infusion pre-medicate according to local institutional 
guidelines.
Restart infusion at 50% of previous rate under continuous observation. 
Ensure that there is a minimum observation period of 1 hour prior to 
restarting the infusion.
If the AE recurs at the reinitiat ed slow rate of infusion, and despite oral 
pre-medication, then discontinue patient from PDR001
Grade 3 or 4 Discontinue infusion immediately, and discontinue patient from PDR001
Stevens -Johnson syndrome (SJS), or 
Lyell syndrome/toxic epidermal 
necrolysis (TEN)Permanently discontinue study treatment
Pulmonary: Pneumonitis Management Algorithms ( Appendix 11 )
Renal : Serum Creatinine Management Algorithms ( Appendix 11 )
Gastro -intestinal: Diarrhea/Colitis M anagement Algorithms ( Appendix 11 )
Skin: Rash Management Algorithms ( Appendix 11 )
Endocrinopathy : TSH Management Algorithms (Appendix 11 )
Other clinically significant toxicities thought to be immune -mediat ed and not covered in Appendix 11
Grade 1 Monitor closely until resolution and treat symptoms as appropriate
Grade 2 Delay PDR001 treatment until resolved to ≤ Grade 1
Grade 3 or 4 Permanently discontinue PDR001 treatment
Cytokine Release Syndrome (CRS)
Grade 2, 3 or 4 If CRS is suspected (very high fever and precipitous drops in blood 
pressure) treat with corticosteroids. 
Take blood for cytokine measurements immediatel y after the occurrence
and during treatment (Section 7.2.2.5.10 ).Following approval of protocol 
amendment 05, no further sample collection will be performed for the 
cytokine measurements.
If very high levels of IL -6 can be confirmed, a more specific treatment 
may be used.
*for infusion reaction and cytokine release syndrome the dose modifications are applicable anytime during a cycle 
of therapy (including intended day of dosing)
6.3.2 Follow -up for toxicities
Patients whose treatment is interrupted or permanently discontinued due to an adverse event or 
clinically  significant laboratory  value, must be followed up at least once a week (or more 
frequentl y if required by institutional practices, or if clinically  indicated) until resolution or 
stabilization of the event, whichever comes first. For patients with ≥Grade 2 hepatic toxicities 
which relationship to study  treatment cannot be ruled out
, the hepatic laboratory  parameters 
should be followed up within 72 hour s. 
The emergence of irAE may be anticipated based on general experience in clinical studies with 
similar class of compounds that block the negative immune regulators.

Novartis Confidential Page 65
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
An irAE is any clinically significant adverse event affecting any organ that is associat ed with 
study  drug exposure, is consistent with an immune -mediated mechanism, and where alternative 
explanations have been investigated and ruled out or are considered to be unlikely . Serologic, 
histologic (tumor sample) and immunological assessments shoul d be performed as deemed 
appropriate b y the Investigator to verify  the immune -related nature of the AE . An empiric trial 
of corticosteroids may also contribute to understanding the etiology  of a potential irAE
.
Management Algorithms (Appendix 11) have been developed to assist Investigators in 
assessing and managing specific groups of AEs.
All patients whose treatment is interrupted or permanently  discontinued due to an irAE, AE or 
clinically  significant laboratory  value, must be followed-up at least once a week (or more 
frequentl y if required by institutional practices, or if clinically  indicated) for 4 weeks, and 
subsequently  at approximately  4-weeks intervals, until resolution or stabilization of the event, 
whichever comes first. Appropriate clinical experts should be consulted as deemed necessary . 
In case of toxicity suspected to be a cytokine release syndrome, the assessments outlined in 
Section 7.2.2.5.10 must be performed .Following approval of protocol amendment 05, no 
further sample collection will be performed for the cy tokine analy sis.
All patients must be followed-up for irAEs, AEs and SAEs as described in Section 7.1.6.
6.3.3 Anticipated risks and safety  concerns of the study  drug
Appropriate eligibility  criteria and specific DLT definitions, as well as specific dose 
modification and stopping rules are included in this protocol . 
Prophylactic or supportive 
treatment for expected toxicities, including management of study -treatment induced adverse 
events will be as per institutional guidelines . Recommended guidelines for the management of 
FGF401 -induced diarrhea and hyperphosphatemia are provided in Appendix 5andAppendix 6
respectivel y.Moreover, patients will not initially  receive proph ylactic treatment with anti-
emetics in cycle 1, but should receive treatment for nausea/vomiting as per institutional 
guidelines. 
In addition, recommended guidelines for prophy lactic or supportive treatment for expected 
toxicities with the FGF401 and PDR001 combination, including management of immune 
related toxicities
, are provided in Section 6.3 and Appendix 11.
Refer to Section 1.2  
6.4 Concomitant medications
6.4.1 Permitted concomitant therapy
In general, concomitant medications and therapies deemed necessary  for the supportive care
(e.g. phosphate lowering therapy  and anti-diarrhea therapies) and safety  of the patient are 
allowed, except for those prohibited as stated in Section 6.4.3.
Prophy lactic phosphate lowering 
and/or anti -diarrhea therapies should be considered as per the 
management guidelines provided in Appendix 5and Appendix 6. Prophy lactic phosphate 
lowering and/or anti-diarrhea therapies arealso recommended once the MTD and/or RP2D have

Novartis Confidential Page 66
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
been established during the FGF401 single agent phase I and dose -related hyperphosphatemia 
and diarrhea have been well -characterized.
The patient must be told to notify  the investigational site about any new medications he/she 
takes after the start of the study  drug. All medications (other than study treatment ) and 
significant non-drug therapies (including physical therap y, herbal/natural medications and 
blood transfusions) admin istered during the study  must be listed on the Prior and Concomitant 
Medications eCRF or the Surgical and Medical Procedures eCRF.
6.4.2 Permitted concomitant therapy  requiring caution and/or action
Medications that are inducers or inhibitors of CYP3A4/5 are notprohibited but should be 
administered with caution. Concomitant medications that may potentiall y inhibit BSEP ( the 
known BSEP inhibitors  are prohibited), MRP2/3/4, NTCP and OATP1B1/3 ,which are 
involved in bile acid transport ,should be administered with caution, as increase in bile acid 
synthesis is expected at efficacious doses. Refer to Appendix 4for a list of the medications that 
require caution when concomitantly  used with FGF401 as single agent or in combination with 
PDR001 .
Anti
-hypertensives are allowed as concomitant medications; however, because transient 
hypotension has occurred during infusions of monoclonal antibodies, consideration should be 
given to withholdin g anti -hypertensive medications for 12 hours prior to infusion with PDR001
for patients receiving the FGF401 and PDR001 combination treatment.
6.4.3 Prohibited concomitant therapy
FGF401 is a time-dependent inhibitor of CYP1A2, CYP2C9 and CYP3A 4/5. CYP1A2, 
CYP2C 9 and CYP3A4/5 substrates with a narrow therapeutic index (NTI) are prohibited during 
the course of the study . FGF401 treatment may increase the levels of bile acids as a result of 
mechanism of action. Therefore medications that are reported to beinhibito rs of the bile acid 
efflux transporter BSEP shall be prohibited during this study
.
Additionally , for patients receiving FGF401 in combination with PDR001:
Treatment with the following agents is not permitted within 2 weeks prior to the first dose of 
study  treatment:
hematopoietic colon y
-stimulating growth factors (e.g. G- CSF, GM -CSF, M -CSF)
thrombopoietin mimetics or 
erythroid stimulating agents; however, if erythroid stimulating agents were initiated more 
than 2 weeks prior to the first dose of study  treatment and the patient is on a stable dose, 
they can be maintained. 
The use of systemic steroid therapy  and other immunosuppressive drugs is not allowed except 
for the treatment of infusion reaction, irAEs, for proph ylaxis against imaging contrast dye 
allergy or replacement -dose steroids in the setting of adrenal in sufficiency  (providing this is ≤
10 mg/day  prednisone or equivalent), or transient exacerbations of other underly ing diseases 
such as chronic obstructive pulmonary  disease (COPD ) requiring treatm ent for ≤ 3 weeks. 
Systemic corticosteroids required for the control of infusion reactions or irAEs must be tapered 
and be at non-imm unosuppressive doses (≤10 mg/day  of prednisone or equivalent) before the 

Novartis Confidential Page 67
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
next study  drug administration. If more than 10 mg/day  predniso ne is used, study  treatment 
should be suspended. Topical, inhaled, nasal and ophthalmic steroids are allowed.
The use of live vaccines is not allowed through the duration of the study . Inactivated vaccines 
are allowed .
During the course of th e study, patients must not receive other additional investigational drugs, 
devices, chemotherap y, or any other therapies that may be active against cancer or modulate 
the immune responses. However, limited -field palliative radiotherap y to non-target lesion (s) 
may be allowed as concomitant therap
y after documented discussion with Novartis. Such local 
therapies administered during the study  treatment must be entered into the CRF. Additionally , 
no other therapeutic monoclonal antibodies and no immunosuppressive medication may be 
administered while on this study  unless given for the management of immune toxicity .
Refer to Appendix 4for a list of the medications that are prohibited when concomitantly  used 
with FGF401 as single agent and in combination with PDR001 .
6.5 Patient numbering, treatment assignment or randomization
6.5.1 Patient numbering
Each patient is identified in the study  by a Subject Number (Subject No.), that is assigned when 
the patient is first enrolled for molecular pre-screening or screening as applicable and is retained 
as the primary  identifier for the patient throughout his/her entire participation in the trial. The 
Subject No. consists of the Center Number (Center No. as assigned by Novartis to the 
investigative site) with a sequential patient number suffixed to it, so that each subject is 
numbered uniquely  across the entire database. Upon signing the informed consent form, the 
patient is assigned to the next sequential Subject No. available to the investigator through the 
Oracle Clinical RDC interface.
6.5.2 Treatment assignment
This is a non-randomized trial and Integrated Response Technology  (IRT) will not be used. The 
assig nment of a patient to a particular cohort during the phase I parts,and during the  phase II
parts will be coordinated by  Novartis.
6.6 Stud y drug preparation and dispensation
The investigator or responsible site personnel must instruct the patient or caregive r to take 
FGF401 as per protocol. FGF401 will be dispensed to the patient by  authorized site personnel 
only. All dosages prescribed to the patient and all dose changes during the study  must be 
recorded on the Dosage Administration Record 
eCRF.
PDR001  will be administered intravenousl y as a 30 
minute infusion (up to 2 hour, if clinically  indicated). Further instructions for the preparation 
and dispensation of PDR001 are described in the Pharmacy  Manual .
6.6.1 Study drug pa ckaging and labeling
The FGF401 packaging has a 2-part label. Responsible site personnel will add the patient 
number on the 
label. Immediately  before dispensing the package to the patient, site personnel 

Novartis Confidential Page 68
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
will detach the outer part of the label from the packaging and affix it to the source document
for that patient’s unique subject number.
 
Medication labels will be in the local language and comply  with the legal requirements of each 
country . They  will include stora ge conditions for the drug and but no information about the 
patient.
6.6.2 Drug supply  and storage
Study  treatments must be received by designated personnel at the study  site, handled and stored 
safel y and properl y, and kept in a secured location to which only the investigator and designated 
site personnel have access. Upon receipt, FGF401 and PDR001 should be stored according to 
the instructions specified on the drug labels  
6.6.3 Study drug compliance and accountability
6.6.3.1 Study drug compliance 
Compliance will be assessed by the investigator and/or study  personnel at each patient visit and 
information provided by the patient and/or care giver will be captured in the drug a ccountability 
record . This information must be captured in the source document at each patient visit.
6.6.3.2 Study drug accountability
The investigator or designee must maintain an accurate record of the shipment and dispensing
of study  treatment in a drug accountability  logaccording to local institutional drug 
accountability  processes . Drug accountability  will be noted by the field monitor during site 
visits and at the completion of the study . Patients will be asked to return all unused study 
treatment and packaging on a regular basis, at the end of the study  or at the time of study  
treatment discontinuation.
At study  close-out, and, as appropriate during the course of the study , the investigator will return 
all used and unused study  treatment, packaging, drug labels, and a copy  of the completed drug 
accountability  logto the Novartis monitor or to the Novartis address provided in the investigator 
folder at each site.
6.6.4 Disposal and destruction
The study  drug suppl y can be destro yed at the local Novartis facility , Drug Supply  group or 
third party , as appropriate.
Arrange for drug supply  to be destroy ed at the site only if permitted by local regulations and 
authorized by  Novartis in a prior agreement.

Novartis Confidential Page 69
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
7 Visit schedule and assessments
7.1 Stud y flow and visit schedule
Table 7-1lists all of the assessments and indicates with an “X”, the visits when they are 
performed. All data obtained from these assessments must be sup
ported in the pati ent’s source 
documentation. No CRF will be used as a source document. The table indicates which 
assessments produce data to be entered into the clinical database (D) or remain in source 
documents only  (S) (“Category ” column).
For Japan only , patients are r equired to be hosp italized in Cy cle 1 of the dose escalation part s.
For all visits, there is a ± 3 days window on assessments if not explicitly  specified otherwise. 
In particular, full PK sampling should be performed on the specified day of dosing and time-
point. In any case, if the dosing schedule is changed, the visit evaluation schedule will follow 
Table 7 -1without changes. In  general, where possible, every effort must be made to follow the 
schedule 
outlined in Table 7 -1.
Screening assessments need to be performed within 14 days from the first dose of study  
treatment with the exception of pregnancy  test which must be performed within 72 hours from 
study  treatment start. Laboratory  assessments performed as part of the screen
ing evaluations 
and within 72 hours of the cycle 1 day 1, are not required to be repeated on the first dosing day. . 
Screening radiological assessment should be performed preferabl y within 7 days prior to the 
first study  treatment dose; however radiologica l assessments that areperformed up to21 days 
before the first study  treatment dose will be acceptable ; (except whole body  scans, if applicable, 
which can be performed within 6 weeks of study  treatment start) On-study  radiological 
assessments can be performed within a ± 7 days window from the scheduled date of the 
assessment.
Following approval of protocol amendment 05, the ongoing patients will follow a reduced 
schedule of safet y and efficacy  assessments as detailed in Table 7-1b. The assessments in Table 
7-1will no longer be applicable. Table 7-1bindicates which assessments produce data to be 
entered into the clinical database (D) or remain in source documents only (S) (“Category ” 
column).
Other assessments may be performed at the Investigator’s discretion following standard of care 
at the site.When abnormal laboratory  values or test results const itute an adverse event, they 
must be recorded on the Adverse Events eCR F.

Novartis Confidential Page 70
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Table 7-1 Visit evaluation schedule (applicable for protocol amendment 04 -following approval of protocol amendment 05
refer to Table 7 -1b below) Category
Protocol 
Section 
Molecular 
pre-screening
ScreeningCycle 1 Cycle 2Subsequent 
Cycle
End of study 
treatment 
30 or 150-day 
Safety -FUa
Disease 
progression
Survival FU
Visit Name
Day -14 to 
Day 1
Day 1
Day 2
Day 8
Day 9
Day 15
Day 1
Day 2 Day 8
Day 15
Day 1
Day 15Obtain molecular pre -
screening Informed 
ConsentD 7.1.1 Xas 
appicable
Obtai n Informed 
ConsentD 7.1.2 X
Patie nt History
Demography D 7.1.2.2 X X
Inclu sion/exclusion 
criteriaD 5 X X
Relev ant medical 
history/current medical 
conditionsD 7.1.2.2 X
Diagn osis and extent of 
cancerD 7.1.2.2 X
Child -Pugh and BCLC 
classification, 
applicable to HCC 
patientsD 7.1.2.2 X
Prior antineoplastic 
therapiesD 7.1.2.2 X

Novartis Confidential Page 71
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101Category
Protocol 
Section 
Molecular 
pre-screening
ScreeningCycle 1 Cycle 2Subsequent 
Cycle
End of study 
treatment 
30 or 150-day 
Safety -FUa
Disease 
progression
Survival FU
Visit Name
Day -14 to 
Day 1
Day 1
Day 2
Day 8
Day 9
Day 15
Day 1
Day 2 Day 8
Day 15
Day 1
Day 15Prior /concomitant 
medicationsD 7.1.2.2 X Continuous (for 150 -day safety FU: until the 30 -day safety FU or the start of new 
antineoplastic therapy, whatever occurs first)
Physical examinationS 7.2.2.1 X X X X X
Vital signs D 7.2.2.2 X X X X X X X X X
Heigh t D 7.2.2.3 X
Weight D 7.2.2.3 X X X X X
ECOG Performance 
statusD 7.2.2.4 X X X X X
Laboratory  assessments
Hematology D 7.2.2.5.1 X X X X X X X X X
C3/C4 
onlyX
Chemi stry D 7.2.2.5.2 X X X X X X X X X
C3/C4 
onlyX
Coagulation D 7.2.2.5.3 X X X X X X
Urinalysis D 7.2.2.5.4 X X X
Pregn ancy test D 7.2.2.5.8 X X X X
S Xb

Novartis Confidential Page 72
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101Category
Protocol 
Section 
Molecular 
pre-screening
ScreeningCycle 1 Cycle 2Subsequent 
Cycle
End of study 
treatment 
30 or 150-day 
Safety -FUa
Disease 
progression
Survival FU
Visit Name
Day -14 to 
Day 1
Day 1
Day 2
Day 8
Day 9
Day 15
Day 1
Day 2 Day 8
Day 15
Day 1
Day 15AFP, applicable to HCC 
patients, every 6 weeksD 7.2.2.5.5 X X
Hepatitis markers , 
every 6 weeks starting 
from C3D 7.2.2.5.6 X X X
HIV(for 
FGF401+PDR001 only)D 7.2.2.5.6 X
Thyro id function (for 
FGF401+PDR001 only)D 7.2.2.5 X X X X X
Cytok ines for safety 
(FGF401+PDR001 
only)D 7.2.2.5.10 X any time when a suspected cytokine release syndrome occurs, within 5 hours (or 
as soon as possible) after the occurrence of the AE, and one week after 
occurrence of the AE
Efficacy  assessments
Tumor response 
assessment , every 6 
weeks starting by C3D1D 7.2.1 X X X X
Cardi ac assessments
12-lead ECG D 7.2.2.6.1 X X X X X
PK sa mpling
FGF401 PK sampling 
(Phase I part s)-all 
patientsD 7.2.3.1 X X X X X X X X
C3/C4 
only

Novartis Confidential Page 73
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101Category
Protocol 
Section 
Molecular 
pre-screening
ScreeningCycle 1 Cycle 2Subsequent 
Cycle
End of study 
treatment 
30 or 150-day 
Safety -FUa
Disease 
progression
Survival FU
Visit Name
Day -14 to 
Day 1
Day 1
Day 2
Day 8
Day 9
Day 15
Day 1
Day 2 Day 8
Day 15
Day 1
Day 15FGF40 1 PK sampling 
(Phase II part s)-all 
patientsD 7.2.3.1 X X X X X X X
C3-
C6 
only
PDR001 PK sampling 
(Phase I part) -for 
FGF401+PDR001 onlyD 7.2.3.1 X X X X X up 
to C6X for 
C3 
onlyX Xc
PDR001 PK sampling 
(Phase I Ipart)-for 
FGF401+PDR001 onlyD 7.2.3.1 X X X up 
to C6X Xc
PDR001
immunogenicity (IG) 
sampling -for 
FGF401+PDR001 onlyD 7.2.3.1 X X X up 
to C6X Xc

Novartis Confidential Page 74
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101Category
Protocol 
Section 
Molecular 
pre-screening
ScreeningCycle 1 Cycle 2Subsequent 
Cycle
End of study 
treatment 
30 or 150-day 
Safety -FUa
Disease 
progression
Survival FU
Visit Name
Day -14 to 
Day 1
Day 1
Day 2
Day 8
Day 9
Day 15
Day 1
Day 2 Day 8
Day 15
Day 1
Day 15

Novartis Confidential Page 75
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101Category
Protocol 
Section 
Molecular 
pre-screening
ScreeningCycle 1 Cycle 2Subsequent 
Cycle
End of study 
treatment 
30 or 150-day 
Safety -FUa
Disease 
progression
Survival FU
Visit Name
Day -14 to 
Day 1
Day 1
Day 2
Day 8
Day 9
Day 15
Day 1
Day 2 Day 8
Day 15
Day 1
Day 15FGF40 1administration D 6 Continuous
PDR001 infusion (for 
FGF401+PDR001 only)D 6 i.v. every 3 weeks (in case of sequential schedule start from C3D1)
Antineoplastic therapies 
since discontinuation of 
study treatmentD 7.1.5 X X X
Adver se events D 8 SAE
OnlyContinuous (for 150 -day safety FU : after initiation of new antineoplastic therapy only AEs/SAEs 
suspected to be related to study treatment will be collected)
Survival contact D 7.1.5 X
aforFGF401 single agent safety evaluations for 30 days after the last dose of FGF401 . For FGF401 and PDR001 combination safety evaluations for 150 days afte r the 
last dose of PDR001 with contacts at 30 -, 90-and 150 -day (see Section 7.1.6 ).
bonly f orFGF401 and PDR001 combination with tests every month until the end of 150 -day safety FU. Pregnancy tests can be performed at home or at a local 
doctor’s office if the patient is not coming to the clinic.
conly for patients coming to the site for the 150- day safety follow -up visit
ecollect at screening or anytime thereafter

Novartis Confidential Page 76
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Table 7-1b Visit evaluation schedule –applicable upon approval of protoc ol amendment 05CategoryTreatment Phase -all cy cles until end of study treatment End of 
study  
treatment 30 or 
150-
day  
Safety
-FUa
Disease 
progression 
FU
Survival FUFGF401 single agent:
Visit every  2 cycles (i.e. every 6 
weeks)FGF401+PDR001 combination:
Visit every  cycle (i.e. every  3 
weeks)
Visit Name Day 1 
Physical examination S X X X
Vital signs D X
Hematology D X X X
Chemistry D X X X
Pregnancy test D XcX X
S Xb
Hepatitis markers D X X every 6 weeks X
Tumor response assessment D X every 12 weeks X X
FGF401 administration D Continuous
PDR001 infusion D X i.v. every 3 weeks
Adverse events D Continuous a
Concomitant medications D Continuous a
Antineoplastic therapies since 
discontinuation of study treatmentD X X X
Survival contact D X
a for FGF401 single agent safety evaluations for 30 days after the last dose of FGF401. For FGF401 and PDR001 combination safet y evaluations for 150 days after the 
last dose of PDR001 with contacts at 30 -, 90-and 150 -day (see Section 7.1.6 ). 
For the 150 -day safety FU: After initiation of new antineoplastic therapy only AEs/SAEs suspected to be related to study treatment will b e collected. Collection of 
concomitant medications will be until the 30 -day safety FU or the start of new antineoplastic therapy, whatever occurs first.
bonly for FGF401 and PDR001 combination with tests every month until the end of 150 -day safety FU. Pregnancy tests can be performed at home or at a local 
doctor’s office if the p atient is not coming to the clinic. 
c Serum pregnancy test at Day 1 of each cycle ( note that on the release date of protocol amendment 05, there were no female participant s that are of child -bearing
potential on study ).

Novartis Confidential Page 77
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
7.1.1 Molecular pre -screening
During the phase I partof FGF401 single agent , FGFR4 and KLB expression will be assessed 
using RT-PCR and/or IHC assay s. 
Biomarker positivity  will be defined by a Novartis 
designated laboratory  that is certified to perform clinical assay s.FGF19 mRNA expression will 
be also assessed by RT-PCR, but it will not be used as inclusion criteri on. During the phase II 
partof the FGF401 single agent , evidence of positive expression of FGFR4 and KLB is required 
in order to begin screening activities only for patients in Group 3.FGF19 expression will be 
also assessed, but it will not be used as inclusion criteri on.In exceptional cases, patients with a 
tumor harboring a documented FGFR4 mutation can be enrolled in the study  following 
discussion and agreement with Novartis
.
Molecular pre -screening will not be pe rformed for the FGF401 and PDR001 combination part.
However, should, the Stage 2 of the FGF401 and PDR001 combination part proceed, based on 
the interim analy ses results (Section 4.2), the FGF pathway  expression level and/or FGF19 
pathway  activation as deemed necessary ,will be requi red for enrollment and molecular pre-
screening will be initiated at that stage.
The molecular status must be obtained through the submission of newl y obtained tumor samples 
which are collected after the
latest anti-neoplastic treatment failure to a Novarti s designated 
laboratory  for testing. The potential patients will be asked to sign a “molecular pre-screening 
informed consent” to allow for the collection and analy sis of the newly  obtained tumor samples. 
The newl y obtained tumor samples can be submitted for analy sis as formalin fixed tumor 
sample or FFPE block prepared from multiple (3 -6)passesof a core needle tumor biopsy . For 
details of sample quality  requirements refer to theapplicable study Laboratory Manual . If the 
patient is enrolled in the main study , the newl y obtained tumor sample submitted for molecular 
pre-screening can be used for other  study  assessments. For other details, refer to
Section 7.2.4.
7.1.2 Screening
The allocation of patients to treatment cohorts and Groups will be handled by Novartis study 
team.
A written informed consent form (ICF) will be obtained from each patient before any study 
related procedures are initiated. Laboratory and radiological evaluations which are part of the 
patient’s standard of care may  be performed before obtaining the ICF, if within the acceptable 
screening window ( Section 7.1 ).
Patients will be evaluated against study  inclusion and exclusion criteria and safet y assessments.
A complete list of screening evaluations is provided in the visit of assess ments table ( Table 7-
1).
7.1.2.1 Information to be collected on screening failures
Patients who signed a molecular pre-screening ICF but are considered ineligible after molecular 
pre-screening, as well as patients who are found not eligible after signing the main study  consent 
will be considered screening failures, and data will be handled in the same manner. The reas on 

Novartis Confidential Page 78
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
for molecular pre -screening failure or screening failure will be entered on the Screening Phase 
Disposition Page.
The demographic information, informed consent, and Inclusion/Exclusion pages must also be 
completed for Screen Failure patients. No other data will be entered into the clinical database 
for patients who are screen failures, unless the subject experienced a Serious Adverse Event 
during the Screening Phase (see Section 8 for SAE reporting details). For molecular pre-
screening failures, only SAEs possibly related to a study procedure will be reported.
7.1.2.2 Patient demographics and other baseline characteristics
Data will be collected on patient characteristics including demographic information (age, 
gender, race) and other background or relevant medical history , including history  of disease and 
current disease 
status, diagnosis and extent of cancer (for HCC patients, BCLC staging and 
Child -Pugh classification systems are applied), prior anticancer therapies, prior medication/ 
significant non-drug therapies and any other assessments that are done for the purpose of 
determining eligibility  for inclusion in the study .
7.1.3 Treatment period
A treatment cycle 
is defined as 21 days (3 calendar weeks) for the purposes of scheduling 
procedures and evaluations. Please refer to Table 7-1or Table 7-1b following approval of 
protocol amendment 05for details of the timing of required assessments and Section 7.1for 
visit windows.
Patients may continue treatment with FGF401 single agent or in combination with PDR001
until the patient experiences unacceptable tox icity that precludes an y further treatment, disease 
progression, and/or treatment is discontinued at the discretion of the investigator or by patient 
request. 
In general, p atients who have disease progression and have evidence of clinical benefit, such as
disease shrinkage at other sites or symptomatic improvement, may continue receiving study 
treatment. In addition, study treatment may be temporarily  interrupted to permit local therap y 
for symptomatic metastases after disease progression has been document ed. Patients who 
continue on treatment after disease progression should discontinue study  treatment once they 
are no longer deriving benefit as assessed by the investigator .All patients will continue to 
follow the assessments as outlined in the visit evaluation table, Table 7-1or Table 7 -1b
following approval of protocol amendment 05.
For patients treated with immunotherapy , including PD-1 inhibitor, clinical experience 
indicates that objective responses to immunotherap y follows delay ed kinetics of weeks or 
months, and can be preceded by  initial apparent radiological progression or appearance of new 
lesions or some enlarging lesions while other target lesions are regressing (“mixed response”) 
(Wolchok 2009 ). It is therefore reasonable to allow for these possibilities and continue to treat 
the patient until progression is confirmed and found to be advancing at the next imaging 
assessment 
as per irRC . An outline of the irRC is provided in Appendix 9.
Patients treated with FGF401 in combination with PDR001 will continue study treatment in 
additional cyclesif they  meet the following criteria :
Unconfirmed irPD, SD/irSD, PR/irPR and unconfirmed CR/irCR.

Novartis Confidential Page 79
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Patients treated with FGF401 in combination with PDR001 will notcontinue study treatment 
in additional cy cles if they  meet any  of the following criteria:
Experience unacceptable toxicity .
Confirmed irPD. These patients will then enter the Safety  follow -up period. 
Patients with an unconfirmed irPD who show signs of clinical deterioration or toxicity  will 
enter the Safet y follow- up period, and will contin ue to be followed -up until confirmed 
irPD or initiation of a new treatment .
Patients with confirmed irPD might continue receiving study  treatment, if the Investigator 
considers it to be in the patient’s best interest to remain on the study , and after documented 
discussion with the Novartis medical monitor.
These considerations should be balanced by clinical judgment as to whether the patient is 
clinically  deteriorating and unlikely  to receive any benefit from continued treatment. Such 
deterioration will be assessed to have occurred after a clinical event that, in the Investigator’s 
opinion, is attributable to disease progression, is unlikely  to reverse with continued study  
treatment and therefore indicates that the patient is not benefiting from study  treatm ent and 
cannot be managed by the addition of supportive care .
7.1.4 Discontinuation of Study Treatment
Patients may voluntarily  discontinue from the study  treatment for any reason at any time. If a 
patient decides to discontinue from the study  treatment, the investigator should make a 
reasonable effort (e.g. telephone, e-mail, letter) to understand the primary  reason for this 
decision and record this information in the patient’s chart and on the appropriate CRF pages. 
They  may be considered withdrawn if they state an intention to withdraw, fail to return for visits, 
or become lost to follow -up for an y other reason.
Study  treatment must be discontinued under the following circumstances:
Adverse events, that results in a significant risk to the patient’s safety .
The following deviation from the prescribed dose regimen for stud y treatment: dose 
interruption of > 21 day sfrom the intended day  of the next scheduled dose for FGF401 or 
in case > 12 consecutive weeks are required before recovery  from PDR001- related 
toxicities , unless otherwise specified in Section 6.3.1
Pregnancy
Any other protocol deviation that results in a significant risk to the patient’s safet y
Patients who discontinue study  treatment should NOT be considered withdrawn from the study . 
They  should return for the assessments indicated in Table 7 -1or Table 7-1b following approval 
of protocol am endment 05 (end of stud y treatment visit) and then enter the follow -up epoch. If 
they fail to return for these assessments for unknown reasons, every  effort 
(e.g. telephone, email, 
letter) should be made to contact them as specified in Section 7.1.6. An EOT visit should be 
conducted within 14 days of the last dose of study treatment or within 14 day s of the decision 
to permanentl y discontinue study  treatment . If the patient discontinues from the study treatment
at a scheduled visit, the EOT assessment can be performed on that day. An End of Treatment 
Phase Disposition eCRF page should be completed to include the date and reason for 
discontinuing study  treatment

Novartis Confidential Page 80
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
For patients who discontinue study  treatment for reasons other than documented disease 
progression, death, lost to follow -up, or withdrawal of consent, tumor assessments must 
continue to be performed every  6 weeks or every  12 weeks following approval of protocol 
amendment 05until documented disease progression, death, lost to follow -up, or withdrawal of 
consent .
7.1.4.1 Replacement policy
Phase I Part
Patients will not be replaced on study . However, if a patient is considered as non
-evaluable for 
the DDS, enrollment of a new patient to the current cohort will be considered if there is less 
than the required number of evaluable patients. Enrollment of new patients may be considered 
until at least the minimum number (1 or 3for FGF401 single agent or 3 for FGF401 in 
combination with PDR001 ) orat most the maximum number (6) of evaluable patients is 
achieved within the cohort.
Phase II Part
During the phase II part, no replacement will be needed.
7.1.5 Withdrawal of consent
Subjects may voluntarily  withdraw consent to participate in the study  for any reason at any time. 
Withdrawal of consent occurs only when a subject does not want to participate in the study  
anymore , and does not allow further collection of personal data.
In this situation , the Investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the subject ’sdecision to withdraw his/her consent and 
record this information.
Study  treatment must be discontinued and no further assessments conducted , and the data that 
would have been collected at subsequent visits will be considered missing .
Further attempts to contact the subject are not allowed unless safety  findings require 
communication or follow -
up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
assessment table.
Novartis will continue to keep and use collected study  information (including any data resulting 
from the anal ysis of a subject’s samples until their time of withdrawal) according to applicable 
law.
For US and Japan: All biological samples not yet analyzed at the time of withdrawal may  still 
be used for further testing/analy sis in accordance with the terms of this protocol and of the 
informed consent form.
For EU and RoW: All biological samples not yet analyzed at the time of withdrawal will no 
longer be used, unless permitted by  applicable law. They will be stored according to applicable 
legal requirements.

Novartis Confidential Page 81
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
7.1.6 Follow up period
Safety  follow -up
All patients treated with FGF401 single agent must have safet y evaluations for 30 days after the 
last dose of FGF401. 
All patients treated with FGF401 and PDR001 combination must have safety  evaluations for 
150 day s after the last dose of PDR001 . During the 150 -day safet y follow -up for PDR001, the 
patient should be contacted , by telephone call or visit, at least on day 30, 90, and 150. 
Concomitant medications will be collected until the 30-day safety follow - up has been 
completed, or the start of a new antineoplastic therap y, whichever occurs first. A PK and 
immunogenicit y sample should be collected at 150 days as described in Section 7.2.3. If the 
150-day safet y evaluation is conducted b y phone, samples do not need to be collected .
In case patients disc ontinue PDR001 more than 141 days before the last dose of FGF401, then 
they must have safet y evaluations for 30 day s after the last dose of FGF401
. 
Disease progression follow -up
Any patient who has not progressed at the time of discontinuation of study treatment will 
continue to have tumor assessments performed every  6 w eeks or every  12 weeks following 
approval of protocol amendment 05 until disease progression, initiation of subsequent 
anticancer therapies, or death, whichever occurs first.
Survival follow -up
Upon completion of the 30or 150day safety follow -up as applicable or disease progression 
follow -up, all patients, except those who died, withdrew consent or were lost to fo llow-up, will 
be followed for survival (can be done by telephone call) every  4 weeks (±1 week) until death .
Completion of the survival follow -up period will occur once a minimum of 80% of patients in 
the phase II part for both FGF401 single agent and FGF401 in combination with PDR001 have 
died, have been lost to follow -up, or have been followed for survival for minimum 18months 
after receiving the firstdose of study  treatment , whichever occurs first .
7.1.7 Lost to follow -up
For patients whose status is unclea r because they  fail to appear for study  visits without stating 
an intention to withdraw consent, the 
Investigator should show "due diligence" by contacting 
the patient, family  or family  physician as agreed in the informed consent and by documenting 
in the source documents steps taken to contact the patient (e.g. dates of telephone calls, e -mail, 
letters). A patient should not be considered lost to follow -up until due diligence has been 
completed. Patients lost to follow -up should be recorded as such on the appropriate Disposition 
eCRF page .

Novartis Confidential Page 82
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
7.2 Assessment ty pes
7.2.1 Efficacy  assessments
Following approval of protocol amendment 05, efficacy  assessments will be performed every 
12 weeks until progressi on of disease. 
Table 7-2 Imaging collection plan
Procedure Screening/Baseline During Treatment/Follow-up
Chest, abdomen and pelvis CT 
or MRI with contrast 
enhancement
(for HCC patients, the scan must 
include dual -phase imaging of 
the entire liver)Mandated Mandated, every 6 weeks (±7 
days )
Whole body bone scan If clinical evidence of bone metastasis If clinically indicated
Brain CT or MRI If clinical evidence of brain metastasis If brain lesions at screening
every 6 weeks (±7 days)
Bone X -ray, CT or MRI
(bone lesions only)If lesions on bone scan that are not 
visible on the chest, abdomen or 
pelvis CT/MRIIf bone lesions at screening, then 
every 6 weeks (±7 days)
Skin color photography (skin 
lesions only)If clinical evidence of skin lesions If skin lesions at screening, then 
every 6 weeks (±7 days)
If no skin lesion noted at 
screening, then if clinical 
indicated
Tumor response will be determined locall y according to Response Evaluation Criteria in Solid 
Tumors (RECI ST) v1.1 ( Appendix 1)for patients treated with FGF401 single agent. In addition
for patients treated with FGF401 and PDR001 combination the tumor response will be 
determined according to RECI ST v1.1 
(Appendix 1) and irRC (Appendix 9). The local 
investigator’s assessment will be used for the primary  endpoint analysis and for treatment 
decision making.
Additionally , imaging data from the FGF401 single agent and the FGF401 and PDR001 
combination phase II partsof the study  will be centrally  collected and checked for qualit y by 
an imaging CRO designated by Novartis and may undergo independent review accord
ing to the 
Novartis guideline, based on RECI ST v1.1 and irRC (as applicable) if deemed necessary .
Novartis may also decide to have a central review of the radiologi cal assessments from the dose 
escalation phase I parts of the study .In such case, the Investigators will be instructed on how 
to send data from these radiological assessments to a Novartis designated CRO for central 
review ,when needed.
Following approval of protocol amendment 05, the imaging data (CT/MRI scans) will not be 
centrall y collected.
CT/MRI  scans will be performed at baseline within 21days before start of treatment and 
subsequently  every 6 weeks starting oncycle 3 day 1 until progression of disease (Section 7.1.3). 
There is a ±7 days evaluation window for all tumor assessments ,
see Table 7-2for details. 
CT/MRI  scan will be performed at EOT if not conducted within 30 days prior to EOT. Disease 
progression follow -
up should be performed as described in Section 7.1.6.

Novartis Confidential Page 83
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Imaging evaluations subse quent to an off-schedule confirmatory  scan, should be performed 
according to the original assessment schedule. The same method of assessment and the same 
technique should be used to characterize each individual and reported lesion at baseline and 
during fo llow up.
If at baseline a patient has a medical contraindication to CT i.v. contrast or develops a 
contraindication during the trial, a non-contrast CT of chest plus contrast -enhanced MRI  of 
abdomen is acceptable.
Patients with clinical evidence of bone metastases must have a whole body  bone scan at baseline 
per local institutional practice. 
Lesions identified on the whole body  bone scan at baseline, 
which are not visible on the chest, abdomen or pelvis CT (or MRI ) scan should be imaged at 
baseline and followed at subsequent scheduled visits using localized CT, MRI  or X-ray. After 
baseline, whole bod y bone scans need not be repeated, unless clinically indicated.
Skin lesions present at baseline should be documented using color photography , including a 
ruler, so that the size of the lesion(s) can be determined from the photograph. Skin photographs 
should be continued at subsequent tumor assessments for any lesions that were photographed 
at screening.
Baseline brain CT or MRI will be mandated for patients with clinical sign or symptoms of brain 
metastases. Subsequent brain scans should only be conducted if brain lesions are documented 
at baseline for eligible patients or in patients that develop symptoms indicative of brain 
metastases.
All CRs and PRs must be co nfirmed by a second assessment not earlier than 4 weeks after the 
criteria for response are first met.
Any potentiall y measurable lesion that has been previously  treated with radiotherap y and/or 
loco- regional therapy  should be considered as a non-measurabl e lesion. However, if a lesion 
previously  treated with radiotherapy  and/or loco -regional therapy  has clearly  progressed since 
these therapies, it can be considered as a measurable lesion.
PET/CT may  be used only  if the CT is of similar diagnostic quality a s a CT performed without 
PET, including the utilization of oral and intravenous contrast media.
7.2.2 Safety  and tolerability assessments
Safety  will be monitored by assessment as well as collection of all serious and non-serious 
adverse events. For details on A
E collection and reporting, refer to Section 8 .
Following approval of protocol amendment 05, assessments for height, weight, and 
performance status are not required b y the protocol .
7.2.2.1 Physical examination
A complete physical examination must be performed as indicated in Table 7-1or Table 7-1b
following approval of protocol amendment 05.
Physical exam ination will be performed on the scheduled day , even if study treatment is being 
withheld. More frequent examinations may be performed at the discretion of the Investigator 
and if medicall y indicated.

Novartis Confidential Page 84
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Physical examination will be performed according to the standards at each institution. Usually , 
the physical examination will include the examination of general appearance, skin, neck 
(including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, 
extremities, vascular and neurological. If indicated based on medical history and/or s ymptoms, 
rectal, external genitalia, breast, and pelvic exams should be considered.
Information about the physical examination must be present in source documents at the study  
site. Significant findings that are present prior to signing of informed consent form for the study 
must be included in the Medical History  eCRF. Significant new findings that begin or worsen 
after informed consent for the study  must be recorded on the Adverse Events eCRF.
7.2.2.2 Vital signs
Vital signs (bod y temperature, pulse rate, blood pressure) must be performed before dosing and 
as indicated in Table 7-1or Table 7-1bfollowing approval of protocol amendment 05according 
to the standards at each institution.
Vital signs will be assessed on the scheduled day, even if study  treatment is being withheld. 
More frequent examinations may be performed at the discretion of the Investigator and if 
medically  indicated.
Following approval of protocol amendment 05, vital signs will be performed only for patients 
treated with FGF401 and PDR001 combination as indicated in Table 7-1b.
7.2.2.3 Height and weight
Height (screening only) in centimeters and body  weight in kilograms (in indoor clothing, 
without shoes) will be measured as indicated in Table 7 -1.
7.2.2.4 Performance status
ECOG performanc e status will be assessed as defined in Table 7-1 and Table 7 - 3.
Table 7
-3 ECOG performance status
Grade ECOG Status
0 Fully active, able to carry on all pre -disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature (e.g., light house work, office work)
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up and about more 
than 50% of waking hours
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair
7.2.2.5 Laboratory assessments
The laboratory  parameters assessed for safet y purposes will be evaluated locally  at the site, 
except for  cytokines for safety  (applicable for the FGF401 in combination 
with PDR001 only), which will be analyzed centrally  at the Novartis designed central laboratory. 
Refer to Table 7-4and Table 7-5or Table 7-4b following approval of protocol amendment 05 

Novartis Confidential Page 85
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
for a summary  of the parameters to be evaluated according to Table 7 -1, or Table 7-1bfollowing 
approval of protocol amendment 05. 
Unscheduled assessment can be performed if clinically  indicated.
Table 7-4 Local clinical laboratory  parameters collection plan (applicable for 
protocol amendment 04 -follo wing approval of protocol amendment 
05 refer to Table 7 -4b below) 
Test Category Test Name
Hematology Hematocrit, Hemoglobin, Platelets, Red blood cells, White blood cells, WBC Morphology 
with Differential (Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and 
others)
Chemistry (Fasting) Albumin, Alkaline phosphatase, ALT (SGPT), AST (SGOT), Bicarbonate, Calcium, 
ionized Calcium, Chloride, Creatinine, Creatine kinase, Direct Bilirubin, Glucose, 
Gamma -glutamyl transpeptidase, Inorganic phosphorus, Magnesium, Potassium, 
Sodium, Indirect Bilirubin, Total Bilirubin, Total Cholesterol, LDL, HDL, Total Protein, 
Triglycerides, Blood Urea Nitrogen (BUN) or Urea, Uric Acid , Amylase, Lipase
Coagulation Prothrombin time (PT) or International normalized ratio (INR)
Urinalysis Macroscopic Panel (Dipstick): Bilirubin, Blood, Glucose, Ketones, Leukocytes, pH, 
Protein, Specific gravity
Any clinically significant findings on dipstick will be followed up with a microscopic 
evaluation.
Hepatitis markers HBsAg, HBcAb, HBsAb, HBV -DNA, HCV RNA-PCR
Pregnancy Serum hCG/urine pregnancy test
HCC patients specific labo ratory  parameter
Other Alpha -fetoprotein
Thyroid function * Free T4 and TSH (Thyroid Stimulating Hormone)
Virology * HIV
*applicable only for FGF401 in combination with PDR001
Table 7-4b Local clinical laboratory  parameters collection plan -applicable upon 
approval of protocol amendment 05
Test Category  Test Name 
Hematology Hematocrit, Hemoglob in, Platelets, White blood cells
Chemistry (Fasting) Albumin, Alkaline phosphatase, ALT (SGPT), AST (SGOT), Calcium, Creatinine, 
Inorganic phosphorus , Total Bilirubin, Total Cholesterol, Triglycerides
Hepatitis markers HBsAg, HBcAb, HBsAb, HBV -DNA, HCV RNA-PCR
Pregnancy Serum hCG/urine pregnancy test

Novartis Confidential Page 86
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Table 7-5 Central clinical laboratory  parameters collection plan **
Test Category Test Name
Cytokines for safety* IFN-γ, IL-6
*applicable only for FGF401 in combination with PDR001
** following approval of protocol amendment 05,  cytokines for safety are not required
7.2.2.5.1 Hematology
Hematology  panel outlined in Table 7-4or Table 7-4b following approval of protocol 
amendment 05 will be performed as per the assessment schedule provided in Table 7 -1or Table 
7-1b following approval of protocol amendment 05 .
7.2.2.5.2 Clinical chemistry
Clinical chemistry  panel outlined in Table 7-4or Table 7-4b following approval of protocol 
amendment 05 will be performed as per the assessment schedule provided in Table 7 -1or Table 
7-1b following approval of protocol amendment 05 .The patient should be instructed to fast for 
at least 12 hours before specimen collection. 
7.2.2.5.3 Coagulation
Coagulation panel outlined in Table 7-4will be performed as per the assessment schedule 
provided in Table 7
-1.
Following approval of protocol amendment 05, coagulation panel is not required.
7.2.2.5.4 Urinalysis
Urinaly sispanel outlined in Table 7-4will be performed as per the assessment schedule 
provided in Table 7
-1.
Following approval of protocol amendment 05, urinaly sis panel is not required.
7.2.2.5.5 Alpha -fetoprotein
Alpha- fetoprotein will be anal yzed for HCC patients on Day  1 of every other cycle from C ycle 
1 as per the assessment schedule provided in Table 7 - 1.
Following approval of protocol amendment 05, alpha -fetoprotein analysis will not be performed.
7.2.2.5.6 Hepatitis markers -Virology
During 
the screening period, patients must be screened for HBV and HCV (current or past 
history  of infection). Careful medical history  must be taken for all patients to look for risk 
factors (family  history  of HBV and HCV, intravenous drug abuse, unprotected sex, dialy sis, 
blood transfusions, etc.), and any past or present HBV symptoms (e.g., jaundice, dark urine, 
light colored stools, right upper quadrant pain).
Hepatitis B:
At screening, all patients will be tested for:

Novartis Confidential Page 87
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
HBV -DNA level
Hepatitis B surface antigen (HBsAg)
Hepatitis B core antibody  (HBcAb)
Hepatitis B surface antibody  (HBsAb)
Monitoring for HBV –DNA level on Day 1  of every  other cycle from Cycle 3and EOT is 
required for:
Patients known to have a history  of HBV infection, despite a negative viral load test at 
screening (including those that were treated and are considered ‘cured’)
Patients positive for viral load on HBV -DNA test at screening
Patients positive for any  of the serology  at screening
Hepatitis C:
All patients will be tested for quantitative HCV RNA- PCR at the screening visit.
Monitoring for HCV RNA -PCR level on Day  1 of every  other cycle from Cy cle 3and EOT is 
required for:
Patients known to have a history  of HCV infection, despite a negative viral load test at 
screening (including those that were treated and are considered ‘cured’)
Patients positive for viral load on HCV RNA -PCR test at screening
HIV
In addition to the above assessments, for the FGF401 and PDR001 combination HIV testing 
will be performed at screening for all patients.
 
 
 
 
7.2.2.5.8 Pregnancy and assessments of fertility
All females of childbearing potential will have a serum pregnancy test within ≤72 hours before 
first dose of study  treatment andduring the study  atday 1 of each cy clestarting from Cy cle 2 , 
and at EOT. 
In addition, for the FGF401 in combination with PDR001 aurine pregnancy  test should be 
performed every  month during and at the end of the safet y follow -
up period. If the patient is 
not coming to the clinic during the safet y follow -up, it can be performed at home or at a local 
doctor’s office, and the results will be communicated to the site staff. These follow -up 
pregnancy  tests will be recorded onl y in the source documentation, not in the eCRF .

Novartis Confidential Page 88
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
If apregnancy  test (urine or serum) is positive, but the patient is thought not to be pregnant, 
study  treatment should be stopped until it is determined that the test was falsely  positive, and 
pregnancy  is excluded. In case pregnancy  is confirmed, study  treatment must be permanentl y 
discontinued and reporting requirements must be followed as des
cribed in Section 8.3.
7.2.2.5.9 Thyroid function –for FGF401 in combination with PDR001 only
Thyroid function assessments outlined inTable 7-4will be performed as per the schedule 
provided in Table 7
-1.
Following approval of protocol amendment 05, thyroid function assessments will not be 
performed.
7.2.2.5.10 Cytokines 
–for FGF401 in combination with PDR001 only
Samples analyzed for the cytokine sasoutlined inTable 7-5will be collected at the following 
time points (Table 7
-1):
Screening
On an ad -hoc basis in case a patient has an adverse event suspected to be a cy tokine 
release sy ndrome. In such case, this assessment should be performed at the following time 
points:
a.within 5 hours (or as soon as possible) after the occurrence of the adverse event,
b. one week after the occurrence of the adverse event. 
The analysis of the samples will be done only for patients who experienced an adverse event 
suspected to be a cy tokine release s yndrome and had follow -up samples collected.
Following approval of protocol amendment 05, no further sample collection will be performed 
for the cy tokine anal ysis. 
7.2.2.6 Cardiac assessments
Following approval of protocol amendment 05, cardiac assessments are not required. These 
assessments may  be performed at the investigator’s discretion following local standard of care.
When abnormal results constitute an adverse event, they must be recorded on the Adverse 
Event seCRF .
7.2.2.6.1 Electrocardiogram (ECG)
Standard 12 -lead ECG wil l be performed as per the assessment schedule provided in Table 7-1
and Table 7 -6. For all patients, 3 sequential 12- lead ECGs must be performed dur ing screening
(or Cycle 1 Day 1  if screening assessment was performed >72 hours prior to first dose) and 
Cycle 2 Day 1. One single ECG will be performed for the other time -points during the trial.

Novartis Confidential Page 89
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Table 7-6 Central ECG collection plan
Cycle DayTime ECG Measurement
Screening - - Triplicate 12 -lead
1 1 Pre-dose Triplicate 12 -lead
C1D1 assessment is required only if screening 
assessment was performed >72 hours prior to first 
dose.
1a1a2 hr post -dose (±30 minutes)aTriplicate 12 -leada
2 1 Pre-dose Triplicate 12 -lead
2 1 2 hr post -dose (±30 minutes)bTriplicate 12 -lead
subsequent 1 Pre-dose Single 12 -lead
EOT - Anytime Single 12 -lead
Unscheduled - Anytime Single 12 -lead
a[For Japan only , ECG is performed additionally  at 2 hr post dose (estimated Tmax) on Cy cle 1Day 1]
bECG is performed at 2 hr post -FGF401 administration (estimated Tmax) prior to 2 hr post -FGF401 
administration PK sampling completion
Interpretation of the tracing will be made by a central ECG laboratory . Each ECG tracing should 
be labeled with the study  number, patient initials (where regulations permit), patient number, 
date, and kept as source documents at the study  site. Clinically  significant abnormalities present 
when the patient signed informed consent should be reported on the Medical History  eCRF. 
Such clinically  significant findings must be discussed with Novartis prior to enrolling the 
patient in the study . New or worsened clinically  significant observations occurring after 
informed consent must be recorded on the Adverse Events eCRF.
7.2.3 Pharmacokinetics and immunogenicity  assessments
Serial blood samples will be collected from all patients at all dose levels for the determination
of FGF401 plasma concentration. Serum PDR001 concentrations as well as immunogenicit y 
(IG) analysis will be performed for all patients receiving PDR001. The pharmacokinetic (PK) 
analysis will be performed according to Section 10.5.3 .
 
 
Following approval of protocol amendment 05, 
no further blood sample collection will be 
performed for pharmacokinetics and immunogenicity  assessments.
7.2.3.1 Pharmacokinetic blood sample collection and handling
Blood samples will be collected in both the phase I and phase II parts forFGF401 a nd for 
PDR001 (as applicable) .
The PK blood sampling schedule for all patients receiving FGF401 is outlined in Table 7-7, 
Table 7-8, Table 7-9and Table 7-10 and the sampling time points are relative to the time of 
FGF401 administration.
Blood samples for PDR001 and IG analysis will be collecte d as outlined in Table 7
-11and 
Table 7-12. If the dosing of Cy cle 3 Day  1 is delay ed, the PK sampling for the full PK profile 

Novartis Confidential Page 90
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
should be delay ed accor dingl y to match the scheduled time points for Cycle 3 as outlined in 
Table 7 -
11and Table 7 -12. PK and IG sampl es will be collected also in the event of a clinicall y 
significant AE (such as infusio n reaction/anaphylaxis) or if immunogenicity  by PDR is 
suspected.
Table 7-7 Phase I part s: Pharmacokinetic blood collection log for QD FGF401 
administration
Cycle Day Scheduled Time Point Dose Reference ID Sample number
1 1 Pre-C1D1 dose/0 hr a1 1
1 1 0.5 hr (±10 minutes) 1 2
1 1 1 hr (±10 minutes) 1 3
1 1 2 hr (±10 minutes) 1 4
1 1 3 hr (±15 minutes) 1 5
1 1 4 hr (±15 minutes) 1 6
1 1 6 hr (±30 minutes) 1 7
1 1 8 hr (±1 hr) 1 8
1 1 12 hr (±2 hr) b1 9
1 2 24 hr/pre -C1D2 dose 1/101 10
1 8 Pre-C1D8 dose/0 hr a2/102 c11
1 8 0.5 hr (±10 minutes) 2 12
1 8 1 hr (±10 minutes) 2 13
1 8 2 hr (±10 minutes) 2 14
1 8 3 hr (±15 minutes) 2 15
1 8 4 hr (±15 minutes) 2 16
1 8 6 hr (±30 minutes) 2 17
1 8 8 hr (±1 hr) 2 18
1 8 12 hr (± 2 hr) b2 19
1 9 24 hr/pre -C1D9 dose 2/103 20
1 15 Pre-C1D15 dose/0 hr a3/104 c21
2 1 Pre-C2D1 dose/0 hr a4/105 c22
2 1 0.5 hr (±10 minutes) 4 23
2 1 1 hr (±10 minutes) 4 24
2 1 2 hr (±10 minutes) f4 25
2 1 3 hr (±15 minutes) 4 26
2 1 4 hr (±15 minutes) 4 27
2 1 6 hr (±30 minutes) 4 28
2 1 8 hr (±1 hr) 4 29
2 1 12 hr (± 2 hr) b4 30
2 2 24 hr/pre -C2D2 dose 4/106 31
3 1 Pre-C3D1 dose/0 hr a5/107 c32
4 1 Pre-C4D1 dose/0 hr a6/108 c33
- - Biopsy -matched time pointd- 1001+e
- - Unscheduled - 2001+ e

Novartis Confidential Page 91
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Cycle Day Scheduled Time Point Dose Reference ID Sample number
aTake samples immediately prior to the administration of FGF401
bOptional and only for the Japanese patients hospitalized according to the local guidance
cThe first dose reference ID is for current dose, while the second dose reference ID is for last dose the subject 
received prior to the collection of the PK sample
dTime of the blood sample taken closeto biopsy sample ; this blood sampling needs to be collected within 60
minutes before or after biopsy procedure 
eBlood samples will be uniquely, sequentially numbered as 1001, 1002, etc and 2001, 2002, etc
fSamples will be taken after ECG collection
Table 7-8 Phase II part s: Pharmacokinetic blood collection log for QD FGF401
administration
Cycle Day Scheduled Time Point Dose Reference ID Sample number
1 1 Pre-C1D1 dose/0 hr a11 101
1 1 1 hr (±10 minutes) 11 102
1 1 2 hr (±10 minutes) 11 103
1 1 6 hr (±15 minutes) 11 104
1 2 24 hr/pre -C1D2 dose 11/201 105
1 8 Pre-C1D8 dose/0 hr a12/202 b106
1 15 Pre-C1D15 dose/0 hr a13/203 b107
2 1 Pre-C2D1 dose/0 hr a14/204 b108
2 1 1 hr (±10 minutes) 14 109
2 1 2 hr (±10 minutes) e14 110
2 1 6 hr (±15 minutes) 14 111
2 2 24 hr/pre -C2D2 dose 14/205 112
3 1 Pre-C3D1 dose/0 hr a15/206 b113
4 1 Pre-C4D1 dose/0 hr a16/207 b114
5 1 Pre-C5D1 dose/0 hr a17 115
6 1 Pre-C6D1 dose/0 hr a18 116
- - Biopsy -matched time pointc- 3001+ d
- - Unscheduled - 4001+ d
a Take samples immediately prior to the administration of FGF401
b The first dose reference ID is for current dose, while the second dose reference ID is for last dose the subject 
received prior to the collection of the PK sample
c Time of the blood sample taken close to biopsy sample ; this blood sampling needs to be collected within 60
minutes before or after biopsy procedur e
d Blood samples will be uniquely, sequentially numbered as 3001, 3002, etc and 4001, 4002, etc
eSamples will be taken after ECG collection
Table 7-9 Phase I part s: Pharmacokinetic blood collection log for BID FGF401
administration (if BID dosing is implemented)
Cycle Day Scheduled Time Point Dose Reference ID Sample number
1 1 Pre-C1D1 dose/0 hr a21 201
1 1 1 hr (±10 minutes) 21 202
1 1 2 hr (±10 minutes) 21 203
1 1 6 hr (±30 minutes) 21 204
1 8 Pre-C1D8 dose/0 hr a22/301 c205
1 8 0.5 hr (±10 minutes) 22 206
1 8 1 hr (±10 minutes) 22 207
1 8 2 hr (±10 minutes) 22 208

Novartis Confidential Page 92
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Cycle Day Scheduled Time Point Dose Reference ID Sample number
1 8 3 hr (±15 minutes) 22 209
1 8 4 hr (±15 minutes) 22 210
1 8 6 hr (±30 minutes) 22 211
1 8 8 hr (±1 hr) 22 212
1 15 Pre-C1D15 dose/0 hr a24/302 c213
2 1 Pre-C2D1 dose/0 hr a25/303 c214
2 1 1 hr (±10 minutes) 25 215
2 1 2 hr (±10 minutes) b25 216
2 1 6 hr (±30 minutes) 25 217
3 1 Pre-C3D1 dose/0 hr a27/304 c218
4 1 Pre-C4D1 dose/0 hr a28/305 c219
- - Biopsy -matched time pointd- 5001+e
- - Unscheduled - 6001+ e
aTake samples immediately prior to the administration of FGF401
bSamples will be taken after ECG collection
cThe first dose reference ID is for current dose, while the second dose reference ID is for last dose the subject 
received prior to the collection of the PK sample
dTime of the blood sample taken close to biopsy sample ; this blood sampling needs to be co llected within 60
minutes before or after biopsy procedure 
eBlood samples will be uniquely, sequentially numbered as 5001, 5002, etc and 6001, 6002, etc
Table 7-10 Phase I I part s: Pharmacokinetic blood collection log for BID FGF401
administration (if BID dosing is implemented)
Cycle Day Scheduled Time Point Dose Reference ID Sample number
1 1 Pre-C1D1 dose/0 hr a31 301
1 1 1 hr (±10 minutes) 31 302
1 1 2 hr (±10 minutes) 31 303
1 1 6 hr (±15 minutes) 31 304
1 8 Pre-C1D8 dose/0 hr a32/401 b305
1 15 Pre-C1D15 dose/0 hr a33/402 b306
2 1 Pre-C2D1 dose/0 hr a34/403 b307
2 1 1 hr (±10 minutes) 34 308
2 1 2 hr (±10 minutes) e34 309
2 1 6 hr (±15 minutes) 34 310
2 2 Pre-C2D2 dose/0 hr a35/405 b311
3 1 Pre-C3D1 dose/0 hr a36/404 b312
4 1 Pre-C4D1 dose/0 hr a37/40 6b313
5 1 Pre-C5D1 dose/0 hr a38 314
6 1 Pre-C6D1 dose/0 hr a39 315
- - Biopsy -matched time pointc- 7001+ d
- - Unscheduled - 8001+ d
a Take samples immediately prior to the administration of FGF401
b The first dose reference ID is for current dose, while the second dose reference ID is for last dose the subject 
received prior to the collection of the PK sample
c Time of the blood sample taken close to biopsy sample ; this blood sampling needs to be collected within 60
minutes before or after biopsy procedure
d Blood samples will be uniquely, sequentially numbered as 7001, 7002, etc and 8001, 8002, etc
eSamples wil l be taken after ECG collection

Novartis Confidential Page 93
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Table 7-11 Schedule of blood (serum) collectio n for PDR001 PK and IG for 
patients participating in phase I of FGF401 and PDR001 combination 
Cycle* Day Scheduled Time Point (h) Anal ytes
1 1 0 hr/pre-C1D1 doseaPDR001 and IG
1 1 1 hr(±5 min)bPDR001
1 8 168 hr (±8hr) PDR001
1 15 336 hr (±24hr) PDR001
2 1 504hr (±24hr)/ pre-C2D1 doseaPDR001 and IG
3 1 0hr/pre -C3D1 doseaPDR001 and IG
3 1 1 hr (±5 min)bPDR001
3 15 336 hr (±24hr) PDR001
4 1 504 hr (±24hr)/ pre -C4D1 doseaPDR001 and IG
5 1 0hr/pre -C5D1 doseaPDR001 and IG
6 1 0hr/pre -C6D1 doseaPDR001 and IG
EOT PDR001 and IG
150-day safety follow -up** PDR001 and IG
Unscheduled PDR001 and IG
*refers to PDR001 administration cycle
**only for patients who come to the site for the 150 -day safety follow -up visit
atake samples immediately prior to PDR001 infusion
b take samples after completion of PDR001 infusion
Table 7-12 Schedule of blood (serum) collection for PDR001 PK and IG for 
patients participating in Phase II of FGF401 and PDR001 combination
Cycle* Day Scheduled Time Point (h) Analytes
1 1 0 hr/pre -C1D1 doseaPDR001 and IG
1 1 1 hr (±5 min)bPDR001
2 1 0 hr/pre -C2D1 doseaPDR001 and IG
3 1 0 hr/pre -C3D1 doseaPDR001 and IG
3 1 1 hr (±5 min)bPDR001
4 1 0 hr/pre -C4D1 doseaPDR001 and IG
5 1 0hr/pre -C5D1 doseaPDR001 and IG
6 1 0hr/pre -C6D1 doseaPDR001 and IG
EOT PDR001 and IG
150-day safety follow -up** PDR001 and IG
Unscheduled PDR001 and IG
*refers to PDR001 administration cycle
**only for patients who come to the site for the 150 -day safety follow -up visit
atake samples immediately prior to PDR001 infusion
b take samples after completion of PDR001 infusion
The exact date and clock times of drug administration and the actual collection date and time 
of each sample will be recorded on the appropriate eCRF pages. The timing of meals related to 
the dose , on da ys when PK profiles are drawn, should be recorded inthe source documents and 
eCRF. If vomiting occurs within 4 hours following FGF401 administration on the day of PK 
blood sampling, the clock time of v omiting should be recorded on the corresponding eCRF. 

Novartis Confidential Page 94
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Blood samples will be taken by  either direct venipuncture or an indwelling cannula inserted in 
a forearm vein. Blood samples should be collected from the arm opposite the one from PDR001 
infusion, or from another site, or alternatively  the infusion site will need to be flushed with 
10mL  saline . At specified time points, a total of 3mL blood will be collected for FGF401
analysis and 2 mL blood for PDR001 as applicable. For time points when PDR001 (mAb) PK 
and IG are to be measured, a single blood sample of 5 mL in total will be col lected. . Refer to 
the applicable study  Laboratory Manual  for detailed instructions for thecollection, handling 
and shipment of samples .
7.2.3.2 Analytical method
FGF401 and PDR001 concentrations in human plasma and serum will be determined using  
validated LC-MS/MS assay s, respectively . Any results below the lower limit of quantification 
(LLOQ) and an y missing samples will be labeled accordingl y.

Novartis Confidential Page 95
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 96
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 97
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 98
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and reporting
An adverse event is defined as the appearance of (or worsening of any pre-existing) undesirable 
sign(s), s ymptom(s), or medical condition(s) that occur after pa tient’s signed informed consent 
has been obtained.
For patients who sign the molecular pre -screening ICF, AEs which occur after signature of this 
consent will only be captured if they meet the definition of serious as outlined in Section 8.2
and are reported to be causally  related with study  procedures (e.g. an invasive procedure such 
as biopsy ). Once the main study  ICF is signed, all AEs per the descriptions below will be 
captured in the Adverse Event e CRF.
Abnormal laboratory  values or test results occurring after informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are considered clinically  significant, 
require therapy  (e.g., hematologic abnormalit y that requires transfusion or hematological stem 
cell support), or require changes in study  medication(s).

Novartis Confidential Page 99
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Adverse events that begin or worsen after informed consent should be recorded in the Adverse 
Events eCRF. Conditions that were alread y present at the time of inform ed consent should be 
recorded in the Medical History  page of the patient’s eCRF. Adverse event monitoring should 
be continued for at least 150 days following the last dose of PDR001 (for patients who have 
been treated with PDR001), or at least 30 days following the last dose of FGF401 (Section 
7.1.6). Adverse events (including lab abnormalities that constitute AEs) should be described 
using a diagnosis whenever possible, rather than individual underly ing signs and symptoms. 
When a clear diagnosis cannot be identified, each sign or symptom should be reported as a 
separate Adverse Event.
After initiation of new post
-treatment antineoplastic therapy , only  AEs suspected to be related 
to study  treatment will be collected in the Adverse Events eCRF.
Adverse events will be assessed according to the Common Terminology  Criteria for Adverse 
Events (CTCAE) version 4.03.
If CTCAE grading does not exist for an adverse event, the severit y of mild, moderate, severe, 
and life -threatening, corresponding to Grades 1 -4, will be used . CTCAE Grade 5 (death) will 
not be used in this study ; rather, information about deaths will be collected though a Death 
eCRF.
The occurrence of adverse events should be sought by  non-directive q uestioning of the patient 
(subject) during the screening process after signing informed consent and at each visit during 
the study . Adverse events also may be detected when they are volunteered by the patient 
(subject) during the screening process or betwe en visits, or through physical examination, 
laboratory  test, or other assessments. As far as possible, each adverse event should be evaluated 
to determine:
1.The severit y grade (CTCAE Grade 1 -4)
2.Itsduration (Start and end dates)
3. Its relationship to the study treatment (Reasonable possibility  that AE is related: No, Yes)
4.Action taken with respect to study  or investigational treatment (none, dose adjusted, 
temporaril y interrupted, permanentl y discontinued, unknown, not applicable)
5.Whether medication or therap ywas given (no concomitant medication/non -drug therap y, 
concomitant medication/non -drug therap y)
6.
Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequalae, fatal, unknown)
7.Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.1
All adverse events should be treated appropriately . If a concomitant medication or non-drug 
therap y is given, this action should be recorded on the Adverse Event eCRF.
Once an adverse event is detected, it should be followed until its resolution or until i t is judged 
to be permanent, and assessment should be made at each visit (or more frequently , if necessary ) 
of any changes in severity , the suspected relationship to the study  treatment, the interventions 
required to treat it, and the outcome.

Novartis Confidential Page 100
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Progression of malignancy  (including fatal outcomes), if documented by use of appropriate 
method (for example, as per RECI STor irRC criteria for solid tumors), should not be reported 
as a serious adverse event.
Adverse events separate from the progression of malignan cy (example, deep vein thrombosis 
at the time of progression or hemopty sis concurrent with finding of disease progression) will 
be reported as per usual guidelines used for such events with proper attribution regarding 
relatedness to the drug.
8.1.2 Laboratory  test abnormalities
8.1.2.1 Definitions and reporting
Laboratory  abnormalities that constitute an Adverse event in their own right (are considered 
clinically  significant, induce clinical signs or symptoms, require concomitant therap y or require 
changes in study  treatment), should be recorded on the Adverse Events eCRF. Whenever 
possible, a diagnosis, rather than a symptom should be provided (e.g. anemia instead of low 
hemoglobin). Laboratory abnormalities that meet the criteria for Adverse Events should be 
followed until they have returned to normal or an adequate explanation of the abnormality  is 
found. When an abnormal laboratory or test result corresponds to a sign/s ymptom of an already 
reported adverse event, it is not necessary  to separately  record the lab/test result as an additional 
event.
Laboratory  abnormalities, that do not meet the definition of an 
adverse event, should not be 
reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE does not automatically 
indicate a SAE unless it meets the definition of serious as defined below and/or as per 
investigator’s discretion. A dose hold or medication for the lab abnormality  may be required b y 
the protocol in which case the lab abnormality  would still, by definition, be an adverse event 
and must be repo rted as such.
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the outcomes listed above
Requires inpatient hospitalization or prolongation of existing hospitalization, 
Note that hospitalizations for the following reasons should not be reported as serious 
adverse events:
Routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition
Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent

Novartis Confidential Page 101
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Social reasons and respite care in the absence of any  deterioration in the patient’s 
general condition
Note that treatment on an emergenc y outpatient basis that does not result in hospital 
admission and involves an event not fulfilling an y of the definitions of a SAE given above 
is not a serious adverse event
8.2.2 Reporting
For patients who sign the molecular pre -screening ICF (applicable onl y forPhase 1 and Group 
3 in Phase II  of FGF401 single agent and for Stage 2 of the FGF401 and PDR001 combination 
should it proceed ), SAE collection will start upon signing the molecular pre-screening ICF. 
SAEs will only  be reported if the event is suspected to be causally  related to a study  procedure 
as assessed by the investigator (e.g. an invasive procedure such as biopsy ). SAEs will be 
followed until resolution or until clinically  relevant improvement or stabilization. If the main 
ICF is not signed (molecular pre -screen failure), SAE collection ends 30 days after the last study  
related procedure.
For all other patients who sign the main study  ICF, SAE collection starts at time of main study 
informed consent whether the patient is a screen failure or not.
Toensure patient safet y, every  SAE, regardless of suspected causality , occurring after the 
patient has provided main informed consent and until at least 150 day s following the last dose 
of PDR001 (for patients who have been treated with FGF401 and PDR001 combination ), or at 
least 30 day s after discontinuation of FGF401 (for patient who have been treated with FGF401
single agent ), must be reported to Novartis within 24 hours of learning of its occurrence. If a 
patient starts a post treatment antineoplastic th erapy, then only SAEs suspected to be related to 
study  treatment will be reported.
Any SAEs experie nced after the above defined period should only be reported to Novartis if the 
investigator suspects a causal relationship to the study  treatment. Any additional information 
for the SAE including recurrent episodes, complications, or progression of the initial SAE must 
be reported as follow -up to the original episode within 24 hours of the investigator receiving 
the follow -up information. An SAE occurrin g at a different time interval or otherwise 
considered completel y unrelated to a previously  reported one should be reported separately  as 
a new event.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applic able sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Report 
Form in English, and submit the completed form within 24 hours to Novartis. Detailed 
instructions regarding the SAE submission process and requirements for signatures are to be 
found in the investigator folder provided to each site.
Follow -up information issubmitted in the same way as the original SAE Report. Each re-
occurrence, complication, or progression of the original event should be reported as a follow -
up to that event regardless of when it occurs. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the patient continued or withdrew from study  participation.

Novartis Confidential Page 102
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
If the SAE is not previously documented in the Investigator’s Brochure or P ackage Insert (new 
occurrence) and is thought to be related to the Novartis study  treatment, a Novartis Chief 
Medical Office and Patient Safet ydepartment associate may urgently  require further 
information from the investigator for Health Authority  report ing. Novartis may need to issue 
an Investigator Notification (IN), to inform all investigators involved in any study with the same 
drug that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions 
(SUSARs) will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with Directive 2001/20/EC or as per national regulatory  requirements 
in participating countries.
8.3 Pregnancies
Study  treatment must be stopped if a patient becomes pregnant .
To ensure patient safet y, each pregnancy occurring while the patient is on study treatment must 
be reported to Novartis within 24 hours of learning of its occurrence. The pregnancy should be 
followed up to determine outcome, including spontaneous or voluntary  termin ation, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications. After the mother has provided consent, the newborn will be 
followed- up for 12 months .
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by the 
investigator to Novartis Chief Medical Office and Patient Safety (CMOPS &). Pregnancy 
follow -up should be recorded on the same form and should include an assessment of the 
possible relationship tothe study  treatment and any pregnanc y outcome. Any SAE experienced 
during pregnancy  must be reported on the SAE Report Form.
Pregnancy  outcomes should be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother.
8.4 Warnings and precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided Investigator 
Brochure ’s. Additional safet y information collected between IB updates will be communicated 
in the form of Investigator Notifications. This information will be included in the patient 
informed consent and should be discussed with the patient during the stud y as needed.
8.5 Data Monitoring Committee
Phase I Part s:
A data monitoring board will not be used for this study . This is an open -label, Phase I/II study  
and Novartis will have access to the Safet y Data on a regular basis. Novartis will host 
investigator teleconferences on a regular basis during the study . Further, Novartis and the 
investigators will meet at the end of each treatment cohort to discuss and evaluate all of the 
gathered safet y data. At the dose escal ation teleconference, the clinical course (safet y 
information including both DLTs and all CTCAE Grade 2 or higher toxicity  data during the 

Novartis Confidential Page 103
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
first cycleof treatment, and all available PK data) for each patient in the current dose cohort 
will be described indetail. Updated safety  data on other ongoing patients, including data in later 
cycles, will be discussed as well.
Dose escalation decisions will be based on a clinical synthesis of all relevant available data and 
not solely  on DLT information. Selection o f the actual dose for the next cohort of patients will 
be guided by the Bayesian model’s (with EWOC) recommendation, and a medical review of 
relevant clinical, PK,  and laboratory  data. Novartis and the investigator parties must reach 
a consensus on whet her to declare MTD and/or RP2D, escalate the dose any further, or whether 
to de-escalate and/or recruit an additional cohort of patients at the current dose level, see Section 
10.4.2.1.
Phase II Part s
:
An independent data monitoring committee will not be formed for this exploratory  phase II 
partsof the study . Individual patient data will be reviewed on an ongoing basis and aggregate 
safet y data and the pri mary  endpoint will be monitored frequently by the study  team across the 
duration of the trial. The data review and analysis will be based on the available data in the 
clinical database at the respective time.
8.6 Steering Committee
A Steering Committee constituted of members of the Translational Clinical Oncology 
Leadership Team will be formed for this study . If the monitoring of the study  data requires a 
decision to be taken on the continuation of the study, then the relevant data (e.g., safet y data or 
primary  analysis and predictive probability  of success (PPOS)) will be communicated to the 
Steering Committee for decision making purposes .
In the Phase II part of the FGF401 in combination with PDR001, an interim analysis for efficacy 
and futility  will be performed after the first 35 patients have been enroll ed and have had at least 
one-post treatment tumor evaluation or discontinued earlier (Stage 1) . Interim decision making 
will be based on the Bayesian posterior probability  of ORR and posterior median ORR. The 
interim analy sis of ORR will be based on unconf irmed response. The phase II part in the 
combination arm will be stopped due to efficacy if the posterior probability  of ORR in the 
unselected population included in the no/limited anti-tumor activity  interval [0, 0.15) is less 
than 0.10 and the posterior median ORR is 0.30 or more. Considering the exploratory  nature of 
the study , when the aforementioned success criteria are not met but the evaluation of overall 
efficacy  and safet y suggests the treatment is promising for development, decision of stop at 
Stage 1 for success can also be made b y Novartis. 
Should the study  not stop at Stage 1 for success in the unselected HCC population, go/no go 
decision to Stage 2 will be made by  evaluating the anti- tumor activity  in subgroups defined by 
FGF19 expression and/or FGF19 pathway  activation based on the predictive probability  of 
ORR. For an individual subgroup, if that predictive probabilit y to not meet the efficacy criteria 
(i.e. posterior probability of ORR included in the no/limited anti -tumor activity  interval is less 
than 0.10 and the posterior median ORR is 0.30 or more) at the final analysis is not greater than 
0.90, and the number of patients in the subgroup is less than 25, the study  will move to Stage 2 
and more patients will be enrolled to the subgroup until a sample size of approximately  25 is 
reached. If25 or more patients are alread y enrolled to the subgroup at the time of interim 

Novartis Confidential Page 104
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
analysis, interim analy sis will be performed but no further enrollment will be allowed in that 
subgroup .
9 Data collection an d management
9.1 Data confidentiality
Information about study  subjects will be kept confidential and managed under the applicable 
laws and regulations. Those regulations require a signed subject authorization informing the 
subject of the following:
What protec ted health information (PHI) will be collected from subjects in this study
Who will have access to that information and wh y
Who will use or disclose that information
The rights of a research subject to revoke their authorization for use of their PHI .
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability  to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safet y information (e.g. has the subject 
experienced an y new or worsened AEs) at the end of their scheduled study period.
The data collection system for this study  uses built-in security  features to encry pt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individually  assigned 
user identification code s and passwords, made available only to authorized personnel who have 
completed prerequisite training.
Prior to entering key sensitive personally  identifiable information (Subject Initials and exact 
Date of Birth), the system will prompt site to verify  that this data is allowed to be collected. If 
the site indicates that country  rules or ethics committee standards do not permit collection of 
these items, the system will not solicit Subject Initials. Year of birth will be solicited (in the 
place of exact dat e of birth) to establish that the subject satisfies protocol age requirements and 
to enable appropriate age -related normal ranges to be used in assessing laboratory  test results.
9.2 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, Novartis 
personnel (or designated CRO) will review the protocol and CRFs with the investigators and 
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the CRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be ava ilable to assist the field monitor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on CRFs must be traceable to source documents in the 

Novartis Confidential Page 105
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
patient's file. The investigator must also keep the original signed informed consent form (a 
signed cop y is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the CRF entries. Novartis monitoring standards require full verification for the 
presence of informed c onsent, adherence to the inclusion/exclusion criteria and documentation 
of SAEs. Additional checks of the consistency  of the source data with the CRFs are performed 
according to the stud y-specific monitoring plan.
9.3 Data collection
For studies using Electron ic Data Capture (EDC), the designated investigator staff will enter 
the data required by the protocol into the Electronic Case Report Forms (eCRF). The eCRFs 
have been built using fully validated secure web-enabled software that conforms to 21 CFR Part 
11 requirements, Investigator site staff will not be given access to the EDC system until they 
have been trained. Automatic validation programs check for data discrepancies in the eCRFs 
and, allow modification or verification of the entered data b y the invest igator staff.
The Principal Investigator is responsible for assuring that the data entered into eCRF is complete, 
accurate, and that entry and updates are performed in a timely  manner.
Blood and tumor samples for PK  will be collected by sites and sent to a Central 
laboratory  for processing. The Laboratory  results will be sent electronically  to Novartis. 
Radiological and photography data will be acquired by the sites and interpreted locall y. Details 
regarding all CRO procedures including collection and shipment of data will be described in 
the manual provided by therespective CRO. ECG data collected during the study  will be 
reviewed and processed centrall y by a specialist CRO.
9.4 Database management and quality  control
Novartis personnel (or designated CRO) will review the data entered by investigational staff 
for completeness and accuracy . Electronic data queries stating the nature of the problem and 
requesting clarification will be created for discrepancies and missing values and sent to the
investigational site via the EDC system. Designated investigator site staff isrequired to respond 
promptly  to queries and to make an y necessary  changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical classification 
system. Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
PK  samples will be processed centrally  and the results will be sent electronicall y 
to Novartis (or a designated CRO). At some sites, part(s) of thehospital data may also be 
processed centrally .
After the data has been verified to be complet e and accurate, the database will be declared 
locked and made available for data analysis. Authorization is required prior to making any 
database changes to locked data, by joint written agreement between the Global Head of 
Biostatistics and Data Managemen t and the Global Head of Oncology  Translational Medicine.

Novartis Confidential Page 106
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
After database lock, the investigator will receive a CD -ROM or paper copies of the patient data 
for archiving at the investigational site.
10 Statistical methods and data analy sis
Study  data will be summarized with respect to demographic and baseline characteristics, 
efficacy  observations and measurements, safety  observations and measurements, and all 
relevant pharmacokinetics (PK) measurements. Categorical data 
will be present ed as contingency  tables (frequencies and percentages). For continuous data,
summary  statistics of mean, standard deviation, median, minimum, and maximum will be 
presented. In addition, individual listings of all raw data captured in the clinical database will 
be presented b y treatment group and patient.
All data from participating centers in this protocol will be combined, so that an adequate number 
of patients will be available for analysis.The following rules will be followed for reporting 
results unless otherwise stated:
Phase I part: Patients with the same dose level, feeding regimen and schedule of FGF401
single agent or FGF401 in combination with PDR001 will be pooled into a single 
treatment group. All summaries, listings, figures and anal yses will be performed by  
treatment group , unless otherwise stated.
Phase II part: Patients will be anal yzed according to the Group to which they  were 
assigned for FGF401 single agent. For FGF401 in combination with PDR001, if 
subgroups based on FGF19 expression and/ or pathway  activation are identified, patients 
will be anal yzed according to the subgroup. All summaries, listings, figures and anal yses 
will be performed b y Group (FGF401 single agent) or subgroup (FGF401 in combination 
with PDR001) , unless otherwise stat ed.
Screen failure patients are those who signed the informed consent, but never started the study
treatment for any reason. For these patients, the eCRF data collected according to Section 
7.1.2.1 will notbe included in an y analysis, but will be reported in the CSR as separate listings.
The study  data will be analy zed and reported based on all patients’ data of the phase I and the 
phase II parts up to the time when all patients have potentially  completed at least six cy cles of 
treatment or discontinued the study . Any additional data for patients continuing to receive study  
treatment past the data cutoff date for the primary CSR, as allowed by the protocol, will be 
reported following the end of stud y (refer to Section 4.3 for definition).
Details of the statistical analysis and data reporting will be provided in the Novartis Report and 
Analy sis Plan (RAP) document finalized prior to database lock.
10.1 Analysis sets
10.1.1 Full A nalysis Set
The full analysis set (FAS) comprises all patients who received at least one dose of study 
medication. Patients enrolled in the phase I part will be analyzed according to the treatment 
they have been assigned to. Patients enrolled in the phase II part will be analyzed by Group.
Unless otherwise specified, the FAS will be the default anal ysis set used for all anal yses.

Novartis Confidential Page 107
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
10.1.2 Safety Set
The Safety  Set includes all patients who received at least one dose of study  medication. Patients
enrolled in the phase I part will be analyzed according to the study  treatment (regimen) they 
actuall y received. Patients enrolled in the phase II part will be anal yzed by Group.
A precise definition of “actually received” will be added in the RAP.
10.1.3 Per-Protocol Set
The Per-Protocol Set (PPS) will consist of a subset of patients from the FAS who have an 
adequate tumor assessment at baseline and at least one post treatment tumor assessment with a 
result other than UNK, and no major protocol deviations.
All m ajor protocol deviations leading to exclusion from the PPS will be detailed in the RAP.
The PPS will be used in the phase II part of the study  only  and will define the patients used in 
the sensitivity  analysis of the primary  endpoint (see Section 10.4 ). If the PPS and the FAS are 
identical, then anal yses described b y the PPS below will not be performed.
10.1.4 Dose -determining analy sis set
The dose-determining analy sis set (DDS) consists of all patients from the safety set from the 
Phase I parts who either meet the following minimum exposure criterion and have sufficient 
safet y evaluations, or have experienced a DLT during theapplicable evaluation period of DLTs . 
FGF401 single agent
A patient is considered to hav e met the minimum exposure criterion if he /she received at least 
66% of the planned doses of FGF401 in the first cycleof dosing i.e. at least 14out of the 21full 
planned dail y dose of FGF401 .
Patients who do not experience DLT during the first cycleof treatment are considered to have 
sufficient safet y evaluations if they  have been observed for ≥ 21days following the first dose, 
and are considered by both the Sponsor and Investigators to have enough safety  data to conclude 
that a DLT did not occur.
FGF401 in combination w ith PDR001
A patient is considered to have met the minimum exposure criterion if he /she received at least 
66%, (i.e. at least 28 days) of the planned doses of FGF401 , and all planned doses of PDR001 
in cy cle 1 and cy cle 2 of dosing.
Patients who do not experience DLT during the first 2 cycles of treatment are considered to 
have sufficient safet y evaluations if they have been observed for ≥42 days following the first 
dose, and are considered by both Novartis and Investigators to have enough safet y data to 
conclude that a DLT did not occur
.
10.1.5 Pharmacokinetic analy sis set
The pharmacokinetic analy sis set (PAS) includes all subjects who provide at least one evaluable 
drug concentration . For those requiring non-compartment analyses, the PAS includes all 

Novartis Confidential Page 108
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
subjects who provide an evaluable PK profile. Patients will be removed from the determination 
of individual PK parameters on a case by case basis ( to be described in detail in the Clinical 
Study  Report ).
The PAS will be used for summaries of drug concentration data, non-compartment PK analysis 
and/or population PK analy sis
. The analysis of the food effect on the FGF401 PK exposures 
will also use the PAS.
10.2 Patient demographics/other baseline characteristics
Demographic and other baseline data including disease characteristics will be summarized 
descriptivel y using the FAS.
10.3 Treatments (study  treatment, concomitant therapies, 
compliance)
The safet y set will be used for the analy ses of treatments .
10.3.1 Study treatment
Duration of exposure to FGF401 andPDR001 and as well as the actual total dose,the dose 
intensity  (calculated as the ratio of actual dose received to actual duration) and the relative dose 
intensity  (calculated as the ratio of dose intensity toplanned dose received/planned duration) of 
the study  treatment will be summarized descriptive ly.
Categories for relative dose intensity  of FGF401 and PDR001 will be specified as < 0.5, ≥ 0.5 
-< 0.75, ≥ 0.75 -< 0.9, ≥ 0.9 -< 1.1 and ≥ 1.1. The number and proportion of patients falling 
in each categ ory will be presented.
10.3.2 Concomitant therapies
Concomitant medications and significant non-drug therapies prior to and after the start of the 
study  treatment will be summarized by Anatomic -Therapeutic -Chemical classification (ATC) 
term.
10.3.3 Compliance
Compliance to the protocol will be assessed by the number and proportion of patients with 
protocol deviations. These will be identified prior to database lock and will be listed and 
summarized by treatment group for the FAS.
10.4 Primary  objective
Phase I part s
The prima ry objective is to determine the maximum tolerated dose (MTD) and/or the 
recommended Phase II dose (R P2D) of single agent FGF401 andFGF401 in combination with 
PDR001 .

Novartis Confidential Page 109
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Phase II part s
For FGF401 single agent, t he primary  objective is to assess preliminary  anti-tumor activity   in 
the following three groups of patients :
Group 1: HCC patients from Asian countries 
Group 2: HCC patients from non -Asianregions 
Group 3: patients who have other solid tumors regardless of geograph yand positive 
FGFR4/KLB expression
For FGF401 in combination with PDR001, the primary  objective is to assess the preliminary 
anti-tumor activity  of this combination in adult patients with HCC.
10.4.1 Variable
Phase I part s
The primary  endpoint is the incidence of dose limiting toxicities (DLTs). For FGF401 single 
agent and in combination with PDR001, respectively, estimation of the MTD of the treatment 
will be based upon the estimation of the probability  of DLT during the evaluation period for 
patients in the DDS. This probability  is estimated by the corresponding model described in 
Section 10.4.2.
Phase II part s
Group 1 and 2 -FGF401 single agent :The primary  endpoint is time to progression (TTP), as 
per local assessment, defined as the time from the date of baseline evaluation to the date of 
the 
first documented event that the radiological confirmation of disease progression or death due to 
underly ing cancer (RECIST v1.1) . 
Group 3-FGF401 single agent :The primary  endpoint is overall response rate, defined as the 
proportion of patients having a best overall response of either complete response ( CR) or PR at 
any time on study  as per local assessment according to RECIST v1.1.
FGF401 and PDR001 combination :The primary endpoint is overall response rate, defined as 
the proportion of patients having a best overall response of either CR or PR at any time on study 
as per local assessment according to RECI ST v1.1 .
10.4.2 Statistical hypothesis, model, and method of analy sis
10.4.2.1 FGF401 single agent
Phase I part
A Bayesian hierarchical logistical regression model (BHLRM) will be applied to estimate the 
relationship between dose and the probability  of a patient experiencing a dose limiting t oxicity  
(DLT) for patients in fasted condition (stratum 1) and in fed condition (stratum 2). The standard 
Bayesian hierarchical model assumes full exchangeability  of strata parameters; for the 
methodology  and an application to binary  data see Thall et al. 2003 and Chugh et al. 2009. Here, 
we extend the standard 
Bayesian hierarchical model to dose -toxicity  data, and exchangeable as 
well as non
-exchange able strata parameters. 

Novartis Confidential Page 110
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
For the two patient strata, the probability  of experiencing a DLT is modeled as follows:
logit          =log         +        log(   ∗⁄ )
logit       =log      +    log(   ∗⁄ )
where  denotes dose;  ∗is a fixed reference dose;         and      are the probability  of a 
patient experiencing a DLT at dose  in respectively  fasted and fed conditions; and the two 
parameter vector s        =    (       ),   (       )  and     =
    (    ),   (    ) describe the relationship between dose and toxicity for the two strata.
We further let the parameter vector s         and     be either exchangeable or non-
exchangeable, with probability   and(1
− ),respectivel y.
1.Under exchangeability , the parameter vector s         and     are assumed to follow a 
bivariate normal distribution:
       ,   ~   (μ    ,     ),
where      =(   ,   )and      =             
            are the mean vector and 
covariance matrix.
Prior distributions for μ    and      of the exchangeability distribution complete the model 
specifications for the exchangeability  component of the model 
The prior distributions forthecomponent ofμ    will be normal and the prior distributions for 
the standard deviations and the correlation in      will be log-normal and uniform, 
respectivel y.
2.Under non -exchangeability , the parameter vector s        and     are assumed to have a 
weakl y informative bivariate normal prior distribution.
       ,    ~   (  ,S ),
where   =(   ,   )and   =             
            are the mean vector and 
covariance matrix .
Thespecification of prior distributions is described in Appendix 10.
Change in dosing schedule
In the event of a change in dosing schedule, a new B LRM will be set up. This new B LRM will 
have the same funct ional form as that described above and will incorporate existing dose 
escalation data in the prior distributions. For comparability , doses for the new and old model 
will be normalized to dose in mg per day .
Dose recommendation
After each cohort of patients, the posterior distributions for the probabilities of DLT rates at 
different dose levels for fasted and fed conditions are obtained. The results of this analy sis are 

Novartis Confidential Page 111
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
summarized in terms of the probabilities that the true rate of DLT for fasted and fed conditions 
at each dose -level will lie within each of the following intervals:
[0, 0.16) under- dosing
[0.16, 0.33) targeted toxicity
[0.33, 1.00] excessive toxicity
The overdose control criterion mandates that under each of the patient conditions, any  dose of 
FGF401 for which the DLT rate has more than a 25% risk of being excessively  toxic, i.e. P(DL T) 
is 0.33 or higher, will not be considered for the next dose cohort. The final estimate of the 
MTD/RP2D will also satisfy  this condition.
Details of the criteria for dose escalation and the estimation of the MTD are provided in Section 
6.2.3.
Summary  of DLTs
DLTs will be li
sted and their incidence summarized by primary  system organ class and
preferred term. The dose -determining anal ysis set will be used for these summaries.
Phase II part
The FAS will be used for the primary  analy sis.
Group 1 and 2: The distribution of TTP wi ll be e stimated using the Kaplan -Meier method. A 
positive trend regarding the activity  of FGF401 will be concluded if the observed lower limit 
of one-sided 90% confidence interval (CI) of TTP ≥ 1.5 months (Group 1) and 2.2 months 
(Group 2), which are the expected median TTPs without FGF401 treatment in group 1 and 2, 
respectivel y. The median TTP and quantiles (along with one-sided 90% CI) will be presented. 
The 
Kaplan -Meier curve will be presented graphically . TTP rate estimates (along with one-
sided 90% CI) at 1.5, 3 and 6 months will be presented, as given b y the Kaplan -Meier analysis.
Group 3 : BOR , defined in Appendix 1
,will be summarized by  tumor type. The number (%) of 
patients having BOR as CR, PR, SD, PD and unknown per RECI ST 1.1 will be provided. T he 
overall response rate (ORR), the proportion of patients having BOR of either CR or PR, of an 
individual tumor ty pe will be summarized if the number of observations is reasonable large .
10.4.2.2 FGF401 in comb ination w ith PDR001
Phase I part
A
5-parameter adaptive Bayesian logistic regression model (BLRM), guided by the EWOC 
principle will be used to make dose recommendations and estimate the MTD/RDE of the 
combination.
The respective single agent dose -DLT rela tionships are defined as follows:
FGF401: logit 
π (d ) =log(α )+β log(    ∗⁄ )
PDR001: logit π (d ) =log(α )+β log(    ∗⁄ )

Novartis Confidential Page 112
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Where, π1(d1) and π2(d2) are respectivel y the probability  that a patient has a DLT during the 
first 2 cycles of combination treatment with FGF401 and PDR001 given at the Q3W dose d1
and d 2 respectively, and   ∗=120 mg and   ∗=300 mg are respectivel y the FGF401 and PDR001 
reference doses. α i, βi> 0 are the parameters of the model.
Then, the dose -DLT relationship of the combination FGF401 + PDR001 is defined as follows:
        (  ,  ) =   (  ,  )
1−   (  ,  )=exp(η  
  ∗  
  ∗)   (  )+  (  )−  (  )  (  )
(1−  (  ))(1−  (  )) 
Where η is the log -odds ratio between the interaction and no -interaction model at the reference 
doses. Here η= 0corresponds to no-interaction, η> 0represents s ynergistic toxicity , and η< 0 
represents antagonistic toxicity .The specification of prior distributions is described in 
Appendix 10.
Change in dosing schedule
In the event of a change in dosing schedule, a new BL RM will be set up. This new BL RM will 
have the same functional form as that described above and will incorporate existing dose 
escalation data in the prior distributions. 
Dose recommendation
After each cohort of patients, the posterior distributions for the probabilities of DLT rates at 
different dose levels for FGF401 in combination with PDR001 are obtained. The results of this 
analysis are summarized in terms of the probabilities that the true rate of DLT for FGF401 in 
combination with PDR001 at each dose -level will lie within each of the following intervals:
[0, 0.16) under- dosing
[0.16, 0.33) targeted toxicity
[0.33, 1.00] excessive toxicity
The overdose control criterion mandates that unde r each of the patient conditions, any  dose of 
FGF401 for which the DLT rate has more than a 25% risk of being excessively  toxic, i.e. P(DL T) 
is 0.33 or higher, will not be considered for the next dose cohort. The final estimate of the 
MTD/RP2D will also sa tisfy this condition.
Details of the criteria for dose escalation and the estimation of the MTD are provided in Section 
6.2.3.
Summary  of DLTs
DLTs will be listed and their incidence summarized by primary system organ class and 
preferred term
. The dose -determining anal ysis set will be used for these summaries .
Phase II part
The FAS will be used for the primary  analy sis.
The number (%) of patients having BOR as CR, PR, SD, PD and unknown per RECI ST 1.1 will 
be provided. T he overall response rate (ORR), the proportion of patients having BOR of eith er 
CR or PR, will be summarized.

Novartis Confidential Page 113
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
If at interim analysis the efficacy is declared (for more details, refer to Section 10.7.2), the 
primary  analysis will be overall. In addition, summary  by subgroup
(s)defined by FGF19 
expression and/or FGF19 pathway activation will be conducted as an exploratory analysis. If at 
interim analy sis the efficacy  is not declared , the primary  analysis will be done by subgroup(s)
defined b y the FGF19 expression and/or FGF19 pathway  activation .
A Ba yesian method will be used in order to estimate the distribution of the ORR and to provide 
inferential summaries (mean, median, interval probabi lit ies). Aminimally  informative Beta 
prior distribution (Neuenschwander 2008) with b = 1 and a = 3/7 is specified for the ORR 
assumin
g the true mean ORR is 30% . 
Anti-tumor activity  is classified based on ORR intervals as following : 
[0, 0.15) no/limited anti
-tumor activity
[0.15, 0.30) moderate anti- tumor activity
[0.30, 1.00] clinically  significant anti -tumor activi ty
10.4.3 Handling of missing values/censoring/discontinuations
Phase I part s
Patients in the phase I partswho are ineligible for the DDS will be excluded from the primary 
analysis, although their additional data (e.g., safety , PK,  efficacy  etc.) will be used in the 
review of patient data at the dose-escalation meeting. Missing data will simpl y be treated as 
missing on appropriate tables/listings.
Phase II part s
FGF401 single agent Group 1 and 2: If a patient has not had the event at the date of analy sis 
cut-off or when he/she received an y further anti-neoplastic therap y, TTP will be censored a t the 
time of the last adequate assessment before the cut-off date, or start date of other anti-neoplastic 
therap y.
FGF401 single agent Group 3and FGF401 and PDR001 combination treatment group:
BOR will be considered missing if the patient does not have both baseline and at least one post-
baseline RECI ST assessment by the investigator , allowing the assignment of a BOR under 
RECI ST 1.1 (see Appendix 1). For ORR calculation, patients who have missing BOR will be 
considered as non -responder (non
-CR/PR) .
10.4.4 Supportive analy ses
For the phase II parts , the analyses of the primary endpoint will be repeated using the PPS, if 
PPS is different from FAS. 
For the FGF401 in combination with PDR001, the same analyses will be performed using the 
tumor response evaluation as per irRC (Appendix 9 ).
For the FGF401 in combination with PDR001, supportive analysisby geographical region 
(Asian vs. non- Asian) will be performed for key  efficacy  endpoints.

Novartis Confidential Page 114
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Additional supportive or exploratory  analyses will be conducted to support the primar y 
objective if appropriate and details of the analy sis will be defined in the Reporting and Anal ysis 
Plan (RAP).
10.5 Secondary  objectives
Please refer to Section 3 for the secondary objectives.
10.5.1 Efficacy  objectives
For all efficacy  analy ses, the FAS will be used unless otherwise specifi ed.
Phase I part s
BOR, ORR and DCR will be summarized by  treatment group.
The Kaplan -Meier plot for TTP at the MTD/RP2D will be presented. The estimated TTP rate 
at the MTD/RP2D along with 95% CI at 1.5, 3 and 6 months will be presented. If appropriate, 
the Kaplan -Meier plots for OS at the MTD/RP2D will also be presented. Theseanaly ses will 
only be provided if there are at least 10 enrolled patients at MTD/RP2D . Otherwise, data will 
only be listed.
Phase II part s
FGF401 single agent -Group 1 and 2: BOR, ORR and DCR will be summarized by treatment 
group. 
The Kaplan -Meier plot for OS will be presented by group, and by FGF19 status within 
individual HCC groups. The estimated OS rate along with 95% CI  at 3, 5, 7 and 9 months will 
be presented b y group.
FGF401 single agent -Group 3: BOR and DCR will be summarized by  tumor ty pe. 
The Kaplan -Meier analysis for PFS and OS will be provided by  tumor ty pe. This anal ysis will 
only be provided for tumor type with which there are at least 10 enrolled patients. Otherwise,
data will only  be listed.
FGF401 and PDR001 combination: The Kaplan -Meier analysis for TTP, PFS, OS and DOR 
will be provided. BOR and DCR will be summarized. The same analyses will be performed 
using the 
tumor response evaluation as per irRC ( Appendix 9 ).
10.5.2 Safety  objectives
10.5.2.1 Analysis set and grouping for the analy ses
For all safet y analy ses, the safet y set will be used unless otherwise specified. Listings and 
summary  tables will be presented b y treatment group.
The overall observation period will be divided into three mutually  exclusive segments:
1.pre-treatment period: from day  of patient’s pre -screening informed consent to the day  
before first dose of stud y medication

Novartis Confidential Page 115
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
2. on -treatment period: from day  of first dose of study  medication to 30 day s after the last 
dose of study  medication
3. -For patients receiving FGF401 single agent: post-treatment period: starting at day  31 after 
last dose of study  medication. 
-For patients re ceiving FGF401 in combination with PDR001: extended safety  follow -up 
period: starting at day  31 after last dose of study  medication, ending at least 150 day s 
after last dose of PDR001.
10.5.2.2 Adverse events (A Es)
Summary  tables for adverse events (AEs) have to include only AEs that started or worsened 
during the on-treatment period, the treatment -emergent AEs. However, all safet y data 
(including those from the pre and post-treatment periods) will be listed and those collected 
during the pre -treatment and post -treatment period are to be flagged.
The incidence of treatment- emergent adverse events (new or worsening from baseline) will be 
summarized by system organ class and or preferred term, severit y (based on CTCAE grades) 
and relation to study  treatment.
Deaths reportable as SAEs and non-fatal serious adverse events will be listed by patient and 
tabulated b y type of adverse event.
Specific safet y event categories (SEC) will be considered. Such categories consist of one or 
more well-defined safet y events 
which are similar in nature and for which there is a specific 
clinical interest in connection with the study treatment(s). For each specified SEC, number and 
percentage of patients with at least one event part of the SEC will be reported.
For patients receiving FGF401 in combination with PDR001, additional summaries of related 
AEs, related SAEs, and related AESIs will be produced covering all events with onset or 
worsening at an y time during the extended safet y follow -up period.
10.5.2.3 Laboratory  abnormalities
For laboratory  tests covered by the Common Terminology  Criteria for Adverse Events 
(CTCAE) version 4.03, laboratory  data will be graded accordingl y. For laboratory  tests covered 
by CTCAE, aGrade 0 will be assigned for all non-missing values not graded as 1 or higher. 
Grade 5 will not be used.
For laboratory  tests where grades are not defined by CTCAE, results will be graded by the 
low/normal/high classifications based on laboratory  normal ranges.
The following by-treatment summaries will be generated separately  for hemat ology , 
biochemistry  and urinary laboratory  tests:
frequency  table for newly  occurring on -treatment grades 3 or 4
shift tables using CTCAE grades to compare baseline to the worst on -treatment value
for laboratory  tests where CTCAE grades are not defined, sh ift tables using the 
low/normal/high/(low and high) classification to compare baseline to the worst on-
treatment value.

Novartis Confidential Page 116
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
listing of all laboratory  data with values flagged to show the corresponding CTCAE 
grades and the classifications relative to the laboratory  normal ranges.
In addition to the above mentioned tables and listings, other exploratory  analy ses, for example 
figures plotting time course of raw or change in laboratory  tests over time or box plots might 
be specified in the RAP.
10.5.2.4 Other safety  data
ECG
shift table baseline to worst on- treatment result for overall assessments
listing of ECG evaluations for all patients with at least one abnormality .
Vital signs
shift table baseline to worst on-treatment result
table with descriptive statistics at baseline, one or several post -baseline time points and 
change from baseline to this/these post -baseline time points.
10.5.2.5 Tolerability
Tolerability  of study  drug will be assessed by summarizing the number of dose interruptions 
and dose reductions. Reasons for d ose interruption and dose reductions will be listed b y patient 
and summarized.
10.5.3 Pharmacokinetics
The PAS will be used in the pharmacokinetic data anal ysis and PK summary  statistics.
Concentration data will be listed by time point, patient and treatment group. Descriptive 
statistics (n, m (number of non-zero concentrations), mean, CV%, SD, median, geometric mean, 
geometric CV%, minimum and maximum) for PDR001 and FGF401 concentrations will be 
presented at each scheduled timepoint by  treatment. 
All concentrat ion data for PDR001 and FGF401 will be display ed graphically . Individual 
concentration -time profile as well as mean concentration-time profile will be plotted.
PK parameters will be determined for all PK-evaluable patients with noncompartmental 
method(s) using Phoenix WinNonlin version 6.2 or above (Pharsight, Mountain View, CA). 
Exploratory  population PK analyses will be conducted to derive PK parameters using 
compartmental modeling method when necessary. For FGF401, the PK parameters include but 
may be n ot limited to those listed in Table 10 -
1.For PDR001, PK parameters would be limited 
to Cmax, Tmax, AUClast and Ctrough. The descriptive statistics (n, mean, CV%, standard 
deviation (SD), median, geomet ric mean, geometric CV%, minimum and maximum) will be 
presented by treatment for all PK parameters defined in Table 10-1except Tmax, where only n, 
median, minimum and maximum will be presented. Missing data will not be imputed.

Novartis Confidential Page 117
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Table 10-1 Noncompartmental pharmacokinetic parameters
AUClast The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x 
volume-1)
AUCinf The AUC from time zero to infinity (mass x time x volume-1)
AUCtau The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1)
Cmax The maximum (peak) observed plasma drug concentration (mass x volume-1)
Tmax The time to reach maximum (peak) plasma drug concentration (time)
T1/2 The elimination half -life associated with the terminal slope ( z) of a semi logarithmic concentration -
time curve (time). Use qualifier for other h alf-lives
CL/F The apparent total body clearance of drug from the plasma after oral administration (vol x time-1)
Racc Accumulation ratio calculated using AUCtau at steady state divided by AUCtau at day 1
10.5.3.1 Data handling principles
Only  PK blood samples with date and time and for which the last prior dose dates and times are 
adequatel y recorded will be included in the PK analyses. For FGF401 , samples taken from 
patients who vomited within 4 hours of dosing may be excluded from the an alysis.
All concentrations below their respective LLOQs (lower limits of quantification) or missing 
data will be labeled as such in the concentration data listings. Concentrations below the LLOQ 
will be treated as zero in summary  statistics and for the calculation of pharmacokinetic 
parameters.
10.5.3.2 Data analy sis principles
10.5.3.2.1 Summary tables and figures
The individual plasma concentration time profiles and mean concentration time profile of
analyteswill be summarized descriptively  and graphically  by treatment group in phase I part 
and group in phase II part.
Descriptive statistics of PK parameters shown in Table 10 -1will be provided if appropriate .
Further graphical exploratory  anal yses will be carried out if deemed appropriate. 
10.5.3.2.2 Dose proportionality
The assessment of dose proportionality  will be conducted for AUC and Cmax of FGF401 using 
a power model on log-transformed scale. The log-transformed PK parameters will each be 
regressed onto a fixed factor for log (dose). The 90% CI of the slope for each parameter will be 
computed from the model and presented in the summary  table. The dose proportionalit y
assessment is exploratory analysis due to insufficient power to demonstrate dose proportionalit y.
10.5.3.2.3 Food effect
Asexploratory  analysisto assess the food effect on FGF401 pharmacokinetics , exposure 
measures (Cmax, Tmax and AUC) will be compared among patients taking study  drug under 
different feeding regimens (fasted or fed) as appropriate. 

Novartis Confidential Page 118
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
10.5.3.2.5 Immunogenicity 
Immunogenicit y of PDR001 will be characterized descriptively  by tabulating antidrug 
antibodies (ADA) prevalence at baseline and ADA incidence on-treatment. The impact of ADA 
on the occur rence of safety  endpoints, efficacy  endpoints, and PDR001 
PK will be assessed 
using appropriate methods. Further details will be provided in the SAP or in a stand -alone 
analysis plan document .
10.7 Interim analy sis
10.7.1 FGF401 single agent
Phase I part
No formal interim analy sis is planned. However, the dose-escalation design foresees that 
decisions based on the current data are taken before the end of the study . More precisel y, after 
each cohort in the dose -escalation part, the next dose will be chosen depending on the observed 
data. Details of this procedure and the process for communication with investigators are 
provided in Section 6.2.3.
Phase II part
No formal interim analy sis is conducted. However, individual patient data will
be reviewed on 
an ongoing basis by the study  team across the duration of the trial (Section 8.5 and Section 8.6).

Novartis Confidential Page 119
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
10.7.2 FGF401 in combination w ith PDR001
Phase I part
No formal interim analy sis is planned. However, the dose-escalation design foresees that 
decisions based on the current data are taken before the end of the study . More precisel y, after 
each cohort in the dose -escalation part, the next dose wi ll be chosen depending on the observed 
data. Details of this procedure and the process for communication with investigators are 
provided in Section 6.2.3.
Phase II part
An interim analy sis 
for efficacy  and futility  will be performed after the first 35 patients have 
been enrolled a
nd have had at least one -post treatment tumor evaluation or discontinued earlier
(Stage 1 ).Interim decision making will be based on the Bayesian posterior probability  of ORR 
and posterior median ORR. The interim analysis of ORR will be based on unconfirmed respons e.
The phase II part in the combination arm will be stopped due to efficacy  if the posterior 
probability  of ORR in the unselected population included in the no/limited anti-tumor activit y 
interval [0, 0.15) is less than 0.10 and the posterior median ORR is 0.30 or more. Considering 
the exploratory  nature of the study , when the aforementioned success criteria are not met but 
the evaluation of overall efficacy  and safet y suggests the treatment is promising for 
development, decision to stop at S tage 1 for success can als o be made by  Novartis . 
Should the study  not stop at Stage 1 for success in the unselected HCC population, go/no go 
decision to Stage 2 will be made by  evalu ating the anti- tumor activity  in subgroups defined by 
FGF19 expression and/or FGF19 pathway activation based on the predictive probability  of 
ORR. For an indivi dual subgroup, if that predictive probabilit y to not meet the efficacy criteria 
(i.e. posterior probability of ORR included in the no/limited anti -tumor activity  interval is less 
than 0.10 and the posterior median ORR is 0.30 or more) at the final analysis is not greater than 
0.90, and the number of patients in the subgroup is less than 25, the study  will move to Stage 2 
and more patients will be enrolled to the subgroup until a sample size of approximately  25 is 
reached. If25 or more patients are alread y enrolled to the subgroup at interim analysis, interim 
analysis will be performed but no further enrollment will be allowed in that subgroup.
10.8 Sample size calculation
10.8.1 FGF401 single agent
10.8.1.1 Phase I part
Initiall y, c
ohorts of 1to 6 evaluable patients will be enrolled in the phase I part. Upon 
observation of specific toxicities (see Section 6.2.3 for details), cohorts of 3 to 6 evaluable 
patients will be enrolled 
including at least six evaluable patients at the MTD/R P2D level, as 
described in Section 6.2.3 . Multiple cohorts may be sequentially  enrolled to the same dose level. 
Additional cohorts of 1 to 6 evaluable patients may be enrolled at any dose level below the 
estimated MTD/R P2D for further elaboration of safet y and pharmacokinetic parameters as 
required. At least 21evaluable patients are expected to be treated in the phase Ipart, for the 
model to have reasonable operating characteristics relating to its MTD and/or RP2D 
recommendation.

Novartis Confidential Page 120
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
10.8.1.2 Phase II part 
Group 1
Group 1 is designed to assess the preliminary  anti-tumor activity  of FGF401 in HCC patients 
with positive expression of FGFR4 and KLB from Asian countries . If the lower limit of one-
sided 90% CI  of TTP is equal to or greater than 1.5 months, which is the expected median TTP 
without FGF401 treatment, it will be considered as preliminary  evidence of clinically  relevant 
efficacy  of FGF401 in G roup 1. 
It is assume d thatTTP has anexponential distribution and the true median TTP with FGF401 
treatment is 3.0 months, which is considered aclinically  relevant improvement with treatment 
in this patient population, and the enrollment rate is 3.5 patients per month. Analysis will be 
provided when all patients have potentiall y completed at least six cycles of treatment or 
discontinued the study . Table 10 -
2shows the probability of success (PoS), i.e., the probability 
of the lower limit of observed one-sided 90 %CI of TTP equal to or greater than 1.5 months, 
calculated b y simulation given these assumptions and different sample sizes. 
Approximately  40 patients will be enrolled, however, more patients with double positive tumors 
may be enrolled if the emerging cli nical data supports, see Section 4.1 . Considering a drop -out 
rate of 15%, the PoS is 90. 6%.
Table 10
-2 Probability  of Success under different number of sample size in 
Group 1 (drop rate = 15%)
Sample size Expected number of ev ents P(lower limit of one-sided 9 0% CI ≥1.5)
30 20.4 0.833
35 24.2 0.888
40 28.9 0.906
Group 2
Group 2 is designed to assess the preliminary  anti-tumor activity  of FGF401 in HCC patients 
with positive expression of FGFR4 and KLB from non-Asian regions . If the lower limit of one -
sided 90% CI  of TTP is equal to or greater than 2.2 months, which is the expected median TTP 
without FGF401 treatment, it will be considered as preliminary  evidence of c linically  relevant 
efficacy  of FGF401 in 
Group 2.
It is assume dthatTTP has anexponential distribution and the true median TTP with FGF401 
treatment is 4.2 months, which is considered aclinically  relevant improvement with treatment 
in this patient population, and the enrollment rate is 3.5 patients per month. Analysis will be 
provided when all patients have potentiall y completed at least six cycles of treatment or 
discontinued the study . Table 10-3 shows the PoS, i.e., the probability  of the lower limit of 
observed one-sided 90% CI of TTP equal to or greater than 2.2 months, calculated by simulation 
given these assumptions and differe nt sample sizes. 
Approximately  40 patients will be enrolled
, however, more patients with double positive tumors 
may be enrolled if the emerging clinical data supports, see Section 4.1. Considering a dr op-out 
rate of 15%, the PoS is 
87.7 %.

Novartis Confidential Page 121
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Table 10-3 Probability  of Success under different number of sample size in 
Group 2 (drop rate = 15%)
Sample size Expected number of ev ents P(lower limit of one-sided 9 0% CI ≥ 2.2)
30 17.8 0.800
35 21.2 0.857
40 25.6 0.877
Group 3
Group 3 is designed to assess the preliminary  anti-tumor activity  of FGF401 in other solid 
tumors with positive expression of FGFR4 and KLB. Overall approximately  20 patients are 
planned to be enrolled. Table 10-4 shows the probabilities of observing at least a certain number 
of responders given different values of true ORR.
If the true ORR of a tumor type is 0.05 , 0.10 and 0.25
, the probabilities of o bserving 1 or more 
responders with 20 patients are 0.642 , 0.878 and0.997 , respectivel y.
Table 10-4 Cumulative probability  (upper tail) of responses observed or more 
given true ORR and 20 patients
True ORR (p) Responses observed (n) P(responses ≥ n | N=2 0, p)
0.05 1 0.642
2 0.264
3 0.075
4 0.016
0.10 1 0.878
2 0.608
3 0.323
4 0.133
5 0.043
6 0.011
0.25 1 0.997
2 0.976
3 0.909
4 0.775
5 0.585
6 0.383
10.8.2 FGF401 in combination w ith PDR001
10.8.2.1 Phase I part
Cohorts of 3to 6 evaluable patients will be enrolled including at least six evaluable patients at 
the MTD/R P2D level, as described in Section 6.2.3. Multiple cohorts may be sequentiall y 
enrolled to the same dose level. Additional cohorts of 1 to 6 evaluable patients may  be enrolled 
at any dose level below the estimated MTD/R P2D for further elaboration of safet y and 
pharmacokinetic parameters as requi
red. At least 12evaluable patients are expected to be 
treated in the phase I part, for the model to have reasonable operating characteristics relating to 
its MTD and/or RP2D recommendation .

Novartis Confidential Page 122
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
10.8.2.2 Phase II part
The phase II part is designed to assess the prelimi nary anti-tumor activity  of FGF401 in 
combination with PDR001 in HCC patients. I f the posterior probability  of ORR in the 
unselected population included in the no/limited anti-tumor activity  interval [0, 0.15) is less 
than 0.10 and the posterior median ORR is 0.30 or more, it will be considered as preliminary 
evidence of clinicall y relevant efficacy of FGF401 in combination with PDR0 01. 
At interim analysis, if the predictive probability  of ORR (based on unconfirmed response) to 
not be considered as prelimi nary evidence of clinically  relevant efficacy  defined abov eat the 
final analysisis more than 0.90, that subgroup will not be open for further enrolment .If 25 or 
more patients are alread y enrolled to the subgroup, interim analysis will be performed but no 
further enrollment will be allowed in that subgroup.
In order to show how the design performs, simulation studies are conducted
assum ing35 
patients areenrolled in the Stage 1,and the biopsy  failure rate is 15%. In addition, due to the 
uncertaint y of the proportions of FGF19 positive and FGF19 negative patients 
(per FGF19 
expression and/or FGF19 pathway  activation status), the following 2 scenarios are investigated:
(1)the percentages of FGF 19positive and FGF 19negative patients enrolled in the Stage 1 are 
20% and 80% respectively ,and (2) the percentages of FGF19positive and FGF19negative 
patients enrolled in the Stage 1 are 40% and 60%. For each scenario, 50,000 trials were 
simulated .
T
heoperating characteristics under several scenarios oftrue ORR sof FGF19positive and 
negative patients are shown in Table 10-5 and Table 10 -6.
Under the scenario 1 (the percentages of FGF 19positive and FGF 19negative patients enrolled 
in the S tage 1 are 20% and 80%) ,
I
f the true ORR in both FGF 19positive and negative patients is 40%, the probability  to 
stop 
at Stage 1 for efficacy i n unselected population is 0.889. 
If the true ORR in FGF19 positive and negative patients
is 10%, probabilities to stop 
enrollm ent earl y for futility  are 0.600 (FGF 19positive group) and 0. 564(FGF 19 ne gative 
group) ,and the probability  to show efficacy  in either unselected or at least one subgroup is 
0.004.
If the true ORRs in FGF19 positive and negative patients are 10% and 40% respectively , 
the probability  to stop enrollment earl y for efficacy is 0.68
5,and the probability  to stop 
enrollment earl y for futility  in FGF 19positive group is 0.232.
If the true ORRs in FGF19 positive and negative patients are 40% and 10% respectively , 
the probability  to stop enrollment earl y for efficacy is 0.017, and probability  to show 
efficacy  in either unselected of at least one subgroup is 0.796 .

Novartis Confidential Page 123
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Table 10-5 Operating Characteristics (scenario 1: the percentages of FGF 19
positive and F GF19negative patients enrolled in the Stage 1 are 20% 
and 80%)
True ORR Probability  to 
stop study  for 
success* at 
Stage 1Probability  to stop 
subgroup 
enrollment for 
futility ** at Stage 1Probability  to 
show clinically  
relevant efficacy * 
at final analy sis***Overall probability  to 
show clinically  relevant 
efficacy *in either 
unselected, or at least 
one subgroup
FGF19+FGF19-FGF19+FGF19-FGF19+FGF19-
5% 5% 0.000 0.889 1.000 0.000 0.176 0.000
5% 10% 0.000 0.888 0.994 0.000 0.316 0.002
5% 20% 0.026 0.869 0.850 0.000 0.640 0.105
5% 30% 0.241 0.693 0.450 0.000 0.801 0.488
5% 40% 0.643 0.336 0.125 0.001 0.886 0.849
10% 5% 0.000 0.765 1.000 0.007 0.250 0.002
10% 10% 0.000 0.761 0.994 0.009 0.317 0.004
10% 20% 0.039 0.743 0.847 0.007 0.635 0.113
10% 30% 0.289 0.579 0.443 0.007 0.787 0.500
10% 40% 0.685 0.274 0.120 0.003 0.876 0.856
20% 5% 0 .000 0.501 1.000 0.181 0.111 0.090
20% 10% 0.002 0.502 0.993 0.178 0.271 0.091
20% 20% 0.074 0.489 0.835 0.169 0.598 0.200
20% 30% 0.387 0.368 0.421 0.154 0.757 0.566
20% 40% 0.768 0.162 0.108 0.142 0.853 0.881
30% 5% 0.000 0.294 1.000 0.581 0.154 0.410
30% 10% 0.006 0.292 0.990 0.580 0.298 0.415
30% 20% 0.128 0.283 0.808 0.567 0.572 0.491
30% 30% 0.490 0.206 0.387 0.536 0.730 0.727
30% 40% 0.835 0.085 0.093 0.511 0.836 0.928
30% 5% 0.000 0.294 1.000 0.581 0.154 0.410
40% 5% 0.002 0.151 0.998 0.886 0.000 0.752
40% 10% 0.017 0.150 0.980 0.883 0.264 0.753
40% 20% 0.201 0.144 0.758 0.873 0.564 0.785
40% 30% 0.590 0.101 0.337 0.857 0.715 0.886
40% 40% 0.889 0.039 0.073 0.844 0.815 0.971
*show the posterior probability of ORR included in [0, 0.15) is less than 0.10 and the posterior median ORR is 
0.30 or more
** show the posterior probability of ORR in a FGF19-based subgroup being included in [0, 0.15) is more than 
0.80
*** conditional probability to show clinically relevant efficacy and move to Stage 2 without stop study for success 
or futility at Stage 1
Under the scenario 2 (the percentages of FGF 19positive and FGF 19negative patients enrolled 
in the S tage 1 are 40% and 60%),
I
f the true ORR in both FGF 19positive and negative patients is 40%, the probability  to 
stop 
at Stage 1 for efficacy  in unselected population is 0.889. 
If the true ORR in FGF19 positive and nega tive patients is 10%, probabilities to stop 
enrollment earl y for futility  are 0.817 (FGF 19 positive group) and 0.940 (FGF19 negative 

Novartis Confidential Page 124
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
group), and probability  to show efficacy  in either unselected or at least one subgroup is 
0.004.
If the true ORRs in FGF19 positive and negative patients are 10% and 40% respectively , 
the probability  to stop enrollment earl
y for efficacy is 0.386, and the probability  to stop 
enrollment earl y for futility  in FGF 19positive group is 0.553.
If the true ORRs in FGF19 positive and negative patients are 40% and 10% respectively , 
the probability  to stop enrollment earl y for efficacy is 0.126, and probability to show 
efficacy  in either unselected or at least one subgroup is 0.829 .
Table 10-6 Operating Characteristics (scenario 2: the percentages of FGF 19
positive and FGF 19negative patients enrolled in the Stage 1 are 40% 
and 60%)
True ORR Probability  to 
stop study  for 
success* at 
Stage 1Probability  to stop 
subgroup 
enrollment for 
futility ** at Stage 1Probability  to 
show clinically  
relevant efficacy * 
at final analy sis***Overall probability  to 
show clinically  
relevant efficacy *in 
either unselected, or 
at least one subgroup
FGF19+FGF19-FGF19+FGF19-FGF19+FGF19-
5% 5% 0.000 0.980 0.997 0.000 0.004 0.000
5% 10% 0.000 0.980 0.968 0.001 0.060 0.002
5% 20% 0.006 0.976 0.724 0.001 0.350 0.101
5% 30% 0.076 0.910 0.346 0.001 0.670 0.463
5% 40% 0.287 0.707 0.105 0.000 0.879 0.822
10% 5% 0.000 0.909 0.997 0.019 0.008 0.002
10% 10% 0.000 0.909 0.967 0.021 0.051 0.004
10% 20% 0.018 0.901 0.719 0.019 0.333 0.107
10% 30% 0.128 0.817 0.346 0.015 0.648 0.470
10% 40% 0.385 0.592 0.104 0.010 0.860 0.825
20% 5% 0 .001 0.629 0.996 0.250 0.000 0.094
20% 10% 0.006 0.628 0.965 0.245 0.051 0.097
20% 20% 0.075 0.613 0.710 0.224 0.297 0.206
20% 30% 0.286 0.527 0.337 0.200 0.602 0.545
20% 40% 0.591 0.337 0.097 0.181 0.825 0.857
30% 5% 0.011 0.315 0.988 0.635 0.000 0.439
30% 10% 0.039 0.320 0.939 0.625 0.052 0.441
30% 20% 0.201 0.306 0.658 0.587 0.263 0.521
30% 30% 0.489 0.248 0.290 0.553 0.544 0.737
30% 40% 0.767 0.145 0.078 0.500 0.782 0.920
40% 5% 0.055 0.119 0.944 0.894 0.000 0.793
40% 10% 0.130 0.118 0.857 0.890 0.031 0.800
40% 20% 0.388 0.115 0.538 0.861 0.238 0.827
40% 30% 0.686 0.086 0.216 0.830 0.507 0.908
40% 40% 0.886 0.047 0.054 0.810 0.748 0.972
*show the posterior probability of ORR included in [0, 0.15) is less than 0.10 and the posterior median ORR is 
0.30 or more
** show the posterior probability of ORR in a FGF19 -based subgroup being included in [0, 0.15) is more than 0.80
*** conditional probability to show clinically relevant efficacy and move to Stage 2 without stop study for success or 
futility at Stage 1

Novartis Confidential Page 125
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
10.9 Power for analysis of key  secondary  variables
Not applicable.
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
11.2 Responsibilities of th e investigator and IRB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study  start. Prior to study  start, the investigator is required 
to sign a protocol signature page confirming his/her agreement to conduct the study  in 
accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to allrelevant data and records to Novartis monitors, auditors, 
Novartis Clinical Quality  Assurance representatives, designated agents of Novartis, 
IRBs/IECs/REBs and regulatory  authorities as required.
11.3 Informed consent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required by law or regulation), IRB/IEC/REB -approved informed consent if applicable:  or, if 
incapable of doing so, after such consent has been provided by a  l egall y acceptable 
representative of the patient. In cases where the patient’s representative gives consent, the 
patient should be informed about the study  to the extent possible given his/her understanding. 
If the patient is capable of doing so, he/she should indicate assent by personally signing and 
dating the written informed consent doc ument or a separate assent form .
[For Japan only: written consent is necessary both from the patient and his/her legal 
representative if he/she is under the age of 20 years.]
Informed consent must be obta ined before conducting an y stud y-specific procedures (i.e. all of 
the procedures described in the protocol). The process of obtaining informed consent should be 
documented in the patient source documents. The date when a subject’s Informed Consent was 
actually obtained will be captured in their eCRFs.
Novartis will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study  and complies with the ICH GCP 
guideline and regulatory  requirements. Any changes to this ICF suggested by the investigator 
must be agreed to by Novartis before submission to the IRB/IEC/REB, and a copy of the 
approved version must be provided to the Novartis monitor after IRB/ IEC/REB approval.
Women of child bearing potential should be informed that taking the study  medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 

Novartis Confidential Page 126
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
in order to participate in the study  they must adhere to the contraceptio n requirement for the 
duration of the study . If there is any question that the patient will not reliably compl y, they 
should not be entered in the study .
11.4 Discontinuation of the study
Novartis reserves the right to discontinue this study  under the conditions specified in the clinical 
study  agreement. Specific conditions for terminating the study  are outlined in Section 4.4.
11.5 Publication of study  protocol and results
Novartis is committed to following high ethical standards for reporting study  results for its 
innovative medicine, including the timel y communication and publication of clinical trial 
results, whatever 
their outcome . Novartis assures that the key  design elements o f this protocol 
will be posted on the publicly  accessible database , e.g.  www.clinicaltrials.gov, before study 
start.In addition, results of interventional clinical trials in adult patients are posted on 
www.novartisclinicaltrials.com, a publicl y accessible database of clinical study  results within 
1 year of study  completion (i.e. LPLV), those for interventional clinical trials involving 
pediatric patients within 6 months of study  completion .
Novartis follows the ICMJE authorship guidelines (www.icmje.org) and other specific 
guidelines 
of the journal or congress to which the publication will be submitted.
Authors will not receive remuneration for their writing of a publication, either directl y from 
Novartis or through the professional medical writing agency .Author(s) may be requested to 
present poster or oral presentation at scientific congress; however, there will be no honorarium 
provided for such presentations.
As part of its commitment to full transparency in publications, Novartis supports the full 
disclosure of all funding sources for the study  and publications, as well as any actual and 
potential conflicts of interest of financial and non-financial nature by all authors, including 
medical writing/editorial support, if applicable.
For the Novartis Guidelines for the Publication of Results from Novartis -sponsored Research, 
please refer to www.novartis.com . 
11.6 Stud y documentation, record keeping and retention of 
documents
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with Se ction 4.9 of the ICH E6 GCP, and regulatory and institutional requirements 
for the protection of confidentiality  of subjects. As part of participating in a Novartis -sponsored 
study , each site will permit authorized representatives of the sponsor(s) and reg ulatory  agencies 
to examine (and when required by  applicable law, to copy ) clinical records for the purposes of 
quality  assurance reviews, audits and evaluation of the study  safet y and progress.
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary  for the reconstruction and evaluation of the trial. Examples 
of these original documents and data records include, but are not limited to, hospital records, 
clinical and office charts, laboratory  notes, memoranda, subjects’ diaries or evaluation 

Novartis Confidential Page 127
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
checklists, pharmacy  dispensing records, recorded data from automated instruments, copies or 
transcriptions certified after verification as being accurate and complete, microfiches, 
photographic negatives, microfilm or magnetic media, x-rays, and subject files and records kept 
at the pharmacy , at the laboratories, and medico -technical departments involved in the clinical 
trial.
Data collection is the responsibility  of the clinical trial staff at the site under the supervision of 
the site Principal I nvestigator. The study  case report form (CRF) is the primary  data collection 
instrument for the stud y. The investigator should ensure the accuracy, completeness, legibility, 
and timeliness of the dat a reported in the CRFs and all other required reports. Data reported on 
the CRF, that are derived from source documents, should be consistent with the source 
documents or the discrepancies should be explained. All data requested on the CRF must be 
recorded . Any missing data must be explained. Any change or correction to a paper CRF should 
be dated, initialed, and explained (if necessary ) and should not obscure the original entry . For 
electronic CRFs an audit trail will be maintained by  the sy stem. The inves tigator should retain 
records of the changes and corrections to paper CRFs.
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by applicable 
regulations and/or guidelines. The investigator/institution should take measures to prevent 
accidental or premature destruction of these documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines.
11.7 Confidentiality  of study  documents and patient records
The investigator must ensure anon ymity of the patients; patients must not be identified by names 
in any documents submitted to Novartis. Signed informed consent forms and patient enrollment 
log must be kept strictl y confi dential to enable patient identification at the site.
11.8 Audits and inspections
Source data/documents must be available to inspections by Novartis or designee or Health 
Authorities.
11.9 Financial disclosures
Financial disclosures should be provided by study perso nnel who are directly  involved in the 
treatment or evaluation of patients at the site -prior to study  start.

Novartis Confidential Page 128
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
12 Protocol adherence
Investigators ascertain they will apply  due diligence to avoid protocol deviations. Under no 
circumstances should the investiga tor contact Novartis or its agents, if any, monitoring the study 
to request approval of a protocol deviation, as no authorized deviations are permitted. If the 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IRB/IEC/REB it cannot be implemented. All significant protocol 
deviations will be recorded and reported in the CSR.
12.1 Amendments to the protocol
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, Health Authorities where required, and the IRB/IEC/REB. Only 
amendments that are required for patient safet y may be implemented prior to IRB/IEC/REB 
approval. Notwithstanding the need for approval of formal protocol amendments, the 
investigator is expected to take any immediate action required for the safety  of any patient 
included in this study , even if this action represents a deviation from the protocol. In such cases, 
Novartis should be notified of this action and the IRB/IEC at the study  site should be informed 
according to local regulations (e.g. UK requires the notification of urgent safet y measures 
within 3 day s) but not later than 1 0 working day s.

Novartis Confidential Page 129
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
13 References (available upon request)
Babb J, Rogatko A, Zacks S (1998) Cancer phase I clinical trials: efficient dose escalation 
with overdose control. Stat.Med.; 17 (10):1103 -1120. 
Bailey  S, Neuenschwander B, Laird G, et al (2009) A Bay esian case stud y in oncology  Phase 
I combination dose -finding using logistic regression with covariates. J.Biopharm.Stat.; 19 
(3):469-484. 
Bosch FX, Ribes J, Diaz M, et al (2004) Primary  liver cancer: worldwide incidence and 
trends. Gastroenterology .; 127 (5 Suppl 1):S5 -S16. 
Bruno S, Ignacio M, Thomas C, et al (2016). Safety  and antitumor activity  of nicolumab 
(nivo) in patients (pts) with advanced hepatocellular acrcinoma (HCC): I nterim anal ysis of 
dose-expansion cohorts from the phase1/2 CheckMate -040 study . ASCO Annual Meeting 
2016. Abstr no. 4078
.
Chan SL , Mo FK, Johnson PJ, et al (2011) Prospective validation of the Chinese Universit y 
Prognostic Index and comparison with other staging s ystems for hepatocellular carcinoma in 
an Asian population. J.Gastroenterol.Hepatol.; 26 (2):340-347. 
Cheng AL, Kang YK, Chen Z, et al (2009) Efficacy and safet y of sorafenib in patients in the 
Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double -
blind, placebo -controlled trial. Lancet Oncol.; 10 (1):25-34. 
Child CG, Turcotte JG (1964) Surgery  and portal hy pertension. Major.Probl.Clin.Surg.; 1:1 -
85.:1 -85. 
Chugh R, Wathen JK, Maki RG, et al (2009) Phase II multicenter trial of i matinib in 10 
histologic subty pes of sarcoma using a bay esian hierarchical statistical model. J.Clin.Oncol.; 
27 (19):3148-3153. 
Dawson S, Stahl S, Paul N, et al (2012) In vitro inhibition of the bile salt export pump 
correlates with risk of cholestatic dr ug-induced liver injury  in humans. Drug Metab Dispos.; 
40 (1):130-138. 
Desno yers LR, Pai R, Ferrando RE, et al (2008) Targeting FGF19 inhibits tumor growth in 
colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene.; 
27 (1):85-97. 
Dong Z, Ekins S, Polli JE (2013) Structure -activity  relationship for FDA approved drugs as 
inhibitors of the human sodium taurocholate cotransporting pol ypeptide (NTCP). Mol.Pharm.; 
10 (3):1008-1019. 
El-Serag HB (2012) Epidemiology  of viral hepatitis and hepatocellular carcinoma. 
Gastroenterology .; 142 (6):1264 -1273. 
French DM, Lin BC, Wang M, et al (2012) Targeting FGFR4 inhibits hepatocellular 
carcinoma in preclinical mouse models. PL oS.One.; 7 (5):e36713. 
Guagnano V, Kauffmann A, Wohrle S, et a l (2012) FGFR genetic alterations predict for 
sensitivity  to NVP -BGJ398, a selective pan -FGFR inhibitor. Cancer Discov.; 2 (12):1118-
1133. 
 

Novartis Confidential Page 130
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Ho HK, Pok S, Streit S, et al (2009) Fibroblast growth factor receptor 4 regulates 
proliferation, anti- apoptosis and alpha -fetoprotein secretion during hepatocellular carcinoma 
progression and represents a potential target for th erapeutic intervention. J.Hepatol.; 50 
(1):118-127.
Kim R, Sharma S, MeyerT, et al (2016) .First-in-human study  of BLU - 554, a potent, highly-
selective FGFR4 inhibitor designed for hepato -cellular carcinoma (HCC) with FGFR4 
pathway  activation. ENA .
Johnson PJ, Qin S, Park JW, et al (2013) Brivanib versus sorafenib as first- line therap y in 
patients with unresectable, advanced hepatocellular carcinoma: results from the randomized 
phase III BRISK -FL study . J.Clin.Oncol.; 31 (28):3517-3524. 
Kalliokoski A, Niem i M (2009) Impact of OATP transporters on pharmacokinetics. 
Br.J.Pharmacol.; 158 (3):693-705. 
Lencioni R (2012) Chemoembolization in patients with hepatocellular carcinoma. L iver 
Cancer.; 1 (1):41 -50. 
Lin BC, Desno yers LR (2012) FGF19 and cancer. Adv.Exp .Med.Biol.; 728:183- 94. doi: 
10.1007/978-1-4614- 0887 -1_12.:183-194. 
Lin BC, Wang M, Blackmore C, et al (2007) Liver -specific activities of FGF19 require 
Klotho beta. J.Biol.Chem.; 282 (37):27277 -27284. 
Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular 
carcinoma in 2008. J.Hepatol.; 48 Suppl 1:S20 -37. doi: 10.1016/j.jhep.2008.01.022. 
Epub;%2008 Feb 12.:S20- S37. 
Llovet JM, Ricci S, Mazzaferro V, et al (2008) Sorafenib in advanced hepatocellular 
carcinoma. N.Engl.J.Med.; 359 ( 4):378-390. 
Lopez PM, Villanueva A, L lovet JM (2006) Sy stematic review: evidence- based management 
of hepatocellular carcinoma --an updated analy sis of randomized controlled trials. 
Aliment.Pharmacol.Ther.; 23 (11):1535 -1547. 
Mellor HR (2014) Targeted inhi bition of the FGF19 -FGFR4 pathway  in hepatocellular 
carcinoma; translational safet y considerations. L iver Int.; 34 (6):e1- e9. 
Miura S, Mitsuhashi N, Shimizu H, et al (2012) Fibroblast growth factor 19 expression 
correlates with tumor progression and poore r prognosis of hepatocellular carcinoma. 
BMC.Cancer.; 12:56. doi: 10.1186/1471 -2407-12- 56.:56 - 12. 
Morgan RE, van Staden CJ, Chen Y, et al (2013) A multifactorial approach to hepatobiliary  
transporter assessment enables improved therapeutic compound develo pment. Toxicol.Sci.; 
136 (1):216-241. 
Neuenschwander B, Branson M, Gsponer T (2008) Critical aspects of the Bay esian approach 
to phase I cancer trials. Stat.Med.; 27 (13):2420 -2439. 
Nicholes K, Guillet S, Tomlinson E, et al (2002) A mouse model of hepato cellular carcinoma: 
ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. 
Am.J.Pathol.; 160 (6):2295 -2307. 

Novartis Confidential Page 131
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Poh W, Wong W, Ong H, et al (2012) Klotho -beta overexpression as a novel target for 
suppressing proliferation and fibroblast growth factor receptor- 4 signaling in hepatocellular 
carcinoma. Mol.Cancer.; 11:14. doi: 10.1186/1476 -4598-11- 14.:14 - 11. 
 
Raza A, Sood GK (2014) Hepatocellular carcinoma review: current treatment, and evidence -
based medicine. World J.Gastroentero l.; 20 (15):4115 -4127. 
Rogatko A, Schoeneck D, Jonas W, et al (2007) Translation of innovative designs into phase I 
trials. J.Clin.Oncol.; 25 (31):4982 -4986. 
Sawey  ET, Chanrion M, Cai C, et al (2011) Identification of a therapeutic strategy  targeting 
amplified FGF19 in liver cancer b y Oncogenomic screening. Cancer Cell.; 19 (3):347 -358. 
Thall PF, Wathen JK, Bekele BN, et al (2003) Hierarchical Bay esian approaches to phase II 
trials in diseases with multiple subty pes. Stat.Med.; 22 (5):763 -780. 
 
Wolchok JD, Hoos A, O'Day  S et al (2009) .Guidelines for the Evaluation of I mmune 
Thera py Activity  in Solid Tumors: I mmune -Related Response Criteria. Clin Cancer Res; 
15:7412-20.

Novartis Confidential Page 132
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
14 Appendices
14.1 Appendix 1 –Guidelines for response, duration of overall 
response, TTF, TTP, progression-free survival and overall 
survival (based on RECIST 1.1)
Harmonization of Efficacy  Analysis of Solid Tumor Studies
Document type: TA Specific Guideline
Document status: Version 3.1: 29-Nov-2011
Version 3:0: 19-Oct-2009
Version 2: 0: 18- Jan-2007
Version 1: 0: 13- Dec- 2002
Release date: 29-Nov-2011
Authors (Version 3.1):
 
Authors (Version 3):  
Authors (Version 2):
Authors (Version 1):

Novartis Confidential Page 133
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Glossary
CR Complete response
CRF Case Report Form
CSR Clinical Study Report
CT Computed tomography
DFS Disease -free survival
eCRF Electronic Case Report Form
FPFV First patient first visit
GBM Glioblastoma multiforme
MRI Magnetic resonance imaging
LPLV Last patient last visit
OS Overall survival
PD Progressive disease
PFS Progression -free survival
PR Partial response
RAP Reporting and Analysis Plan
RECIST Response Evaluation Criteria in Solid Tumors
SD Stable disease
SOD Sum of Diameter
TTF Time to treatment failure
TTP Time to progression
UNK Unknown

Novartis Confidential Page 134
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
14.1.1 Introduction
The purpose of this document is to provide the working definitions and rules necessary  for a 
consistent and efficient analy sis of efficacy  for oncology  studies in solid tumors. This document 
is based on the RECI ST criteria for tumor responses (Therasse et al 2000 ) and the revised 
RECI ST 1.1 guidelines ( Eisenhauer et al 2009 ).
The efficacy  assessments described in Section 14.1.2 and the definition of best response in
Section 
14.1.17 are based on the RECIST 1.1criteria but also give more detailed instructi ons 
and rules for determination of best response. Section 14.1.18 is summarizing the “time to event” 
variables and rules 
which are mainl y derived from internal discussions and regulatory 
consultations , as the RECI ST criteria do not define these variables in detail. Section 14.1.28 of 
this guideline describes data handling and programming rules. This section is to be referred to
in the RAP (Reporting and Analy sis Plan) to provide further details needed for programming.
14.1.2 Efficacy  assessments
Tumor evaluations are made based on RECIST criteria ( Therasse et al 2000 ), New Guidelines 
to Evaluate the Resp onse to Treatment in Solid Tumors, Journal of National Cancer Institute, 
Vol. 92; 205-16 and revised RECI ST guidelines (version 1.1) (Eisenhauer et al 2009) European 
Journal of Cancer; 45:228 -
247.
14.1.3 Defin itions
14.1.4 Disease measurability
In order to evaluate tumors throughout a study , definitions of measurability  are required in order 
to classify  lesions appropriately  at baseline. In defining measurability , a distinction also needs 
to be made between nodal lesi ons (pathological l ymph nodes) and non -nodal lesions.
Measurable disease -the presence of at least one measurable nodal or non -nodal lesion. 
If the measurable disease is restricted to a solitary  lesion, its neoplastic nature should be 
confirmed b y cytology/histology .
For patients without measurable disease see Section 14.1.26.
Measurable lesions (both nodal and non -nodal)
Measurable non- nodal -As a rule of thumb, the minimum size of a measurable non -nodal 
target lesion at baseline should be no less than double the slice thicknes s or 10mm 
whichever is greater -e.g. the minimum non-nodal lesion size for CT/MRI  with 5mm cuts 
will be 10 mm, for 8 mm contiguous cuts the minimum size will be 16mm.
Lytic 
bone lesions or mixed ly tic-blastic lesions with identifiable soft tissue components, 
that can be evaluated b y CT/MRI , can be considered as measurable lesions, if the soft 
tissue component meets the definition of measurability .
Measurable nodal lesions (i.e. ly mph nodes) -Lymph nodes 15 mm in short axis can be 
considered for selection as target lesions. Lymph nodes measuring 10 mm and <15 mm 
are considered non -measurable. Ly mph nodes smaller than 10 mm in short axis at 
baseline, regardless of the slice t hickness, are normal and not considered indicative of 
disease.

Novartis Confidential Page 135
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Cystic lesions :
Lesions that meet the criteria for radiographicall y defined simple cy sts (i.e., spherical 
structure with a thin, non -irregular, non -nodular and non-enhancing wall, no 
septations, and low CT density  [water -like] content) should not be considered as 
malignant lesions (neither measurable nor non -measurable) since they  are, by  
definition, simple cy sts.
‘Cystic lesions’ thought to represent cy stic metastases can be considere d as 
measurable lesions, if they meet the definition of measurability  described above. 
However, if noncy stic lesions are present in the same patient, these are preferred for 
selection as target lesions.
Non-measurable lesions - all other lesions are consid ered non -measurable, including small 
lesions (e.g. longest diameter <10 mm with CT/MRI  or pathological ly mph nodes with 
10 to < 15 mm short axis), as well as trul y non -measurable lesions e.g., blastic bone 
lesions, leptomeningeal disease, ascites, pleura l/pericardial effusion, inflammatory  breast 
disease, l ymphangitis cutis/pulmonis, abdominal masses/abdominal organomegaly  
identified by  physical exam that is not measurable by  reproducible imaging techniques.
14.1.5 Eligibility  based on measurable disease
If no m easurable lesions are identified at baseline, the patient may  be allowed to enter the study 
in some situations (e.g. in Phase III studies where PFS is the primary  endpoint). However, it is 
recommended that patients be excluded from trials where the main focus is on the Overall 
Response Rate (ORR). Guidance on how patients with just non- measurable disease at baseline 
will be evaluated for response and also handled in the statistical analy ses is given in Section 
14.1.26.
14.1.6 Methods of tumor measurement -general guidelines
In this document, the term “contrast” refers to intravenous (i.v) contrast.
The following considerations are to be made when evaluating the tumor:
All measurements should be taken and record ed in metric notation (mm) , using a ruler or 
calipers. All baseline evaluations should be performed as closel y as possible to the 
beginning of treatment and never more than 4 weeks before the beginning of the 
treatment.
Imaging
-based evaluation is preferre d to evaluation by  clinical examination when both 
methods have been used to assess the antitumor effect of a treatment.
For optimal evaluation of patients, the same methods of assessment and technique should 
be used to characterize each identified and repo rted lesion at baseline and during follow -
up. Contrast- enhanced CT of chest, abdomen and pelvis should preferably be performed 
using a 5 mm slice thickness with a contiguous reconstruction algorithm. CT/MRI  scan 
slice thickness should not exceed 8 mm cuts using a contiguous reconstruction algorithm. 
If, at baseline, a patient is known to have a medical contraindication to CT contrast or 
develops a contraindication during the trial, the following change in imaging modalit y will 
be accepted for follow up: a non- contrast CT of chest (MRI  not recommended due to 
respiratory  artifacts) plus contrast
-enhanced MRI of abdomen and pelvis.

Novartis Confidential Page 136
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
A change in methodology  can be defined as either a change in contrast use (e.g. keeping 
the same technique, like CT, but switching from with to without contrast use or vice-versa, 
regardless of the justification for the change) or a change in technique (e .g. from CT to 
MRI , or vice -versa), or a change in an y other imaging modality . A c hange in methodology  
will r esult by default in a UNK overall lesion response assessment . However ,another 
response assessment than the Novartis calculated UNK response may  be accepted from the 
investigator or the central blinded reviewer if a definitive response assessment can be 
justified, based on the available information.
FDG -PET : can complement CT scans in assessing progression (particularly  possible for 
‘new’ disease). New lesions on the basis of FDG- PET imaging can be identified according 
to the following algorithm:
Negative FDG -PET at baseline, wi th a positive FDG -PET at follow -up is a sign of PD 
based on a new lesion.
No FDG -PET at baseline with a positive FDG- PET at follow -up:
If the positive FDG -PET at follow -up corresponds to a new site of disease confirmed by  
CT, this is PD.
If the positive FDG -PET at follow -up is not confirmed as a new site of disease on CT, 
additional follow -up CT are needed to determine if there is trul y progression occurring at 
that Site (if so, the date of PD will be the date of the initial abnormal CT sc an).
If the positive FDG -PET at follow -up corresponds to a pre -existing site of disease on CT 
that is not progressing on the basis of the anatomic images, this is not PD.
Chest x -ray: Lesions on chest x -ray are acceptable as measurable lesions when they  are 
clearl y defined and surrounded by aerated lung. However, CT is preferable.
Ultrasound : When the primary  endpoint of the study  is objective response evaluation, 
ultrasound (US) should not be used to measure tumor lesions. I t is, however, a possible 
altern
ative to clinical measurements of superficial palpable l ymph nodes, subcutaneous 
lesions and thy roid nodules. US might also be useful to confirm the complete 
disappearance of superficial lesions usually  assessed by  clinical examination.
Endoscopy and lapar oscopy : The utilization of endoscopy  and laparoscopy  for objective 
tumor evaluation has not y et been full y and widely validated. Their uses in this specific 
context require sophisticated equipment and a high level of expertise that may  only be 
available in some centers. Therefore, the utilization of such techniques for objective tumor 
response should be restricted to validation purposes in specialized centers. However, such 
techniques can be useful in confirming complete pathological response when biopsies are 
obtained.
Tumor markers : Tumor markers alone cannot be used to assess response. However, 
some disease specific and more validated tumor markers (e.g. CA -125 for ovarian cancer, 
PSA for prostate cancer, alpha -FP, LDH and Beta-hCG for testicular cancer) can be 
integrated as non -target disease. If markers are initially  above the upper normal limit they  
must normalize for a patient to be considered in complete clinical response when all 
lesions have disappeared.
Cytology and histology: Cy tology  and histolog y can be used to differentiate between PR 
and CR in rare cases (i.e., after treatment to differentiate between residual benign lesions 

Novartis Confidential Page 137
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
and residual malignant lesions in tumor ty pes such as germ cell tumors). Cytologic 
confirmation of neoplastic nature of a ny effusion that appears or worsens during treatment 
is required when the measurable tumor has met the criteria for response or stable disease. 
Under such circumstances, the cy tologic examination of the fluid collected will permit 
differentiation between r esponse and stable disease (an effusion may  be a side effect of the 
treatment) or progressive disease (if the neoplastic origin of the fluid is confirmed).
Clinical examination : Clinical lesions will only  be considered measurable when they  are 
superficial (i.e., skin nodules and palpable l ymph nodes). For the case of skin lesions, 
documentation by  color photography , including a ruler to estimate the size of the lesion, is 
recommended.
14.1.7 Baseline documentation of target and non-target lesions
For the evaluatio n of lesions at baseline and throughout the study , the lesions are classified at 
baseline as either target or non-target lesions:
Target lesions
: All measurable lesions (nodal and non-nodal) up to a maximum of five 
lesions in total (and a maximum of two le sions per organ), representative of all involved 
organs should be identified as target lesions and recorded and measured at baseline. Target 
lesions should be selected on the basis of their size (lesions with the longest diameter) and 
their suitability  foraccurate repeated measurements (either by  imaging techniques or 
clinically ). Each target lesion must be uniquely  and sequentially  numbered on the CRF 
(even if it resides in the same organ).
Minimum target lesion size at baseline
Non-nodal target : Non-noda l target lesions identified by  methods for which slice 
thickness is not applicable (e.g. clinical examination, photograph y) should be at least 10 
mm in longest diameter. See Section 14.1.4.
Nodal target : See 
Section 14.1.4 .
A sum of diameters (long axis for non -nodal lesions, short axis for nodal) for all target lesions 
will be calculated and reported as the baseline sum of diameters (SOD). The baseline sum of 
diameters will be used as reference by which to characterize the objective tumor response. Each 
target lesion identified at baseline must be followed at each subsequent evaluation and 
documented on eCRF .
Non-target lesions: All other lesions are considered non-target lesions , i.e. lesions not 
fulfilling the criteria for target lesions at baseline.
Presence or absence or worsening of 
non-target lesions should be assessed throughout the study ; measurements of these lesions
are not required. Multiple non -target lesions involved in the same organ can be assessed as 
a group and recorded as a single item (i.e. multiple liver metastases). Each non -target 
lesion identified at baseline must be followed at each subsequent evaluation and 
documented on e CRF.
14.1.8 Follow -up evaluation of target and non-target lesions
To assess tumor response, the sum of diameter sfor all target lesions will be calculated (at 
baseline and throughout the study ). At each assessment response is evaluated first separately 

Novartis Confidential Page 138
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
for the target (Table 14-1) and non-target lesions (Table 14 -2) identified at baseline. These 
evaluations are then used to calculate the overall lesion response considering both the target and 
non-target lesions together ( Table 14 - 3) as well as the presence or absence of new lesions.
14.1.9 Follow -up and recording of lesions
At each visit and for each lesion the actual date of the scan or procedure which was used for the 
evaluation of each specific lesion should be recorded. This applies to target and non-target 
lesions as well as new lesions that are detected. At the assessment visit all of the separate lesion 
evaluation data are examined by the investigator in order to derive the overall visit response. 
Therefore all such data applicable to a particular visit should be associated with the same 
assessment number .
14.1.10 Non
-nodal lesions
Following treatment, lesions may  have longest diameter measurements smaller than the image 
reconstruction interval. Lesions smaller than twice the reconstruction interval are subject to 
substantial “partial volume” effects (i.e., size may be underestimated because of the distance of 
the c ut from the longest diameter; such lesions may appear to have responded or progressed on 
subsequent examinations, when, in fact, they  remain the same size).
If the lesion has completely disappeared, the lesion size should be reported as 0 mm.
Measurements of non-nodal target lesions that become 5 mm or less in longest diameter are 
likely  to be non -reproducible . Therefore, it is recommended to report a default value of 5 mm ,
instead of the ac
tual measurement. This default value is derived from the 5mm CT slice 
thickness (but should not be changed with varying CT slice thickness). Actual measurement 
should be given for all lesions larger than 5 mm in longest diameter irrespective of slice 
thickness/reconstruction interval.
In other cases where the lesion ca nnot be reliably measured for reasons other than its size (e.g., 
borders of the lesion are confounded by neighboring anatomical structures), no measurement 
should be entered and the lesion cannot be evaluated.
14.1.11 Nodal lesions
A nodal lesion less than 10 mm in size by short axis is considered normal. Lym ph nodes are not 
expected to disappear completely , so a “non- zero size” will alway s persist.
Measurements of nodal target lesions that become 5 mm or less in short axis are likely  to be
non-reproducible. Theref ore,it is recommended to report a default value of 5 mm ,instead of 
the actual measurement. This default value is derived from the 5mm CT slice thickness (but 
should not be changed with varying CT slice thickness). Actual measurement should be given 
for all lesions larger than 5 mm in short axis irrespective of slice thickness/reconstruction 
interval.
However, once a target nodal lesion shrinks to less than 10 mm in its short axis, it will be 
considered normal for response purpose determination. The lymph node measurements will 
continue to be recorded to allow the values to be included in the sum of diameters for target 
lesions, which may  be required subsequentl y for response determination.

Novartis Confidential Page 139
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
14.1.12 Determination of target lesion response
Table 14-1 Response criteria for target lesions
Response Criteria Evaluation of target lesions
Complete Response (CR): Disappearance of all non -nodal target lesions. In addition, any pathological lymph 
nodes assigned as target lesions must have a reduction in short axis to < 10 mm 1
Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesion s, taking as 
reference the baseline sum of diameters.
Progressive Disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, taking 
as reference the smallest sum of diameter of all target lesions recorded at or after 
base line. In addition to the relative increase of 20%, the sum must also demonstrate 
an absolute increase of at least 5 mm2.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which 
would qualify for PD.
Unknown (UNK) Progression has not been documented and one or more target lesions have not been 
assessed or have been assessed using a different method than baseline.3
1. SOD for CR may not be zero when nodal lesions are part of target lesions
2. Following an initial CR, a PD cannot be assigned if all non -nodal target lesions are still not present and all nodal 
lesions are <10 mm in size. In this case, the target lesion response is CR
3. Methodology change See Section 14.1.6 .
Notes on target lesion response
Reappearance of lesions: If the lesion appears at the same anatomical location where a target 
lesion had previousl y dis appeared, it is advised that the time point of lesion disappearance (i.e., 
the “0 mm” recording) be re-evaluated to make sure that the lesion was not actually  present 
and/or not visualized for technical reasons in this previous assessment. If it is not possible to 
change the 0 value, then the investigator/radiologist has to decide between the following three 
possibilities:
The lesion is a new lesion, in which case the overall tumor assessment will be considered 
as progressive disease
The lesion is clearl y a reappearance of a previously  disappeared lesion, in which case the 
size of the lesion has to be entered in the CRF and the tumor assessment will remain based 
onthe sum of tumor measurements as presented in Table 14-1 above (i.e., a PD will be 
determined if there is at least 20% increase in the sum of diameters of allmeasured target 
lesions, taking as referen ce the smallest sum of diameters of all target lesions recorded at or 
after baseline with at least 5 mm increase in the absolute sum of the diameters). Proper 
documentation should be available to support this decision. This applies to patients who 
have not achieved target response of CR. For patients who have achieved CR, please refer 
to last bullet in this section.
For those patients who have onl y one target lesion at baseline, the reappearance of the 
target lesion which disappeared previousl y, even if sti ll small, is considered a PD.
Missing measurements : In cases where measurements are missing for one or more target 
lesions it is sometimes still possible to assign PD based on the measurements of the 
remaining lesions. For example, if the sum of diameters for 5 target lesions at baseline is 
100mm at baseline and the sum of diameters for 3 of those lesions at a post -baseline visit 
is 140 mm (with data for 2 other lesions missing) then a PD should be assigned. However, 

Novartis Confidential Page 140
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
in other cases where a PD cannot definitel y be attributed ,the target lesion response would 
be UNK.
Nodal lesion decrease to normal size : When nodal disease is included in the sum of target 
lesions and the nodes decrease to “normal” size they  should still have a measurement 
recorded on sc ans. This measurement should be reported even when the nodes are normal 
in order not to overstate progression should it be based on increase in the size of nodes.
Lesions split : In some circumstances, disease that is measurable as a target lesion at 
baseli ne and appears to be one mass can split to become two or more smaller sub -lesions. 
When this occurs, the diameters (long axis - non- nodal lesion, short axis -nodal lesions) of 
the two split lesions should be added together and the sum recorded in the diameter field on 
the case report form under the original lesion number. This value will be included in the 
sum of diameters when deriving target lesion response. The individual split lesions will not 
be considered as new lesions, and will not automatically  trigger a PD designation.
Lesions coalesced : Conversel y, it is also possible that two or more lesions which were 
distinctly  separate at baseline become confluent at subsequent visits. When this occurs a 
plane between the original lesions may
 be maintained that would aid in obtaining diameter 
measurements of each individual lesion. I f the lesions have trul y coalesced such that they 
are no longer separable, the maximal diameters (long axis - non- nodal lesion, short axis -
nodal lesions) of the “merged lesion” s hould be used when calculating the sum of 
diameters for target lesions. On the case report form, the diameter of the “merged lesion” 
should b
e recorded for the size of one of the original lesions while a size of “0”mm should 
be entered for the remaining le sion numbers which have coalesced.
The measurements for nodal lesions , even if less than 10 mm in size, will contribute to 
the calculation of target lesion response in the usual way  with slight modifications.
Since lesions less than 10 mm are considered no rmal, a CR for target lesion response 
should be assigned when all nodal target lesions shrink to less than 10 mm and all 
non-nodal target lesions have disappeared.
Once a CR target lesion response has been assigned a CR will continue to be 
appropriate (in the absence of missing data) until progression of target lesions.
Following a CR, a PD can subsequently  only be assigned for target lesion response if 
either a non
-nodal target lesion “reappears” or if any  single nodal lesion is at least 10 
mm and there is at least 20% increase in sum of the diameters of all nodal target 
lesions relative to nadir with at least 5 mm increase in the absolute sum of the 
diameters.
14.1.13 Determination of non -target lesion response
Table 14-2 Response criteria for non-target lesions
Response Criteria Evaluation of non -target lesions
Complete Response (CR): Disappearance of all non -target lesions. In addition, all lymph nodes assigned a non -
target lesions must be non -pathological in size (< 10 mm short axis)
Progressive Disease (PD): Unequivocal progression of existing non -target lesions.1
Non-CR/Non-PD: Neither CR nor PD
Unknown (UNK) Progression has not been documented and one or more non -target lesions have not 
been assessed or have been assessed using a different method than baseline.

Novartis Confidential Page 141
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Response Criteria Evaluation of non -target lesions
1. Although a clear progression of non -target lesions only is exceptional, in such circumstances, the opinion of the 
treating physician does prevail and the progr ession status should be confirmed later on by the review panel (or 
study chair).
Notes on non -target lesion response
The response for non- target lesions is CRonly if all non- target non- nodal lesions which 
were evaluated at baseline are now all absent and with all non- target nodal lesions 
returned to normal size (i.e. < 10 mm). If any  of the non -target lesions are still present, or 
there are an y abnormal nodal lesions (i.e. 10 mm) the response can onl y be ‘ Non-
CR/Non -PD’ unless an y of the lesions was not assessed (in which case response is UNK ) 
or there is unequivocal progression of the non -target lesions (in which case response is 
PD).
Unequivocal progression: To achieve “unequivocal progression” on the basis of non -target 
disease there must be an overal l level of substantial worsening in non- target disease such 
that, even in presence of CR, PR or SD in target disease, the overall tumor burden has 
increased sufficientl y to merit discontinuation of therap y. A modest “increase” in the size 
of one or more no n-target lesions is usually  not sufficient to qualify  for unequivocal 
progression status. The designation of overall progression solely  on the basis of change in 
non-target disease in the face of CR, PR or SD of target disease is therefore expected to be 
rare.In order for a PD to be assigned on the basis of non- target lesions, the increase in the 
extent of the disease must be substantial even in cases where there is no measurable 
disease at baseline. If there is unequivocal progression of non -target lesion (s),then at least 
one of the non -target lesions must be assigned a status of “Worsened”. Where possible, 
similar rules to those described in Section 14.1.12 for assigning PD following a CR for the 
non-target lesion response in the presence of non -target lesions nodal lesions should be 
applied.
14.1.14 New lesions
The a ppearance of a new lesion is alway s associated with Progressive Disease (PD) and has to 
be recorded as a new lesion in the New Lesion CRF page.
If a new lesion is equivocal , for example because of its small size, continued therap y and 
follow -up evaluation will clarify  if it represents truly  new disease. If repeat scans confirm 
there is definitel y a new lesion, then progression should be declared u sing the date of the 
first observation of the lesion.
If new disease is observed in a region which was not scanned at baseline or where the 
particular baseline scan is not available for some reason, then this should be considered as 
a PD. 
The one exception to this is when there are no baseline scans at all available for a 
patient in which case the response should be UNK, as for an y of this patient's assessment 
(see Section 14.1.15).
A lymph node is consi dered as a “new lesion” and, therefore, indicative of progressive 
disease if the short axis increases in size to 
10 mm for the first time in the study  plus 5 
mm absolute increase.
FDG -PET : can complement CT scans in assessing progression (particularly  possible for 
‘new’ disease). See 
Section 14.1.6 .

Novartis Confidential Page 142
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
14.1.15 Evaluation of overall lesion response
The evaluation of overall lesion response at each assessment is a composite of the target lesion 
response, non-target lesion response and presence of new lesions as shown below in
Table 14-3.
Table 14
-3 Overall lesion response at each assessment
Target lesions Non-target lesions New LesionsOverall
lesion response
CR CR No CR1
CR Non-CR/Non-PD3No PR
CR, PR, SD UNK No UNK
PR Non-PD and not UNK No PR1
SD Non-PD and not UNK No SD1, 2
UNK Non-PD or UNK No UNK1
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
1. This overall lesion response also applies when there are no non -target lesions identified at baseline.
2. Once confirmed PR was achieved, all these assessments are considered PR.
3. As defined in Section 14.1.8 .
If there are no baseline scans available at all ,then the overall lesion response at each assessment 
should be considered Unknown (UNK).
If the evaluation of any of the target or non-target lesions identified at baseline could not be 
made during follow -up,the overall status must be ‘unknown’ unless progression was seen.
In some circumstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of complete response depends on this determination, it is recommended 
that the residual lesion be investigated (fine needle aspirate/biopsy ) to confirm the CR.
14.1.16 Efficacy  definitions
The following definitions primarily relate to patients who have measurable disease at baseline. 
Section 14.1.26 outlines the special considerations that need to be given to patients with no 
measurable disease at baseline in order to appl y the same concepts.
14.1.17 Best overall response
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for PD the smallest measurements recorded 
since the treatment started). In general, the patient's best response assignment will depend on 
the achievement of both measurement and conf irmation criteria.
The best overall response will usually  be determined from response assessments undertaken 
while on treatment. However, if an y assessments occur after treatment withdrawal the protocol 
should specificall y describe if these will be include d in the determination of best overall 
response and/or whether these additional assessments will be required for sensitivity  or 
supportive analyses. As a default, any  assessments taken more than 30 day s after the last dose 
of study  treatment will not be included in the best overall response derivation. If any alternative 

Novartis Confidential Page 143
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
cancer therapy  is taken while on study  any subsequent assessments would ordinarily  be 
excluded from the best overall response determination. If response assessments taken after 
withdrawal from study  treatment and/or alternative therap y are to be included in the main 
endpoint determination, then this should be described and justified in the protocol.
Where a study  requires confirmation of response (PR or CR ), changes in tumor measurements 
must be confirmed by  repeat assessments that should be performed not less than 4 weeks after 
the criteria for response are first met.
Longer intervals may  also be appropriate. However, this must be clearl y stated in the protocol. 
The main goal of confirmation of objective response is to avoid overestimating the response 
rate observed. In cases where confirmation of response is not feasible, it should be made clear 
when reporting the outcome of such studies that the responses are not confirmed.
-For non -randomi zed trials where response is the primary  endpoint, confirmation is 
needed.
-For trials intended to support accelerated approval, confirmation is needed
For all other trials, confirmation of response may  be considered optional.
The best overall response foreach patient is determined from the sequence of overall (lesion) 
responses according to the following rules:
CR = at least two determinations of CR at least 4 weeks apart before progression where 
confirmation required or one determination of CR prior to p rogression where confirmation 
not required
PR = at least two determinations of PR or better at least 4 weeks apart before progression 
(and not qualify ing for a CR) where confirmation required or one determination of PR 
prior to progression where confirmati on not required
SD = at least one SD assessment (or better) > 6 weeks after randomization/start of 
treatment (and not qualifying for CR or PR).
PD = progression  12 weeks after randomization/ start of treatment (and not qualify ing 
for CR, PR or SD).
UNK = all other cases (i.e. not qualify ing for confirmed CR or PR and without SD after 
more than 6 weeks or early  progression within the first 12 weeks)
Overall lesion responses of CR must stay the same until progression sets in, with the exception 
of a UNK sta tus. A patient who had a CR cannot subsequently  have a lower status other than a 
PD, e.g. PR or SD, as this would imply  a progression based on one or more lesions reappearing, 
in which case the status would become a PD.
Once an overall lesion response of PR is observed (which may have to be a confirmed PR 
depending on the study) this assignment must stay the same or improve over time until 
progression sets in, with the exception of an UNK status. However, in studies where 
confirmation of response is require d, if a patient has a single PR (30% reduction of tumor 
burden compared to baseline) at one assessment, followed by  a <30% reduction from baseline 
at the next assessment (but not 20% increase from previous smallest sum), the objective status 
at that assessment should be SD. Once a confirmed PR was seen, the overall lesion response 
should be considered PR (or UNK) until progression is documented or the lesions totally  
disappear in which case a CR assignment is applicable. In studies where confirmation of 

Novartis Confidential Page 144
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
response is not required after a single PR the overall lesion response should still be considered 
PR (or UNK) until progression is documented or the lesion totally  disappears in which case a 
CR assignment is applicable.
Example: In a case where confirmation of response is required the sum of lesion diameters is 
200 m m at baseline and then 140 mm - 150 m m - 140 m m - 160 m m - 160 m m at the subsequent 
visits. Assuming that non -target lesions did not progress, the overall lesion response would be 
PR -SD 
-PR -PR -PR. The second assessment with 140 m m confirms the PR for this patient. 
All subsequent assessments are considered PR even if tumor measurements decrease only by 
20% compared to baseline (200 m m to 16 0 mm) at the following assessments.
If the patient progressed but continues study  treatment, further assessments are not considered 
for the determination of best overall response.
Note : these cases may be described as a separate finding in the CSR but not included in the 
overall response or disease control rates.
The best overall response for a patient is alway s calculated, based on the sequence of overall 
lesion responses. However, the overall lesion response at a given assessment ma y be provided 
from different sources:
Investigator overall lesion response
Central Blinded Review overall lesion response
Novartis calculated overall lesion response (based on measurements from either 
Investigator or Central Review)
The primary  analysis ofthe best overall response will be based on the sequence of 
investigator/central blinded review/calculated (investigator)/calculated (central) overall lesion 
responses.
Based on the patients’ best overall response during the study , the following rates are then 
calculated:
Overall response rate (ORR) is the proportion of patients with a best overall response of CR 
or PR. This is also referred to as ‘Objective response rate’ in some protocols or publications.
Disease control rate (DCR) is the proportion of pa tients with a best overall response of CR or 
PR or SD.
Another approach is to summarize the progression rate at a certain time point after baseline. In 
this case, the following definition is used:
Early progression rate (EPR) is the proportion of patients with progressive disease within 
8weeks of the start of treatment.
The protocol should define populations for which these will be calculated. The timepoint for 
EPR is study  specific. EPR is used for the multinomial designs ofDent and Zee (2001) and 
counts all patients who at the specified assessment (in this example the assessment would be at 
8 weeks ± window) do not have an overall lesion response of SD, PR or CR. Patient s with an 
unknown (UNK) assessment at that time point and no PD before, will not be counted as early 
progressors in the anal ysis but may  be included in the denominator of the EPR rate, depending 
on the analy sis population used. Similarly  when examining overall response and disease control, 

Novartis Confidential Page 145
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
patients with a best overall response assessment of unknown (UNK) will not be regarded as 
“responders” but may be included in the denominator for ORR and DCR calculation depending 
on the anal ysis population (e.g. populations based on an ITT approach).
14.1.18 Time to event variables
The protocol should state which of the following variables is used in that study.
14.1.19 Progression -free survival
Usually  in all Oncology  studies, patients are followed for tumor progression after 
discontinuation of study  medication for reasons other than progression or death. If this is not 
used, e.g. in Phase I or II studies, this should be clearl y stated in the protocol. Note that 
randomized 
trials (preferably blinded) are recommended where PFS is to be the primary 
endpoint.
Progression -free survival (PFS) is the time from date of randomization/start of treatment to 
the date of event defined as the first documented progression or death due to any cause. If a 
patient has not had an event, progressi on-free survival is censored at the date of last adequate 
tumor assessment.
14.1.20 Overall survival
All patients should be followed until death or until patient has had adequate follow -up time as 
specified in the protocol whichever comes first. The follow -up data should contain the date the 
patient was last seen alive / last known date patient alive , the date of death and the reason of 
death (“Stud y indication” or “Other”).
Overall survival (OS) is defined as the time from date of randomization/start of treatment to 
date of death due to an y cause. If a patient is not known to have died, survival will be censored 
at the date of last known date patient alive
.
14.1.21 Time to progression
Some studies might consider only death related to underly ing cancer as an event which indicates 
progression. In this case the variable “Time to progression” might be used. TTP is defined as 
PFS except for death unrelated to underl ying cancer.
Time to progression (TTP) is the time from date of randomization/start of treatment to the 
date of eve nt defined as the first documented progression or death due to underly ing cancer. If 
a patient has not had an event, time to progression is censored at the date of last adequate tumor 
assessment.
14.1.22 Time to treatment failure
This endpoint is often appropriate in studies of advanced disease where early discontinuation is 
typicall y related to intolerance of the study  drug. In some protocols, time to treatment failure 
may be considered as a sensitivity  analysis for time to progression. The list of discontinuation
reasons to be considered or not as treatment failure may be adapted according to the specificities 
of the study  or the disease.

Novartis Confidential Page 146
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Time to treatment failure (TTF) is the time from date of randomization/start of treatment to 
the earliest of date of progressio n, date of death due to any cause, or date of discontinuation due 
to reasons other than ‘Protocol violation’ or ‘Administrative problems’. The time to treatment 
failure for patients who did not experience treatment failure will be censored at last adequate
tumor assessment.
14.1.23 Duration of response
The analy sis of the following variables should be performed with much caution when restricted 
to responders since treatment bias could have been introduce d. There have been reports where 
a treatment with a significan
tly higher response rate had a significantly shorter duration of 
response but where this probabl y primaril y reflected selection bias which is explained as 
follows: I t is postulated that there are two groups of patients: a good risk group and a poor risk 
group. Good risk patients tend to get into response readily  (and relativel y quickly ) and tend to 
remain in response after they  have a response. Poor risk patients tend to be difficult to achieve
a response, may have a longer time to respond, and tend to relapse quickly  when they do respond. 
Potent agents induce a response in both good risk and poor risk patients. Less potent agents 
induce a response mainly in good risk patients only. This is described in more detail by Morgan 
(1988)
It is recommended that an analysis of all patients (both responders and non-responders) be 
performed whether or not a 
“responders onl y”descriptive anal ysis is presented. An analy sis of 
responders should only be performed to provide descriptive statistics and even then interpreted 
with caution by evaluating the results in the context of the observed response rates. If an 
inferential compa rison between treatments is required this should only be performed on all 
patients (i.e. not restricting to “responders” only ) using appropriate statistical methods such as 
the techniques described in Ellis et al (2008) . It should also be stated in the protocol if duration 
of response is to be calculated in addition for unconfirmed response.
For summary  statistics on “responders” only the following definitions are appropriate. (Specific 
definitions for an all-patient analysis of these endpoints are not appropriate since the status of 
patients throughout the study  is usuall y taken into account in the anal ysis).
Duration of overall response (CR or PR) : For patients with a CR or PR (which may  have to 
be confirmed the start date is the date of first documented response (CR or PR) and the end date 
and censoring is defined the same as that for time to progression.
The following two durations might be calculated in addition for a large Phase III study  in which 
a reasonable number of responders is seen.
Duration of overall complete response (CR) : For patients with a CR (which may  have to be 
confirmed) the start date is the date of first documented CR and the end date and censoring is 
defined the same as that for ti me to progression.
Duration of stable disease (CR/PR/SD) : For patients with a CR or PR (which may have to be 
confirmed) or SD the start and end date as well as censoring is defined the same as that for time 
to progression.

Novartis Confidential Page 147
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
14.1.24 Time to response
Time to overall response (CR or PR) is the time between date of randomization/start of 
treatment until first documented response (CR or PR). The response may  need to be confirmed 
depending on the ty pe of study  and its importance. Where the response needs to be confirmed 
then time to response is the time to the first CR or PR observed.
Although an analysis on the full population is preferred a descriptive analysis may be performed 
on the “responders ” subset only, in which case the results should be interpreted with caution 
and in the context of the overall response rates, since the same kind of selection bias may be 
introduced as described for duration of response in Section 14.1.23. It is recommended that an 
analysis of all patients (both responders and non-responders) be performed whether or not a 
“responders onl y” descriptive analysis 
is presented. Where an inferential statistical comparison 
is required, then all patients should definitely  be included in the analysis toensure the statistical 
test is valid. For anal ysis including all patients, patients who did not achieve a response (which 
may have to be a confirmed response) will be censored using one of the following options.
at maximum follow -up (i.e. FPFV to LPLV use d for the anal ysis)for patients who had a 
PFS event (i.e. progressed or died due to an y cause). In this case the PFS event is the 
worst possible outcome as it means the patient cannot subsequently  respond. Since the 
statistical analy sis usually  makes use of the ranking of times to response it is sufficient to 
assign the worst possible censoring time which could be observed in the study  which is 
equal to the maximum follow- up time (i.e. time from FPFV to L PLV)
at last adequate tumor assessment date otherwis e. In this case patients have not y et 
progressed so they  theoretically  still have a chance of responding
Time to overall complete response (CR) is the time between dates of randomization/start of 
treatment until first documented CR. Similar analy sis consid erations including (if appropriate) 
censoring rules apply  for this endpoint described for the time to overall response endpoint.
14.1.25 Definition of start and end dates for time to event variables
Assessment date
For each assessment (i.e. evaluation number), the assessment date is calculated as the latest of 
all measurement dates (e.g. X -ray, CT-scan) if the overall lesion response at that assessment is 
CR/PR/SD/UNK. Otherwise -if overall lesion response is progression -the assessment date is 
calculated as the earliest date of all measurement dates at that evaluation number.
Start dates
For all “time to event” variables, other than duration of response, the randomization/ date of 
treatment start will be used as the start date.
For the calculation of duration of response the following start date should be used:
Date of first documented response is the assessment date of the first overall lesion 
response of CR (for duration of ove rall complete response) or CR / PR (for duration of 
overall response) respectively , when this status is later confirmed.

Novartis Confidential Page 148
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
End dates
The end dates which are used to calculate ‘time to event’ variables are defined as follows:
Date of death (during treatment a s recorded on the treatment completion page or during 
follow -up as recorded on the study  evaluation completion page or the survival follow -up 
page).
Date of progression is the first assessment date at which the overall lesion response was 
recorded as progr essive disease.
Date of last adequate tumor assessment is the date the last tumor assessment with overall 
lesion response of CR, PR or SD which was made before an event or a censoring reason 
occurred. In this case the last tumor evaluation date at that ass essment is used. If no post -
baseline assessments are available (before an event or a censoring reason occurred) the 
date of randomization/start of treatment is used.
Date of next scheduled assessment is the date of the last adequate tumor assessment plus 
the protocol specified time interval for assessments. This date may  be used if back-dating 
is considered when the event occurred bey ond the acceptable time window for the next 
tumor a ssessment as per protocol (see Section 14.1.26).
Example (if protocol defined schedule of assessments is 3 months): tumor assessments at 
baseline - 3 months - 6 months -missing -missing -PD. Date of next scheduled assessment 
would then correspond to 9 months.
Date of discontinuation is the date of the end of treatment visit.
Date of last contact is defined as the last date the patient was known to be alive. This 
corresponds to the latest date for either the visit date, lab sample date or tumor assessment 
date. If available, the last known date patient alive from the survival follow- up page is 
used. If no survival follow- up is available, the date of discontinuation is used as last 
contact date.
Date of secondary  anti- cancer therap y is defined as the start date of an y addition al 
(secondary ) antineoplastic therap y or surgery .
14.1.26 Handling of patients with non -measurable disease only  at baseline
It is possible that patients with only non- measurable disease present at baseline are entered into 
the study , either because of a protocol violation or by design (e.g. in Phase III studies with PFS 
as the primary  endpoint). In such cases the handling of the response data requires special 
consideration with respect to inclusion in any analysis of endpoints based on the overall 
response evaluati ons.
It is recommended that any patients with only non-measurable disease at baseline should be 
included in the main (ITT) anal ysis of each of these endpoints.
Although the text of the definitions described in the previous sections primarily relates to 
patients with measurable disease at baseline, patients without measurable disease should also 
be incorporated in an appropriate manner. The overall response for patients with measurable 
disease is derived slightly differentl y according to Table 
14-4.

Novartis Confidential Page 149
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Table 14-4 Overall lesion response at each assessment : patients with non -target 
disease only
Non-target lesions New Lesions Overall lesion response
CR No CR
Non-CR/Non-PD1No Non-CR/non -PD
UNK No UNK
PD Yes or No PD
Any Yes PD
1As defined in Section 14.1.8 .
In general, the non-CR/non -PD response for these patients is considered equivalent to an SD 
response in endpoint determination. In summary  tables for best overall response patients with 
only non- measurable disease may  be highlighted in an appropriate fashion e.g. in particular by 
display ing th e specific numbers with the non -CR/non -PD category .
In considering how to incorporate data from these patients into the analy sis the importance to 
each endpoint of being able to identify  a PR and/or to determine the occurrence and timing of 
progression nee ds to be taken into account.
For ORR it is recommended that the main (I TT) analy sis includes data from patients with only 
non-measurable disease at baseline, handling patients with a best response of CR as “responders” 
with respect to ORR and all othe r patients as “non -responders”.
For PFS, it is again recommended that the main ITT analyses on these endpoints include all 
patients with only non
-measurable disease at baseline, with possible sensitivity analyses which 
exclude these particular patients. Endpoin ts such as PFS which are reliant on the determination 
and/or timing of progression can incorporate data from patients with only non-measurable 
disease.
14.1.27 Sensitivity analy ses
This section outlines the possible event and censoring dates for progression, as well asaddress es
the issues of missing tumor assessments during the study . For instance, if one or more 
assessment visits are missed prior to the progression event, to what date should the progression 
event be assigned? And should progression event be ignor ed if it occurred after a long period 
of a patient being lost to follow -up? It is important that the protocol and RAP specify  the 
primary  analysis in detail with respect to the definition of event and censoring dates and also 
include a description of one o r more sensitivity  analy ses to be performed.
Based on definitions outlined in Section 14.1.25, and using the draft FDA guideline on 
endpoints (Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, April 2005) 
as a reference, the following analy ses can be considered:

Novartis Confidential Page 150
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Table 14-5 Options for event dates used in PFS, TTP, duration of response
SituationOptio ns for end -date (progression or 
censoring)1
(1) = default unless specified differently  in 
the protocol or RAP Outcome
A No baseline assessment (1) Date of randomization/start of treatment3Censored
B Progression at or before next scheduled 
assessment(1)Date of progression
(2) Date of next scheduled assessment2Progressed
Progressed
C1 Progression or death after exactly  one
missing assessment(1) Date of progression (or death)
(2) Date of next scheduled assessment2Progressed
Progressed
C2 Progression or death after two or more
missing assessments(1) Date of last adequate assessment2
(2) Date of next scheduled assessment2
(3) Date of progression (or death)Censored
Progressed
Progressed
D No progression (1) Date of last adequate assessment Censored
E Treatment discontinuation due to ‘Disease 
progression’ without documented 
progression, i.e. clinical progression based 
on investigator claim(1) N/A
(2) Date of discontinuation (visit date at which 
clinical progression was determined)Ignored
Progressed
F New anticancer therapy given (1) Date of last adequate assessment
(2) Date of secondary anti -cancer therapy
(3) Date of secondary anti -cancer therapy
(4) N/ACensored
Censored
Event
Ignored
G Deaths due to reason other than 
deterioration of ‘Study indication’(1) Date of last adequate assessment Censored 
(only TTP and 
duration of 
response)
1.=Definitions can be found in Section 14.1.25
2.=After the last adequate tumor assessment. “Date of next scheduled assessment” is defined in Section 14.1.25 .
3.=The rare exception to this is if the patient dies no later than the time of the second scheduled assessment as 
defined in the protocol in which case this is a PFS event at the date of death.
The primary  analysis and the sensitivity  analyses must be specified in the protocol. Clearl y 
define if and why options (1) are not used for situations C, E and (if applicable) F.
Situation s C (C1 and C2): Progression or death after one or more missing assessments: The 
primary  anal ysis is usually  using option s(1) for situations C 1 and C2, i.e.
(C1) taking the actual progression or death date , in the case of only  one missing 
assessment .
(C2) censoring at the date of the last adequate assessment, in the case of two or more 
consecutive missing assessments.
In the case of two or missing assessments (situation C2), option (3) may be considered jointly 
with option (1) in situation C1 as sensitivity  analysis. A variant of this sensitivity  analysis 
consists of backdating the date of event to the next scheduled assessment as proposed with 
option (2) in situations C1 and C2.
Situation E: Treatment discontinuation due to ‘Disease progression’ without documented 
progressi on:By default, option (1) is used for situation E as patients without documented PD 
should be followed for progression after discontinuation of treatment .However, option (2) may 
be used as sensitivity  analy sis.If progression is claimed based on clinical deterioration instead 
of tumor assessment by e.g. CT-scan, option (2) may be used for indications with high early 
progression rate or difficulties to assess the tumor due to clinical deterioration.

Novartis Confidential Page 151
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Situation F: New cancer therapy given : the handling of this situation must be specified in 
detail in the protocol. However, option (1), i.e. censoring at last adequate assessment may be 
used as a default in this case.
Additional suggestions for sensitivity analyses
Other suggestions for additional sensitivity  analyses may include analy ses to check for potential 
bias in follow -up schedules for tumor assessments, e.g. by assigning the dates for censoring and 
events only  at scheduled visit dates. The latter could be handled b y replacing in Table 14 -5the
“Date of last adequate assessment” by the “Date of previous scheduled assessment (from 
baseline)”, with the following definition:
Date of previous scheduled assessment (from baseline) is the date when a tumor 
assessment would have taken place, if the protocol assessment scheme was strictly  
followed from baseline, immediately  before or on the date of the last adequate tumor 
assessment.
In addition, analy ses could be repeated using the Investi gators’ assessments of response rather 
than the calculated response. The need for these types of sensitivity  anal yses will depend on the 
individual requirements for the specific study  and disease 
area and have to be specified in the 
protocol or RAP documen tation.
14.1.28 Data handling and programming rules
The following section should be used as guidance for development of the protocol, data 
handling procedures or programming requirements (e.g. on incomplete dates).
14.1.29 Study/project specific decisions
For each study  (or project) various issues need to be addressed and specified in the protocol or 
RAP documentation. Any  deviations from protocol must be discussed and defined at the latest 
in the RAP documentation.
The proposed primary  analysis and potential sensitivity  analyses should be discussed and 
agreed with the health authorities and documented in the protocol (or at the latest in the RAP 
documentation before database lock).
14.1.30 End of treatment phase completion
Patients may voluntarily withdraw from the study  treatmen t or may be taken off the study 
treatment at the discretion of the investigator at any time. For patients who are lost to follow -
up, the investigator or designee should show "due diligence" by documenting in the source 
documents steps taken to contact the patient, e.g., dates of telephone calls, registered letters, etc.
The end of treatment visit and its associated assessments should occur within 7 days of the last 
study  treatment.
Patients may  discontinue study  treatment for an y of the following reasons:
Adverse event(s)
Lost to follow -up
Physician decision

Novartis Confidential Page 152
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Pregnancy
Protocol deviation
Technical problems
Subject/guardian decision
Death
Progressi ve disease
Study  terminated by  the sponsor
Non-compliant with study  treatment
No longer requires treatment
Treatme nt duration completed as per protocol (optional, to be used if only  a fixed number 
of cy cles is given)
14.1.31 End of post -treatment follow -up (study  phase completion)
End of post-treatment follow -up visit will be completed after discontinuation of study  treatment
and post -treatment evaluations but prior to collecting survival follow-up.
Patients may  provide study  phase completion information for one of the following reasons:
Adverse event
Lost to follow -up
Physician decision
Pregnancy
Protocol deviation
Technical problems
Subject/guardian decision
Death
New therap yfor stud y indication
Progressi ve disease
Study  terminated by  the sponsor
14.1.32 Medical validation of programmed overall lesion response
As RECI ST is very strict regarding measurement methods (i.e. any assessme nt with more or 
less sensitive method than the one used to assess the lesion at baseline is considered UNK) and 
not available evaluations (i.e. if any target or non-target lesion was not evaluated the whole 
overall lesion response is UNK unless remaining l
esions qualified for PD), these UNK 
assessments may  be re -evaluated by  clinicians at Novartis or external experts. I n addition, data 
review reports will be available to identify  assessments for which the investigators’ or central 
reader’s opinion does not match the programmed calculated response based on RECI ST criteria. 
This may be queried for clarification. However, the investigator or central reader’s response 
assessment will never be overruled.
If Novartis elect to invalidate an overall lesion response as evaluated by the investigator or 
central reader upon internal or external review of the data, the calculated overall lesion response 

Novartis Confidential Page 153
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
at that specific assessment is to be kept in a dataset. This must be clearl y documented in the 
RAP documentation and agreed before database lock. This dataset should be created and stored 
as part of the ‘raw’ data.
Any discontinuation due to ‘Disease progression’ without documentation of progression by 
RECI ST criteria should be carefull y reviewed. Only patients with documen ted deterioration of 
symptoms indicative of progression of disease should have this reason for discontinuation of 
treatment or stud y evaluation.
14.1.33 Programming rules
The following should be used for programming of efficacy  results:
14.1.34 Calculation of ‘time to eve nt’ variables
Time to event = end date -start date + 1 (in day s)
When no post-baseline tumor assessments are available, the date of randomization/start of 
treatment will be used as end date (duration = 1 day ) when time is to be censored at last tumor 
assessment, i.e. time to event variables can never be negative.
14.1.35 Incomplete assessment dates
All investigation dates (e.g. X -ray, CT scan) must be completed with day , month and y ear.
If one or more investigation dates are incomplete but other investigation dates are available, 
this/these incomplete date(s) are not considered for calculation of the assessment date (and 
assessment date is calculated as outlined in Section 14.1.25). If all measurement dates have no 
day recorded, the 1stof the month is used.
If the month is not completed, for any of the investigations, the respective 
assessment will be 
considered to be at the date which is exactly  between previous and following assessment. If a 
previous and following assessment is not available, this assessment will not be used for any 
calculation.
14.1.36 Incomplete dates for last known date patient alive or death
All dates must be completed with day, month and year. If the day is missing, the 15thof the 
month will be used for incomplete death dates or dates of last contact.
14.1.37 Non- target lesion response
If no non- target lesions are identified at baseline (and therefore not followed throughout the 
study ), the non-target lesion response at each assessment will be considered ‘not applicable 
(NA)’.
14.1.38 Study/project specific programming
The standard anal ysis programs need to be adapted for each study/project .

Novartis Confidential Page 154
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
14.1.39 Censoring reason
In order to summarize the various reasons for censor ing, the following categories will be 
calculated for each time to event variable based on the treatment completion page, the study 
evaluation completion page and the survival page.
For survival the following censoring reasons are possible:
Alive
Lost to follow -up
For PFS and TTP (and therefore duration of responses) the following censoring reasons are 
possible:
Ongoing without event
Lost to follow -up
Withdrew consent
Adequate assessment no longer available*
Event documented after two or more missing tumor assessments (optional, see Table 14 -5)
Death due to reason other than underl ying cancer (only used for TTP and duration of 
response)
Initiation of new anti
-cancer therapy
*Adequate assessment is defined in Section 14.1.25 . This reason is applicable when adequate 
evaluations are missing for a specified period prior to data cut-off (or prior to any other 
censoring reason) corresponding to the unavailabil ity of two or more planned tumor 
assessments prior to the cut-off date. The following clarifications concerning this reason should 
also be noted:
This may  be when there has been a definite decision to stop evaluation (e.g. 
reason=“Sponsor decision” on stud y evaluation completion page), when patients are not 
followed for progression after treatment completion or when onl y UNK assessments are 
available just prior to data cut -off).
The reason "Adequate assessment no longer available" also prevails in situations when 
another censoring reason (e.g. withdrawal of consent, loss to follow -up or alternative anti -
cancer therap y) has occurred more than the specified period following the last adequate 
assessment.
This reason will also be used to censor in case of no baseline assessment.

Novartis Confidential Page 155
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
14.1.40 References (available upon request)
Dent S, Zee (2001) application of a new multinomial phase II stopping rule using response 
and earl y progression, J Clin Oncol; 19: 785
-791
Eisenhauer E, et al (2009) New response evaluation cri teria in solid tumors: revised RECI ST 
guideline (version 1.1). European Journal of Cancer, Vol.45: 228 -47
Ellis S, et al (2008) Analysis of duration of response in oncology  trials. Contemp Clin Trials 
2008; 29: 456-465
FDA Guidelines: 2005 Clinical Trial E ndpoints for the Approval of Cancer Drugs and 
Biologics, April 2005
FDA Guidelines: 2007 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, May 2007
Morgan TM (1988) Analy sis of duration of response: a problem of oncology  trials. Cont Clin 
Trials; 9: 11-18
Therasse P, Arbuck S, Eisenhauer E, et al (2000) New Guidelines to Evaluate the Response to 
Treatment in Solid Tumors, Journal of National Cancer Institute, Vol. 92; 205 -16

Novartis Confidential Page 156
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
14.2 Appendix 2 – Child- Pugh classification of severity  of liver
disease
Child -Pugh classification sy stem
The CPC is used to assess the severity  of impaired hepatic function in patients with liver 
cirrhosis (Child 1964, FDA guidance 2003 ). In general, it is used to determine the risk to a 
patient with regard to the treatment(s) (e.g. surgery, transpla
nt, medication), and, to suggest the 
perceived survival of the patient over a period of time.
Hepatocellular carcinom a patients who have Child -Pugh grade A score (5 - 6 points) at the 
baseline screening are eligible for participating in Study  CFGF401X2101 , provided that the 
patients meet all other eligibility criteria , see Section 5 .
Calculation and interpretation for Child -Pugh scores
The severity  of liver disease is based on the CPC criteria, which will be calculated based on 
clinical findings and laboratory  results during the screening period. Five variables are 
considered (severi ty of ascites, hepatic encephalopathy , abnormality  in serum bilirubin, serum 
albumin and clotting times). A score (between 1 and 3) is accordingl y assi gned to each of these 
factors (Table 14 -6). The sum of the scores provides the Child -Pugh score, which corresponds 
to a Child -Pugh grade (or Child’s grade) of A, B or C (Table 14
-7).
Table 14-6 Child -Pugh score calculation
VariablesPoints assigned
Units 1 2 3
Total Bilirubin < 2 (< 34) 2-3 (34 -50) > 3 (> 50) mg/dL (µmol/L)
Serum Albumin > 35 (> 3.5) 28-35 (2.8 -3.5) < 28 (< 2.8) g/L (g/dL)
PT (or INR) < 4 (< 1.7) 4-6 (1.7-2.30) > 6 (> 2.30) sec (no unit)
Ascites Absent Slight Moderate no unit
Hepatic Encephalopathy* None Grade 1 -2 Grade 3 -4 no unit
*Grade 0: normal consciousness, personality, neurological examination, electroencephalogram
*Grade 1: restless, sleep disturbed, irritable/agitated, tremor, impaired handwriting, 5 cps waves
*Grade 2: lethargic, time -disoriented, inappropriate, asterixis, ataxia, slow triphasic waves
*Grade 3: somnolent, stuporous, place -disoriented, hyperactive reflexes, rigidity, slower waves
*Grade 4: unrousable coma, no personality/behavior, decerebrate, slow 2 -3 cps delta activity
Table 14-7 Child -Pugh score interpretation
Severit y (grade) Child -Pugh Score
A 5 - 6
B 7 - 9
C 10 -15
References (available upon request)
Child CG, Turcotte JG (1964). Surgery  and portal hy pertension. In: The liver and portal 
hypertension. Edited by  CG Child. Philadelphia: Saunders:50-64
FDA Guidance for industry  (2003). pharmacokinetics in patients with impaired hepatic 
function: study  design, data anal ysis, and impact on dosing and labeling

Novartis Confidential Page 157
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
14.3 Appendix 3 –Hepatocellular carcinoma staging sy stems
Staging sy stems
Clinical staging is crucial for risk stratification during ca ncer management. For HCC, a number 
of clinical staging systems have been developed mainly  from HCC patients of different 
etiologies and extent of disease. The BCL C system is most widely  studied and will be assessed 
at screening for all patients participati ng in this study :
For more information on patient eligibility , please refer to the core text of the study  protocol.
Barcelona -Clinic Liver Cancer sy stem
The BCLC staging sy stem (Table 14 -8) was develope d based on the combination of data from 
several independent studies representing different disease stag
es and/or treatment modalities. I t 
includes variables related to tumor stage, liver functional status, physical status and cancer 
related s ymptoms (Llovet et al 2008 ) .
Table 14-8 Barcelona -Clinic Liver Cancer system
BCLC stage PS Tumor Features Liver Function
Stage A* (early HCC)
A1 0 Single < 5 cm No portal HTN** and normal bilirubin
A2 0 Single < 5 cm Portal HTN, normal bilirubin
A3 0 Single < 5 cm Portal HTN, abnormal bilirubin
A4 0 Up to 3 tumors < 3 cm Child -Pugh class A - B
Stage B (intermediate HCC) 0 Large multinodular Child -Pugh class A - B
Stage C (advanced HCC) 1 - 2 Vascular invasion or 
extrahepatic spreadChild -Pugh class A - B
Stage D (end -stage HCC) 3 - 4 Any of the above Child -Pugh class C
* Stages A1, A2, A3 and A4 will be considered “Stage A” for data collection.
** HTN = Hypertension
Only  BCLC Stage C HCC patients are eligible for participating in this study , provided that the 
patients meet all other eligibility criteria , see Section 5 .
References (a vailable upon request)
Llovet, J. M., et al. "Sorafenib in advanced hepatocellular carcinoma." N.Engl.J.Med. 359.4 
(2008): 378-90.

Novartis Confidential Page 158
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
14.4 Appendix 4 –Prohibited concomitant medications and permitted 
concomitant medications requiring caution
Table 14-9 Prohibited concomitant medications
Mechanism of Interaction Drug Name
Known BSEP inhibitorsAtorvastatin, cerivastatin, cyclosporine , glyburide , reserpine, rifampicin, 
troglitazone, valinomycin
CYP1A2 substrate with NTI Theophylline, tizanidine
CYP2C9 substrate with NTI Phenytoin, warfarin
CYP3A4/5 substrate with NTIQuinidine, [terfenadine], astemizole, cyclosporine, sirolimus, tacrolimus, 
pimozide, alfentanil, fentanyl, diergotamine, ergotamine, cisapride , 
thioridazine, dihydroergotamine
Source: Adapted from Oncology Clinical Pharmacology Drug -Drug Interactions (DDI) and Co-medication 
considerations   (release date: Apr2015) which was c ompiled from the Indiana University School of Medicine’s 
“Clinically Relevant” Table and supplemented with the FDA Draft Guidance for Industry, Drug Interaction Studies 
–Study Design, Data Analysis, and Implications for Dosing and Labeling (February 2012) , and the University of 
Washington’s Drug Interaction Database
Dawson S et al, Drug Met Dispos, 2012, 40 :130 -138
Morgan et al, Tox Sci, 2013, 136: 216 -241
NTI: narrow therapeutic index
Table 14-10 Permitted concomitant medications requiring caution
Mechanism of Interaction Drug Name
Strong CYP3A4/5 inhibitor Clarithromycin, troleandomycin, indinavir ,  itraconazole, posaconazole, 
voriconazole, boceprevir, telaprevir, cobicistat, conivaptan,  mibefradil,
grapefruit juice, ketoconazole,  lopinavir/ritonavir, nefaz odone, nelfinavir,
ritonavir,  saquinavir, se quinavir/ritonavir,  telithromycin,
indinavir/ritonavir, tip ranoavir/ritonavir, danoprevir/ ritonavir, 
eltegravir/ritonavir
Strong CYP3A4/5 inducer Avasimibe, carbamazepine, mitotane, phenobarbital, rifabutin, St. John's 
wort, rifampin, enzalutamide
Potential BSEP inhibitors Benzbromarone, everolimus, fenofibrate, fusidic acid, indinavir, lopinavir, 
nelfinavir, olmesartan, sitaxsentan, tolcapone
MRP2/3/4 and/or NTCP and/or 
OATP1B1/3 inhibitorsAtazanavir, bendroflumethiazide, clarithromycin, clofazimine, 
clotrimazole, doxazosin, entacapone, epalrestat, ezetimibe, febuxostat, 
gemfibrozil, indomethacin, lopinavir, losartan, lovastatin, nelfinavir, 
nifedipine, olmesartan, repaglinide, rifaximin, rilpivirine, sildenafil, 
simvastatin, telmisartan, tranilast, valsartan
Source: Adapted from Oncology Clinical Pharmacology Drug -Drug Interactions (DDI) and Co -medication 
considerations (release date: Apr2015) which was compiled from the Indiana University School of Medicine’s 
“Clinically Relevant” Table and supplemented with the FDA Draft Guidance for Industry, Drug Interaction 
Studies –Study Design , Data Analysis, and Implications for Dosing and Labeling (February 2012), and the 
University of W ashington’s Drug Interaction Database
Dawson S et al, Drug Met Dispos, 2012, 40 :130 -138
Dong Z et al, Mol Pharmaceutics, 2013, 10 :1008 -1019
Kalliokoski A and Niemi M, Br J Pharmacol, 2009, 158 :693- 705
Morgan et al, Tox Sci, 2013, 136: 216 -241
14.5 Appendix 5 –Guidelines for management of diarrhea
Patients should receive clear instructi ons regarding the possibility  of experiencing diarrhea and 
the necessity  to contact the treating physician. As bile acid-induced diarrhea is a predictable 

Novartis Confidential Page 159
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
effect of the trial drug, patients experiencing diarrhea ≥ grade 1 should be treated with 
cholesty ramine (also named as colest yramine ) , 4 g daily initially , following local prescribing 
guidance.
It is recommended that patients initially  take cholesty ramine at bed time and if needed for 
further control of diarrhea take an extra dose of cholesty ramine in the afternoon (e.g. 3-4 pm) 
and/or late mornin g (e.g. 11 am). Other drugs need to be administered at least 1 hour before or 
4 hours after c holest yram ine administration.
The maximum recommended daily dose is six packets or scoopfuls of cholesty ramine (4 g/dose) 
for oral suspension (24 g anhydrous chole styramine resin), and according to the local 
prescribing document. Although the recommended dosing schedule is maximal 1 to 4 doses
daily , cholest yramine for oral suspension may be administered in 1 to 6 doses per day. 
Cholesty ramine should not be taken inits dry form and should be mixed with water or other 
juices 
before ingesting.
Patients need to be alerted to the possibility  of symptoms of bloating, and should consider 
reducing the dose to 2 g if these s ymptoms are more severe than the diarrhea.
It is recommended that increases in dose be gradual , such as 2 – 4 g every  3days .  Other 
treatment of diarrhea and complications (e.g. repletion of electroly tes) should follow local 
guidance .
Because cholest yramine binds bile acids, long-term treatment with cholesty ramine may 
interfere with normal fat digestion and absorption and thus may prevent absorption of fat-
soluble vitamins such as A, D, E and K. Monitor of vitamins, including vitamin K, should be 
done according to the local clinical guidelines. When c holest yramine is given for long periods 
of time, concomitant supplementation with water -miscible (or parenteral) forms of fat-soluble 
vitamins should be considered. If cholesty ramine is poorl y tolerated loperamide should be 
considered, initially  4–8 mg dai ly and a maximum of 16 mg daily .
Table 14
-11 Criteria for interruption and re -initiation of FGF401 treatment for 
diarrhea management
Worst toxicityaRecommended dose modifica tions any  time during a cy cle of therapy  (including 
intended day  of dosing)c, d
Grade 1 Maintain dose level, then:
If resolved to normal within 24 hours, then no need to prescribe colestyramine
If Grade 1 is persistent after 24 hours, then colestyramine should be considered based on 
investigator’s decision
Grade 2 Maintain dose level and start colestyramine immediately, then:
1. If resolved to ≤ Grade 1 within 24 hours after colestyramine administered, then 
colestyramine should be kept based on investigator’s decision
2. If Grade 2 is persistent after 24 hours of colestyramine administered, then continuously 
administer colestyramine for another 6 days and by then:
a. If resolved to ≤ Grade 1, maintain dose level and keep using colestyramine
b. If Grade 2 is persistent, then ↓ 1 dose level and keep using colestyramine

Novartis Confidential Page 160
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Worst toxicityaRecommended dose modifica tions any  time during a cy cle of therapy  (including 
intended day  of dosing)c, d
Grade 3bMaintain dose level and start colestyramine immediately, then:
1. If resolved to ≤ Grade 1 within 24 hours after colestyramine administered, then keep 
using colestyramine
2. If resolved to Grade 2 by 24 hours of colestyramine administered, then continuously 
administer colestyramine for another 6 days and by then:
a. If resolved to ≤ Grade 1, maintain dose level and keep using colestyramine
b. If Grade 2 is persistent, the n ↓1 dose level and keep using colestyramine
If Grade 3 is persistent after 24 hours of colestyramine administered, then omit dose and 
continuously administer colestyramine for another 6 days, by then:
a. If resolved to ≤ Grade 1, then ↓1 dose level and keep using colestyramine
b. If ≥ Grade 2 is persistent, then discontinue patient from study drug treatment
Grade 4bOmit dose and start colestyramine immediately, then:
1. If resolved to ≤ Grade 1 within 7 days after colestyramine administered, then ↓1dose 
level and keep using colestyramine
2. If not resolved to ≤ Grade 1 within 7 days after colestyramine administered, then 
discontinue patient from study drug treatment
a CTCAE version 4.03 will be used for all grading.
bFor Grade 3 and 4 diarrhea, th e supportive measurement should be implemented based on local clinical 
guidance
cFor any ≥ Grade 2 diarrhea with multiple occurrences, investigator should discuss with Novartis for any 
opportunity to change dosing schedule or further dose reductions.
dInany circumstance if patient needs to be discontinued from study drug treatment due to diarrhea, 
investigator should discuss with Novartis for any opportunity to change dosing schedule or further dose 
reductions.
14.6 Appendix 6 -Guidelines for management of hyperphosphatemia
Hyperphosphatemia is a disorder characterized by laboratory  test results that indicate an 
elevation in the concentration of inorganic phosphorus in blood . Clinical judgment and 
institutional standards in the management of hyperphosphatemia and the timing of stopping 
and/or re-initiating FGF401 treatment as a function of phosphate levels will be left to the 
discretion of the treating physician. Differences inphosphate management will not be 
considered as protocol deviations. Please refer to the Sevelamer Package Insert for additional 
information.
Table 14-12 Criteria for for int erruption and re -initiation of FGF401 treatment for 
hyperphosphatemia management
Serum inorganic phosphorus (Pi) valueRecommended Dose Modifications any  time during a 
cycle of therapy
Serum Pi > 5.5 –7.0 mg/dL Maintain dose level and start phosphorus lowering 
therapy:
Sevelamer dose should be adjusted based on the serum 
phosphorus level with the goal of maintaining ≤ 7.0 
mg/dL. Refer to Package Insert of Sevelamer for dosing 
guidelines.

Novartis Confidential Page 161
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Serum inorganic phosphorus (Pi) valueRecommended Dose Modifications any  time during a 
cycle of therapy
Serum Pi > 7.0 mg/dL lasting more than 7 days 
despite maximal dos ing of Sevelamer 
or
Confirmed single serum phosphorus > 9.0 mg/dL 
regardless of Sevelamer doseOmit dose until resolved to serum Pi ≤ 7.0 mg/dL, then:
● Continue Sevelamer and adjust the Sevelamer dose 
with the goal of maintaining serum phosphorus ≤ 7.0 
mg/dL.  Hold Sevelamer once serum phosphorus is ≤ 5.5 
mg/dL
● If serum phosphorus is resolved to ≤ 7.0 mg/dL within 
14 days of suspending FGF401, then resume FGF401 at 
the same dose level
● If serum phosphorus is not ≤ 7.0 mg/dL within 14 days 
of suspendin g FGF401 despite maximal dosing of 
Sevelamer, discontinue patient from the study drug 
treatment
● All patients will continue to be followed-up until 
resolution to serum phosphorus ≤ 7.0 mg/dL
If hyperphosphatemia recurs and requires another 
FGF401 dose int erruption: FGF401 dose should be 
restarted based on above criteria at ↓1 dose level. 
Further dose reductions of FGF401 may be taken as 
needed, but should first be discussed with Novartis.
Serum phosphorus > 10.0 mg/dL Discontinue patient from the study

Novartis Confidential Page 162
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 163
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
14.8 Appendix 8 –Test meal guidelines
During the food effect portion of the study , food intake should be supervised ondays of PK 
profiles collection . Patients on food effect cohort will consume a low-fat, light breakfast and 
then will receive the treatment wit h FGF401. The meal should be consumed within 30 minutes. 
FGF401 will be administered with one glass of water. No food will be allowed for at least 4 
hours post-dose.  Subjects should receive standardized meals scheduled at the same time in each 
period of t he stud y.
Note: For the fed conditions, the meal should be consumed within 30 minutes. I f > 30 minutes 
is required to complete the meal , then FGF401 should be administered relative to the end of the 
meal .
Recommendations for sample testmeals are outlined inTable 14-14. Alternative meals with 
equivalent nutritional content may
 be used.

Novartis Confidential Page 164
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Table 14-14 Test meal examples
Low-fat Breakfast
(approximately 500 calories and 20 grams of fat)
6 ounces of orange juice (except Seville)
8 ounces of 2% milk
1 banana
¾ cups of cereal
1 slice of toast
2 teaspoons of butter
Coffee, tea, or grapefruit juice is not permit ted as part of either test meal. Water is allowed during the test meal.
A registered dietician at the research site should determine the appropriate meal to be consumed, 
based on the fat and calorie requirements assigned to the patient for that treatment day. The 
start/stop time of meal consumption, and estimated % of test mea l consumed (based on fat and 
caloric content), must be listed in the Meal Record eCRF for patients allocated in exploratory  
food effect cohort .
14.9 Appendix 9 -Guidelines for immune -related Response Criteria 
(irRC) using one -dimensional measurements (simulati ng RECIST 
1.1)
14.9.1 Introduction
The currently  used immune -related response criteria (irRC) uses unidimensional measurements 
to assess tumor response and it is an adaptation of the original irRC published by Wolchok 
(Wolchok 2009
, Nishino 2013).
The purpose of this document is to summarize the irRC guidelines in details focusing on 
differences in tumor response assessments between irRC and RECI ST v1.1. 
The primary  difference between irRC and RECIST 1.1 is the definition of progressive disease. 
The definitions of baseline target/non target lesions, number of lesions selected at baseline,  the 
criteria for lesion measurement method of evaluation of response and definition of response are 
the same for irRC and RECI ST 1.1 and are available in the RECIST 1.1 guidelines ( Appendix 
1).
14.9.2 New lesions and non -target lesions
In irRC a new lesion does not automatically  indicate progressive disease. 
New measurable lesions are added to the sum of diameters of the previously  existing target 
lesions, and the sum of diameters is followed at each subsequent tumor assessment.
New measureable lesions are defined using the same criteria as for baseline target lesions in 
RECI ST v1.1. New 
measurable lesions shall be prioritized according to size, and the largest 
lesions shall be selected as new measured lesions up to 10 lesions in total.
Non-target lesions (baseline and new non-measurable lesions) are used primarily  for 
determination of Complete Response (CR). The RECI ST v1.1 definitions for the assessment of 
non-target lesions apply . A CR requires that all non-target lesions disappear (both those present 

Novartis Confidential Page 165
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
at baseline and any new non-measurable lesions that have appeared during the study ). If after 
worsening a non-target lesion becomes measurable, it should still be followed as a non-target 
lesion. Worsening of non -target lesions and new non -measurable lesions only  indicate disease 
progression if there is unequivocal evidence of disease progression ( Table 14 -15).
14.9.3 Follow -upevaluation of target and non
-target lesions
To assess tumor response, the sum of diameters for all target lesion s is calculated (at baseline 
and throughout the study). The diameters of any new measurable lesions are included in the 
sum of diameters at each assessment to provide the total tumor burden. At each assessment, 
percent change in the sum of diameters is calculated and compared to baseline or to nadir in 
order to evaluate the target lesion response (including new measurable lesions) (Section 14.9.4). 
This evaluation combined with the status of non-target l
esions (baseline and new non-
measurable lesions) is then used to determinate the overall lesion response ( Table 14-15 ). The 
thresholds for irPR and irPD assessment are the same as for RECIST v1.1.
14.9.4 Defini
tions of response categories and evaluation of overall lesion 
response
In irRC, the overall response is primarily based on target lesions (baseline and new measurable 
lesions). The non-target lesions only contribute to define irCR, and irPD in the case of 
unequivocal progression, as shown below in Table 14 -15. 
Like in RECI ST 1.1, irCR and irPR must be confirmed at a new assessment after at least 4 
weeks. Unlike RECI ST 1.1, irPD also requires confirmation at a new assessment after at least 
4 weeks.
The response categories are defined as follows:
Immune related Complete Response (irCR): Disappearance of all non -nodal target lesions 
and non
-target lesions in two consecutive observations not less than 4 weeks apart. In 
addition, any  pathological ly mph nodes assigned as target lesions must have a reduction in 
short axis to < 10 mm. (Sum of diameters may  be greater than zero at the time of CR, if 
nodal lesions are included as target lesions).
Immune related Partial Response (irPR): At least a 30% decrease in the sum of diameters 
of all target lesions including new measurable lesions in two consecutive observations not 
less than 4 weeks apart, taking as reference the baseline sum of diameters. 
Immune related Prog ressive Disease (irPD): At least a 20% increase in the sum of 
diameters of all measured target lesions including new measurable lesions. The irPD must 
be confirmed in a second evaluation not less than 4 weeks later, taking as reference the 
smallest sum of diameter of all target lesions recorded at or after baseline (nadir). In 
addition to the relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5 mm. Worsening of non -target lesions (existing or new) only  indicate 
PD when there is unequivocal evidence of progression, confirmed in a second evaluation 
not less than 4 weeks later. 
Immune related Stable Disease (irSD): Neither a sufficient shrinkage to qualify  for irPR or 
irCR, nor an increase in lesions which would qualify fo r irPD. 

Novartis Confidential Page 166
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
Unknown (UNK):  Progression has not been documented and one or more target lesions 
have not been assessed or have been assessed using a method significantly different from 
baseline that prevents reasonable comparison to the prior assessments .
Table 14- 15 Overall response at each assessment
Target and new measurable 
lesions (Tumor burden), * (%)Non-target lesions 
(both baseline and new non-
measurable)Overall
lesion response
-100 Absent irCRa
-100 Stable/not evaluated irPRa
≤ -30 Absent/Stable/not evaluated irPRa
> -30 and <+20 Absent/Stable/not evaluated irSD
≥ +20 Any irPDa
Any Unequivocal progression irPDa
* the diameter of new measurable lesions is included in the calculation of the sum of diameters
ato be confirmed after at least 4 weeks
14.9.5 References (available upon request )
Wolchok JD, Hoos A, O'Day  S et al (2009) .Guidelines for the Evaluation of I mmune Therap y 
Activity  in Solid Tumors: I mmune -Related Response Criteria. Clin Cancer Res; 15:7412 -20.
Nishino M, Giobbie -Hurder A, Gargano M, et al (2013) .Developing a Common L anguage for 
Tumor Response to Immunotherapy : Immune -Related Response Criteria Using 
Unidimensional Measurements. Clin Cancer Res; 19:3936 -3943.

Novartis Confidential Page 167
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 168
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 169
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 170
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 171
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 172
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 173
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 174
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 175
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 176
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 177
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 178
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 179
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 180
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 181
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101

Novartis Confidential Page 182
Amended Protocol Version 05 (Clean) Protocol No. CFGF401X2101
14.11 Appendix 11 -Recommended management algorithms for 
suspected toxicities
These guidelines for management of toxicities (Postow 2015) constitute guidance to the 
Investigator and are not intended to substitute institutional s
tandard of care practice.
A general principle is that differential diagnoses should be diligently  evaluated according to 
standard medical practice. Non-inflammatory  etiologies should be considered and appropriatel y 
treated .

Novartis Confidential Page 183
Amended Protocol Version 05 (Clean) Protocol No. C FGF401X2101
14.11.1 GI adverse event management algorithm

Novartis Confidential Page 184
Amended Protocol Version 05 (Clean) Protocol No. C FGF401X2101
14.11.2 Renal adverse event management algorithm

Novartis Confidential Page 185
Amended Protocol Version 05 (Clean) Protocol No. C FGF401X2101
14.11.3 Pulmonary  adverse event management algorithm

Novartis Confidential Page 186
Amended Protocol Version 05 (Clean) Protocol No. C FGF401X2101
14.11.4 Endocrinopathy  management algorithm

Novartis Confidential Page 187
Amended Protocol Version 05 (Clean) Protocol No. C FGF401X2101
14.11.5 Skin adverse event management algorithm

Novartis Confidential Page 188
Amended Protocol Version 05 (Clean) Protocol No. C FGF401X2101
14.11.6 Hepatic adverse event management algorithm

Novartis Confidential Page 189
Amended Protocol Version 05 (Clean) Protocol No. C FGF401X2101
14.11.7 References (available upon request)
Postow MA, Chesney  J, Pavlick AC, et al (2015). Nivolumab and ipilimumab versus 
ipilimumab in untreated melanoma. N Engl J Med.;372(21):2006 -17 (supplementary  appendix) .
